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Abstract 
Decisions about the use of medical interventions are frequently based on results from meta-
analyses of randomised clinical trials. Inadequate methodology in randomised trials, selective 
reporting of trials and results, and data extraction from published reports, however, may bias 
results of meta-analyses.  
The objective of this thesis was to examine factors associated with bias and variation in meta-
analyses of randomised clinical trials. These factors include methodological characteristics at 
the level of individual trials and problems with data extraction at the level of meta-analyses. 
This thesis is based on series of meta-epidemiological studies in component trials of different 
meta-analyses and on two clinical examples.  
The first three articles report on a meta-epidemiological study including 21 meta-analyses 
with 190 trials that compared therapeutic interventions with placebo or non-intervention 
control in patients with hip or knee osteoarthritis and used patient reported pain as an 
outcome. Treatment effects tended to be less beneficial in trials with adequate allocation 
concealment, adequate blinding of patients, intention-to-treat analysis and in large trials with 
at least 100 patients per arm. Article 4 provides a clinical example of a systematic review and 
meta-analysis illustrating how dimensions of methodological quality of included trials and 
small study effects affect pooled results. Articles 5 and 6 are based on randomly selected 
Cochrane reviews that presented a result as a standardised mean difference, and the 
corresponding protocols and component trials. Frequently, trials reported multiple 
intervention groups, multiple time points and outcome data from multiple measurement 
scales. Multiplicity of data in trial reports had an impact on the agreement between different 
observers when extracting data from trial reports and on the variability of the pooled results in 
meta-analyses. Article 7 discusses how different methodological approaches including funnel 
plots, stratified analyses accompanied by interaction tests and heterogeneity-adjusted trial 
sequential analysis contribute to our understanding of bias and inconclusive results in meta-
analyses. 
This thesis suggests that flaws in the conduct and design of randomised trials and meta-
analyses frequently result in biased estimates of treatment benefits and that the extent and 
direction of bias might be unpredictable for a specific situation. Methodological 
characteristics of randomised trials (allocation concealment, patient blinding and intention-to-
treat analysis), small sample size, inter-observer variation related to data extraction and 
multiplicity of data in trial reports may affect results and impact on the validity of meta-
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analyses. To avoid potential bias, trialists should ensure adequate concealment of allocation, 
attempt blinding of patients and describe results from intention-to-treat analyses. In 
systematic reviews and meta-analyses, a detailed protocol and independent data extraction by 
at least two investigators might improve the validity of results. Results of meta-analyses of 
methodologically questionable trials should be distrusted. Small study effects should be 
examined and the influence of inadequate allocation concealment, patient blinding and 
exclusions from the analysis should be routinely assessed.  
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Introduction 
Meta-analyses of randomised clinical trials 
Synthesis of relevant evidence, which has accumulated over time, is essential for informed 
decision making about the use of medical interventions by clinicians, researchers, and policy 
makers. Randomised clinical trials are generally considered the best study design for 
obtaining evidence of effectiveness and safety of medical interventions. Systematic reviews 
and meta-analyses are scientific rigorous approaches to synthesise the available evidence from 
randomised trials. Systematic reviews, a review that has been prepared using a documented 
and systematic approach, allow a more objective appraisal of the evidence than narrative 
reviews or expert opinions.1 Meta-analyses, statistical combinations of several randomised 
trials, may enhance precision of estimated treatment effects and allow the exploration of bias 
and confounding as an explanation of variation between trials.  
To combine results from individual trials in a meta-analysis, the treatment effects from 
individual studies need to be expressed as appropriate effect estimates. Estimates of treatment 
effects are usually expressed as risk ratios, odds ratios or risk differences for trials with a 
binary outcome, as rate ratios for trials with count data, as differences in means or 
standardised mean differences for trials with a continuous outcome and as hazard ratios for 
trials with a time-to-event outcome.2 The primary focus of this thesis is on outcomes 
measured on continuous or numerical rating scales. Therefore, effect estimates for continuous 
outcomes are presented in more detail. In the ith trial, the mean response in the experimental 
group of size nEi is denoted mEi with standard deviation SDEi, and the mean response in the 
control group of size nCi is denoted mCi with standard deviation SDCi. If the outcome in all 
individual trials is measured on the same scale, the treatment effect can be expressed as the 
difference in means between experimental and control groups in the ith trial denoted as  
(1) mEi – mCi  
 with variance SDEi2/nEi + SDCi2/nCi 
If the outcome in individual trials is measured on different scales, however, it is necessary to 
express the treatment effects on a uniform scale. The calculation of effect sizes (or 
standardised mean differences) allows that estimates of treatment effects are expressed in a 
standardised way as standard deviation units.2 3 Several methods of standardisation are 
available. The most frequently calculated effect size is Cohen’s d, where the difference in 
means is divided by the pooled standard deviation SDpooled:4 
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(2)  d = (mE – mC) / SDpooled 
 SDpooled2 = ((nE – 1) SDE2 + (nC – 1) SDC2 ) / (nE + nC – 2) 
The variance of Cohen’s d is calculated as follows:3 4 
(3) (nE + nC)/(nE * nC) + d2/(2*(nE + nC – 2)) 
An effect size of 0.20 standard deviation units can be considered a small difference between 
experimental and control group, an effect size of 0.50 a moderate difference, and 0.80 a large 
difference.4 Other standardisation methods include Hedges’ g, which accounts for 
underestimations of standard deviations in small studies,5 and Glass’ ∆, which uses the 
standard deviation of the control group for the standardisation rather than the pooled standard 
deviation.6 The different methods of standardisation will produce similar results unless the 
sample is very small or the standard deviations vary substantially between the groups.3 
In meta-analyses, effect estimates from individual trials i (i = 1,…,k), denoted as ŷi, are 
combined across k trials to calculate a pooled estimate of the treatment benefit ŷ. Generally, 
the pooled effect estimate is a weighted average of the effect estimates from each individual 
trial ŷi with weights based on the variances var(ŷi) = σi2 of these estimates.7 Two approaches 
to combine effect estimates from individual trials exist: fixed-(or common) effect and 
random-effects meta-analysis.3 8 Fixed-effect meta-analysis usually uses inverse-variance 
weights wi = 1/σi2, which gives a pooled effect estimate 
(4)  ŷfixed = Σ wi ŷi / Σ wi  
Fixed-effect meta-analytic models assume a common (fixed) effect that underlies each trial 
and that the true variances σi2 are known, although in practice they are estimated from the 
data. Random-effects meta-analytic models, however, assume that effects from individual 
studies are from a common normal distribution with an overall average treatment effect y and 
between-trial variance τ2: yi ~ N(y, τ2).9 An estimate of the between-trial variance τ2 is 
incorporated into the weights: wi = 1/(σi2 + τ2).9-11 This implies that if τ2 > 0, random-effects 
weights wi = 1/(σi2 + τ2) will be smaller and more similar across trials than fixed-effect 
weights wi = 1/σi2.3 Therefore, smaller and less precise trials will receive more relative weight 
in random-effects meta-analyses than in fixed-effect meta-analyses. The variance of the 
pooled effect estimate ŷ is given by Σwi. Confidence intervals for ŷ and z-statistics to test the 
hypothesis of no difference between groups can be derived.3 
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Generally, results of meta-analyses are presented in forest plots, where the pooled estimates 
with their corresponding confidence intervals are presented. Figure 1 shows an example of a 
forest plot from a meta-analysis comparing opioids with placebo or no control intervention in 
patients with knee or hip osteoarthritis.12 Treatment effects of 10 included randomised trials 
are shown one below the other using red squares for the estimated standardised mean 
difference and horizontal lines for the corresponding 95% confidence intervals. The size of 
the red square symbol is inversely related to the variance of the individual trial. Diamonds 
denote pooled estimated effects with the corresponding 95% confidence intervals derived 
from inverse-variance random effects meta-analysis. This example shows that opioid 
treatment has a moderate effect on pain compared to placebo with a pooled standardised mean 
difference of -0.36 (95% CI -0.47 to -0.26). The plot is stratified according to type of opioids 
and display pooled standardised mean differences derived from random effects meta-analysis 
between different types of opioids and placebo separately.  
 
Figure 1: Forest plot of 10 trials comparing the effects of any type of opioids and control (placebo or no 
intervention) on knee or hip pain. Values on x-axis denote standardised mean differences. The plot is stratified 
according to type of opioids.12 
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Forest plots are a tool to visually examine the variation between trials. More elaborated 
methods for visual inspection of the presence of heterogeneity between trials have been 
proposed by Galbraith13 and L’Abbé.14 Statistical heterogeneity can be assessed using 
hypothesis tests of homogeneity of the ŷi. The most commonly used test is based on the 
Cochran’s Q statistic:15 
(5)  Q = Σ wi (ŷi – ŷfixed)2 
that follows approximately a χ2 distribution with k – 1 degrees of freedom under the null 
hypothesis of homogeneity.10 16 The weights wi are inverse-variance weights. However, 
quantification of between-trial heterogeneity is generally more informative than a formal test 
of homogeneity. The test has often inappropriate power and makes it difficult to decide 
whether heterogeneity is present and clinically meaningful.16 17  
An important objective of random-effects meta-analysis is the estimation of the between-trial 
variance τ2 including its uncertainty. The commonly used estimate of the variance τ2 is based 
on the method of moments originally proposed for binary data by DerSimonian and Laird.10 
Several other methods for the estimation of τ2 are available, including other non-iterative, 
maximum-likelihood based or Bayes estimation procedures.18-20 Standard random-effects 
meta-analyses ignore the imprecision in the τ2 estimate.9 17 Special maximum likelihood 
methods or Bayesian approaches allow for the imprecision of τ2 estimates and reflect more 
accurately the uncertainty in the between-trial heterogeneity variance.9 21 22 A variance 
estimate τ2 < 0.06 might be interpreted as low and τ2 ≥ 0.06 as high heterogeneity between 
trials in a random-effects meta-analysis. A τ2 of 0.06 corresponds to a difference between 
smallest and largest effect sizes of about 1 standard deviation unit.22 Other measures to 
quantify between-trial heterogeneity are also available.17  A widely used measure is the I2 
statistic, which describes the percentage of variation across trials that is attributable to 
heterogeneity rather than to sampling error. I2 can be derived from Cochran’s Q statistic and 
approximate confidence intervals can be calculated.17 23 In the absence of heterogeneity I2 
equals 0. I2 values of 25%, 50%, and 75% may be interpreted as low, moderate, and high 
between trial heterogeneity, although its interpretation depends on the size and number of 
trials included.24  
The variation between trials might arise from differences in studied populations, 
interventions, or outcomes and from differences in methodology and design between included 
trials. Analyses stratified by characteristics of included trials accompanied by appropriate 
interaction tests can be used to explore sources of between-trial heterogeneity. Meta-
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regression analyses are widely used to explore sources of heterogeneity in meta-analyses:25 26 
weighted regression models to estimate the effect of trial-level covariates xi on the overall 
effect, where trials with lower standard errors contribute with higher weights to the regression 
analysis. Random-effects meta-regression analyses are based on hierarchical models with 
normal error terms µi and corresponding variances σi2 that vary between trials, and error terms 
εi with corresponding variance τ2 assumed equal between trials. 
(6) yi = xiβ + µi + εi 
 µi ~ N(0,σi2) 
 εi ~ N(0,τ2)  
It is unlikely that the covariates included in the meta-regression models explain all of the 
variation between trials and therefore, meta-regression models must allow for residual 
heterogeneity.26 27 Figure 2 shows an example of a random-effects meta-regression analysis to 
explore the dose-response relationship between estimates of treatment effects on pain and 
daily morphine equivalence doses in trials comparing opioids with control interventions in 
patients with knee or hip osteoarthritis.12 The example shows no clear association between 
treatment benefit and daily morphine dose; predicted treatment effects from random-effects 
meta-regression do not vary according daily morphine dose. 
 
Figure 2: Standardised mean differences 
of knee or hip pain (y-axis) are plotted 
against total daily dose of morphine 
equivalents (x-axis). The size of the circles 
is proportional to the random-effects 
weights that were used in the meta-
regression. The dotted line indicates 
predicted treatment effects (regression 
line) from univariable meta-regression by 
using daily morphine equivalence doses 
the explanatory variable, and dashed lines 
represent the 95% confidence intervals.12 
The exploration of sources of heterogeneity between trials using meta-regression will be 
limited by the availability of data from trial reports and by the number of included trials in the 
meta-analysis. Meta-regression analyses are based on aggregate level data and may be 
affected by the ‘ecological fallacy’, if the relationship between the covariates and treatment 
effects are not the same within and across trials.26 Ecological fallacy can be interpreted as 
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failure of associations seen at trial level to correspond to associations at patient level.28 Meta-
analyses based on individual patient data rather than on aggregate level data avoid these 
problems. Finally, a naïve use of meta-regression models to determine the association 
between estimated treatment effects and underlying risk can produce artefacts due to 
measurement error in the covariate and regression to the mean.25 
Bayesian approaches to random-effects meta-analysis and meta-regression assuming 
exchangeability of underlying effects are based on hierarchical Bayesian models and allow to 
obtain inferences for the parameters of interest from their posterior distributions simulated 
using Markov Chain Monte Carlo methods.22 29 Meta-analyses methods so far presented only 
considered pair-wise comparisons of treatments. However, clinicians, researchers and policy 
makers may be rather interested in the comparison of multiple treatments for decision making. 
In recent years, network meta-analyses for mixed treatment comparisons have been developed 
that allow comparison of several treatments while fully preserving the randomised treatment 
comparisons within trials.30 31 An overview of Bayesian approaches to classical and network 
meta-analysis is provided elsewhere in more detail.29 32 
Bias in randomised trials and meta-analyses 
The objective of any randomised trial or meta-analysis is to obtain a precise and valid 
estimate of the effect of an intervention on the outcome of interest. Reducing random error in 
the data (sampling error) will result in more precise estimates of intervention effects, while 
avoiding systematic error or bias will result in valid estimates. Internal validity refers to 
methodological rigour of a randomised trial or meta-analysis, whereas external validity refers 
to the extent to which results can be generalised to other circumstances.33 The focus of this 
thesis is on internal validity of randomised trials and meta-analyses. Bias might be defined as 
“any process at any stage of inference which tends to produce results or conclusions that 
differ systematically from the truth”,34 or more formally, the bias bθ of an estimator T for the 
parameter θ is  
(7) bθ (T) = Eθ (T) – θ,  
where Eθ (T) denotes the expected value of the estimator T. Thus, we estimate θ without 
bias if Eθ (T) = θ.  Different authors use different terminology for biases occurring in 
clinical trials. Throughout this thesis the following classification of bias will be used, 
which is explained below in more detail: selection bias (at study entry), performance bias, 
detection bias and attrition bias. In randomised trials, bias can occur at any stage during 
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the trial.33 Figure 3 shows different stages of a randomised trial and the measures that can 
be taken to minimise bias at these different stages.  
 
Figure 3: Measures to minimise bias at different stages of a randomised trial. 
Selection bias in randomised trials arises from biased allocation of patients to comparison 
groups, i.e. if not all patients have the same probability to be assigned to either group. 
Minimisation of selection bias is obtained by two interrelated steps: The generation of a 
random allocation sequence and the concealment of this sequence to prevent personnel 
assigning patients to treatment groups from foreseeing allocation. A random allocation 
sequence can be generated for example by coin tossing, dice throwing or by using a computer 
algorithm.33 Concealment of allocation is adequate if the investigators responsible for patient 
selection and inclusion are unable to know before allocation which treatment was next, for 
example, central randomisation; the use of sequentially numbered, sealed, and opaque 
assignment envelopes; or coded drug packs.33 Performance bias results from an unequal 
provision of care apart from treatments under evaluation. Procedures that prevent therapists 
and patients from knowing which intervention was received, i.e. blinding of therapists and 
patients will minimise this type of bias. Blinding can be achieved by using identically looking 
placebo tablets or by using sham interventions that are indistinguishable from the 
experimental interventions. Detection bias results from biased assessment of outcomes, and 
will be minimised by procedures that prevent outcome assessors from knowing which 
intervention was received, i.e. blinding of outcome assessors. Outcome assessors can be 
Concealment of allocation 
Blinding (patients/therapists) 
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Intention-to-treat analysis 
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blinded if they are independent (not therapists) or – in the case of therapist- or patient-
reported outcomes – if interventions are indistinguishable. Attrition bias will result from 
biased occurrence and handling of deviations from protocol and losses to follow-up. This type 
of bias will be minimised by procedures that prevent exclusion of randomised patients from 
the analyses and minimise protocol deviations and losses to follow-up. Adequate analyses 
include all randomised patients in the group they were originally allocated to, regardless of 
their adherence to the study protocol according to the intention-to-treat principle, avoiding 
any selective exclusion of patients after randomisation.33 35 
Meta-analyses results can be distorted by biases in individual randomised trials as described 
above, but also by bias across trials. For example, trials that do not show a significant benefit 
of the experimental intervention are less likely to be published than trials that found a 
significant result (publication bias).36 37 Bias can result from incomplete and selective 
reporting of outcomes38-40 (outcome reporting bias). Failure to publish non-significant results 
may distort meta-analyses results:41 publication and outcome reporting biases can result in 
overly optimistic estimates of treatment benefits, and can affect the precision of effect 
estimates from random-effects meta-analysis.42 43  
Other potential threats to the validity meta-analyses based on aggregate data relate to 
extraction of data from trial reports and multiplicity of data in trial reports. As meta-analyses 
are usually based on data that have already been processed, interpreted, and summarised by 
other researchers, data extraction can be complicated and can lead to important errors.44 There 
is often a multiplicity of data in trial reports that makes it difficult to decide which ones to use 
in a meta-analysis. Furthermore, data are often incompletely reported,38 44 which makes it 
necessary to perform calculations or impute missing data, such as missing standard 
deviations. Different observers may get different results, but previous studies on observer 
variation have not been informative, because of few observers, few trials, or few data.45 46  
Empirical evidence of bias 
The presence of different types of bias in randomised trials has been empirically assessed in 
several studies. A classical study was published by Schulz et al, who examined dimensions of 
methodological quality associated with estimated treatment effects in 250 randomised trials 
from 33 meta-analyses in pregnancy and childbirth.47 They found that estimates of treatment 
effects were larger in trials were associated with reporting of allocation concealment and 
double-blinding, but found no clear associations with generation of allocation sequence and 
exclusions from the analysis.47 Until now, several additional studies have been published that 
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examined associations between allocation concealment and estimated treatment benefits in 
binary outcomes.48-53 On average, trials with adequate allocation concealment showed more 
beneficial effects compared to trials without adequate concealment.52 However, the different 
studies employed slightly different definitions of adequate allocation concealment, included 
trials from different clinical areas and the results varied between different studies and the 
associations were less pronounced in more recent studies.52  
The association between blinding and estimated treatment benefits has been assessed in 
several studies using binary outcomes.47-53 Results in individual studies were less clear, but in 
a meta-analysis of all published meta-epidemiological studies, estimated treatment effects 
were more beneficial in trials with double-blinding compared to trials without double 
blinding.52 A pilot study including 35 randomised trials examined the associations between 
allocation concealment or blinding with estimated treatment effects in non-binary outcomes, 
but was underpowered to obtain conclusive results.54 To my knowledge, a single 
methodological study nested in a randomised controlled trial compared the effect of blinded 
and unblinded outcome assessments on apparent treatment benefits in a randomised trial and 
found that unblinded physicians were more likely to provide a favourable rating of the 
outcome in experimental group as compared with the control group.55 
The association of withdrawals, dropouts, and exclusions after randomisation with estimated 
treatment effects has been explored in four meta-epidemiological studies of binary 
outcomes.47 49 50 53 56 Direction and magnitude of attrition bias varied between different studies 
according to different methods and definitions used and different clinical areas addressed: 
attrition bias may result in both overestimation and underestimation of treatment effects, and 
its magnitude is difficult to predict.50 56 57 
Several studies reported evidence of within-trial selective reporting of outcomes. A 
comparison between trial protocols and published reports showed that reporting of outcomes 
is frequently incomplete, i.e. with insufficient information to be included in a meta-analysis 
and that statistically significant outcomes are more likely to be reported in trial 
publications.38-40 Trials published in languages other than English tend to be of lower quality 
and show more beneficial treatment effects than trials published in English.51 58 Broad 
literature searches and inclusion of unpublished trials and trials published in languages other 
than English will increase precision and may minimise bias.51 In addition, trials with more 
beneficial results are more likely to be published as full reports and the time to publication is 
shorter than for trials with less beneficial results.37 59 60 Meta-analyses including published 
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trials only, are therefore likely to overestimate treatment benefits. Funnel plots can be used as 
a tool to identify small study effects. Funnel plot asymmetry can arise from publication and 
reporting bias, poor methodological quality of smaller trials or true underlying heterogeneity 
due to differences in intensity of interventions or differences in characteristics of included 
patients between larger and smaller trials.61-63 Figure 4 shows an example of a funnel plot, 
where there is evidence of small study effects.64 Funnel plots are based on the fact that 
precision of an estimated treatment effect will increase as the sample size of component trials 
increases. Results from small trials with large standard errors will scatter widely at the bottom 
of a plot of treatment effect against standard error, with the spread narrowing among larger 
trials. In the absence of small study effects the plot will resemble a symmetrical inverted 
funnel. Conversely, if small study effects are present, funnel plots will often be 
asymmetrical.61 The plot can be enhanced by lines of the predicted treatment effect from 
meta-regression using that standard error as explanatory variable,65 a regression test of 
asymmetry61 62 and contours that divide the plot into areas of statistical significance and non-
significance.66 67 
 
Figure 4: Funnel plot for effects 
on knee pain showing evidence 
of small study effects. Numbers 
on x-axis refer to standardised 
mean differences, on y-axis to 
standard errors of standardised 
mean differences.64  
Based on the presented empirical evidence of bias, the Cochrane Collaboration recommends 
assessing risk of bias in included trials which involves the assessment and presentation of 
individual components, such as allocation concealment, blinding, incomplete outcome data 
and selective reporting.2 
The presence and extent of different types of bias might be related to the type of outcome 
assessed. In general, randomised controlled trials using subjective outcomes are more 
susceptible to bias than trials using objective outcomes such as overall mortality. In a 
combined analysis of data from three meta-epidemiological studies of binary outcomes across 
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different medical fields, the authors recently found that overestimations of treatment benefits 
were more pronounced for subjective outcomes as compared with objective outcomes such as 
overall mortality.68 To my knowledge, no studies so far have systematically assessed different 
types of bias in meta-analyses using patient-reported outcomes measured on continuous or 
rating scale. 
Meta-epidemiological research 
Meta-epidemiological studies examine the association of specific characteristics of a trial, 
such as concealment of allocation or blinding of patients, with estimated treatment effects in a 
collection of meta-analyses and their component trials.69 70 An early example of a meta-
epidemiological study using binary outcomes was published by Schulz et al (see above).47 
Different meta-meta-analytic approaches to the analysis of meta-epidemiological studies for 
binary outcomes expressed as odds ratios are presented in detail by Sterne and co-authors.70 A 
general approach to the analysis of meta-epidemiological studies is to calculate effect 
estimates (ratios of odds ratios or differences in effect sizes) within each meta-analysis. These 
effect estimates are then combined across meta-analyses using fixed or random effects meta-
analysis.70 In a first step, effect sizes are calculated separately for trials with adequate 
methodology and trials with inadequate methodology using standard random-effects models 
within each meta-analysis. This step yields an estimate of bias in each meta-analysis. In a 
second step, differences in effect sizes between trials with and without adequate methodology 
from individual meta-analyses are pooled across meta-analyses using fixed- or random-effects 
models. If the effect of a trial characteristic varies between meta-analyses, then analyses based 
on the fixed-effect approach will underestimate the uncertainty in estimated differences in 
effect sizes.70  
Meta-epidemiological studies are observational studies by design and results might therefore 
be affected by confounding. For example, trials with adequate allocation concealment may be 
more likely to use adequate blinding methods and the association between allocation 
concealment and estimated treatment benefits may be confounded by blinding. One approach 
is to control effect estimates for confounding factors separately in each meta-analysis by 
stratification in analogy to Mantel-Haenszel procedures or with random-effects meta-
regression and then combine these across meta-analyses as described above. This approach 
allows the confounding effect to vary across meta-analyses.70 71 In meta-regression models 
potential confounders can be added as regression terms, or interactions can be modelled to 
allow the average bias to vary according to another characteristic (e.g. type of outcome).72  
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Objective 
The overall objective of this thesis was to examine factors associated with bias and variation 
in meta-analyses of randomised clinical trials. These factors include methodological 
characteristics at the level of individual trials and problems with data extraction at the level of 
meta-analyses. 
Specifically, the objectives were to examine: 
• Whether excluding patients from the analysis of randomised trials is associated with 
biased estimates of treatment effects and higher heterogeneity between trials. (Article 1) 
• The association of adequate allocation concealment and patient blinding with estimates of 
treatment benefits in osteoarthritis trials. (Article 2) 
• The presence and extent of small study effects in clinical osteoarthritis research.  
(Article 3)  
• Whether potential variation between trials can be explained by biases affecting individual 
trials or by publication bias in a meta-analysis comparing transcutaneous 
electrostimulation with sham or no specific intervention in patients with knee 
osteoarthritis. (Article 4) 
• The inter-observer variation related to extraction of continuous and numerical rating scale 
data from trial reports for use in meta-analyses. (Article 5)  
• The scope for multiplicity in a sample of meta-analyses using the standardised mean 
difference as an effect measure and the impact of the multiplicity on the results.  
(Article 6)  
• How different methodological approaches such as funnel plots, stratified analyses 
accompanied by interaction tests and heterogeneity-adjusted trial sequential analysis 
contribute to our understanding of bias and inconclusive results in meta-analyses.  
(Article 7) 
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Abstract 
Objective To examine whether excluding patients from the analysis of randomised trials is 
associated with biased estimates of treatment effects and higher heterogeneity between trials. 
Design Meta-epidemiological study based on a collection of meta-analyses of randomised 
trials. 
Data sources 14 meta-analyses including 167 trials that compared therapeutic interventions 
with placebo or non intervention control in patients with osteoarthritis of the hip or knee and 
used patient reported pain as an outcome. 
Methods Effect sizes were calculated from differences in means of pain intensity between 
groups at the end of follow-up, divided by the pooled standard deviation. Trials were 
combined by using random effects metaanalysis. Estimates of treatment effects were 
compared between trials with and trials without exclusions from the analysis, and the impact 
of restricting meta-analyses to trials without exclusions was assessed. 
Results 39 trials (23%) had included all patients in the analysis. In 128 trials (77%) some 
patients were excluded from the analysis. Effect sizes from trials with exclusions tended to be 
more beneficial than those from trials without exclusions (difference −0.13, 95% confidence 
interval −0.29 to 0.04). However, estimates of bias between individual meta-analyses varied 
considerably (τ2=0.07). Tests of interaction between exclusions from the analysis and 
estimates of treatment effects were positive in five meta-analyses. Stratified analyses 
indicated that differences in effect sizes between trials with and trials without exclusions were 
more pronounced in meta-analyses with high between trial heterogeneity, in meta-analyses 
with large estimated treatment benefits, and in meta-analyses of complementary medicine. 
Restriction of meta-analyses to trials without exclusions resulted in smaller estimated 
treatment benefits, larger P values, and considerable decreases in between trial heterogeneity. 
Conclusion Excluding patients from the analysis in randomised trials often results in biased 
estimates of treatment effects, but the extent and direction of bias is unpredictable. Results 
from intention to treat analyses should always be described in reports of randomised trials. In 
systematic reviews, the influence of exclusions from the analysis on estimated treatment 
effects should routinely be assessed. 
 
Article 1: Excluding patients from the analysis in randomised controlled trials 
28 
Introduction 
In clinical trials, deviations from protocol and losses to follow-up often lead to the exclusion 
of some randomised patients from the analysis.1 2 Patients excluded after randomisation are 
unlikely to be representative of patients remaining in the trial. For example, patients may not 
be available for follow-up because they have an acute exacerbation of their condition or 
severe side effects,3 and patients with protocol deviations may have a worse prognosis than 
those adhering to the protocol.4 The selective occurrence and biased handling of protocol 
deviations and losses to follow-up may lead to results that differ systematically from the true 
values. This is generally referred to as attrition bias.2 To ensure that intervention and control 
groups are comparable and to prevent attrition bias, all randomised patients should be 
included in the analysis and kept in their original groups, regardless of their adherence to the 
study protocol. In other words, the analysis should be done according to the intention to treat 
principle, avoiding any selective exclusion of patients after randomisation.2 5 
Meta-epidemiological studies examine the association of specific characteristics of a trial, 
such as concealment of allocation or blinding of patients, with estimated treatment effects in a 
collection of meta-analyses and their component trials.6 7 The association of withdrawals, 
dropouts, and exclusions after randomisation with estimated treatment effects has been 
explored in four meta-epidemiological studies of binary outcomes.1 6 8-10 The direction and 
magnitude of attrition bias varied between different studies according to different methods 
and definitions used and different clinical areas addressed: attrition bias may result in both 
overestimation and underestimation of treatment effects, and its magnitude is difficult to 
predict.1 9 11 12 In general, randomised controlled trials using subjective outcomes are more 
susceptible to bias than trials using objective outcomes such as overall mortality. A recent 
study found that bias associated with the lack of allocation concealment and lack of blinding 
was restricted to trials using subjectively assessed outcomes.12 In trials of osteoarthritis, 
treatment effects are often evaluated using subjective outcomes, such as intensity of pain or 
disability measured on visual analogue, numerical rating, or Likert scales, whereas objective 
binary outcomes, such as mortality, are addressed rarely. Meta-analyses of osteoarthritis trials 
may therefore be particularly prone to attrition bias associated with exclusions of patients 
from the analysis.2 
We carried out a meta-epidemiological study to assess the impact of attrition bias in meta-
analyses of non-binary patient reported outcomes, such as pain intensity. We examined 
whether excluding patients from the analysis were associated with biased estimates of 
Article 1: Excluding patients from the analysis in randomised controlled trials 
29 
treatment effects and with increased heterogeneity between trials in meta-analyses of 
interventions used for the treatment of pain in osteoarthritis. 
Methods 
Search and selection of meta-analyses and component trials 
We searched the Cochrane Library, Medline, Embase, and CINAHL using a combination of 
keywords and text words related to osteoarthritis. These were combined with validated filters 
for systematic reviews and meta-analyses.13 The last update was carried out on 20 November 
2007 (see web extra appendix table 1 for details of search strategy). 
We included meta-analyses of randomised or quasi-randomised trials in patients with 
osteoarthritis of the knee or hip. Trials using an unpredictable allocation sequence were 
considered as randomised, trials using potentially predictable allocation mechanisms, such as 
alternation or the allocation of patients according to their date of birth, were considered as 
quasi-randomised. Meta-analyses were eligible if they assessed patient reported pain 
comparing any intervention with placebo, sham, or a non-intervention control. Two reviewers 
independently evaluated the reports for eligibility, and disagreements were resolved by 
discussion. If necessary a third reviewer was consulted to reach consensus. Reports of all 
component trials were obtained, and no language restrictions were applied. 
Data collection and quality assessment 
Two reviewers used a standardised form to independently extract data from the original 
reports of individual trials on interventions, funding, year of publication, publication 
language, design, study size, blinding of patients, losses to follow-up, exclusions, handling of 
missing data, and results. When necessary we approximated means and measures of 
dispersion from figures. For crossover trials we extracted data from the first period only.14 
Disagreements were resolved by discussion with a third reviewer and subsequent consensus.  
Trials were classified to have had no exclusions of patients from the analysis if there was an 
explicit statement that all randomised patients were included in the analysis of the outcome 
we extracted or if the reported numbers of patients randomised and analysed on this outcome 
were identical. We classified trials to have had exclusions if they explicitly reported 
exclusions from the analysis, if the number of patients analysed was lower than the number of 
patients randomised, or if it was unclear whether exclusions from the analysis had occurred. 
Concealment of treatment allocation was considered adequate if the investigators responsible 
for patient inclusion were unable to suspect before allocation which treatment was next—
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central randomisation or the use of sequentially numbered, sealed, and opaque randomisation 
envelopes was deemed adequate, for example. Blinding of patients was considered adequate if 
experimental and control interventions were described as indistinguishable or if a double 
dummy technique was used.2 
Outcome measures 
The primary outcome was patient reported pain. If different pain outcomes were reported we 
extracted one outcome per study according to a hierarchy described previously.15 16 If more 
then one time point was reported we extracted the latest time point up to three months after 
the end of treatment for potentially structure modifying agents and up to 12 months after the 
end of treatment for behaviour changing interventions. For all other interventions we 
extracted the outcome at the end of treatment. 
Statistical analysis 
We expressed treatment effects as effect sizes by dividing the difference in mean values at the 
end of follow-up by the pooled standard deviation. Negative effect sizes indicate a beneficial 
effect of the experimental intervention. If some required data were unavailable we used 
approximations as previously described.16 If a trial was included in more than one meta-
analysis we inflated standard errors to avoid double counting of patients—for example, if the 
control group of a trial with three arms was included in two different metaanalyses, we 
inflated the standard error of the estimate for the control group by √2. We used standard 
inverse variance random effects meta-analyses to combine effect sizes across trials and 
calculated the variance estimate τ2 as a measure of heterogeneity.17 
Within each meta-analysis we used random effects meta-analysis to estimate effect sizes 
separately for trials with and trials without exclusions of patients from the analysis. Then we 
derived differences between estimates from trials with exclusions and trials without 
exclusions for each meta-analysis and combined these differences using random effects meta-
analysis, which fully accounted for the variability in bias between meta-analyses.7 A negative 
difference in effect sizes indicates that trials with exclusions show a more beneficial treatment 
effect. Meta-analyses including only trials with exclusions or only trials without exclusions 
did not contribute to the analysis. Formal tests of interaction between exclusions from the 
analysis and estimated treatment benefits were done separately for each meta-analysis based 
on z scores for estimated differences in effect sizes between trials with and trials without 
exclusions and the corresponding standard errors. We carried out stratified analyses 
accompanied by interaction tests according to the following characteristics: between trial 
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heterogeneity in the overall meta-analysis (low, τ2<0.06, v high, τ2≥0.06), treatment benefit in 
the overall meta-analysis (small, effect sizes >−0.5, v large, effect sizes ≤−0.5),15 18 and type 
of intervention assessed in the meta-analysis (drug v other interventions, conventional v 
complementary medicine). A τ2 of 0.06 corresponds to a difference between smallest and 
largest effect sizes of about 1 standard deviation unit.19 To control confounding by 
concealment of allocation and by patient blinding, we used stratification by these factors to 
derive differences between trials with and trials without exclusions adjusted for concealment 
of allocation and adjusted for patient blinding. 
Finally, we compared pooled effect sizes, between trial heterogeneity, precision defined as the 
inverse of the standard error, and P values for pooled effect sizes between overall random 
effects meta-analyses including all trials and restricted meta-analyses including trials without 
exclusions only. Measures were compared using scatter plots and Wilcoxon rank tests for 
paired observations. P values were two sided. All analyses were done in STATA version 10. 
Results 
Characteristics of included meta-analyses 
Overall, 354 reports of reviews of interventions in osteoarthritis were identified (fig 1). 
Seventeen reports including 21 meta-analyses were eligible. Of these, 14 meta-analyses 
included at least one trial with and one without exclusion of patients from the analysis and 
contributed to the study.16 20-30  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Identification of meta-analyses in 
osteoarthritis 
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Table 1 shows the characteristics of the included meta-analyses. The metaanalyses included 
167 trials in 41 170 patients. Eight meta-analyses assessed the efficacy of drug interventions 
and five assessed interventions in complementary medicine. The number of trials per 
metaanalysis ranged from three to 24 (median 11) and the number of patients contributing to 
the meta-analysis from 278 to 13 659 (median 1731). The pooled effect sizes derived from 
random effects meta-analyses including all trials ranged from −0.07, indicating essentially no 
benefit, to −0.88, representing a large benefit (median −0.40). All meta-analyses favoured the 
experimental intervention and 11 of 14 showed statistically significant differences between 
experimental and control intervention at the conventional level of P=0.05. The variance τ2 as a 
measure of between trial heterogeneity varied between 0.00 and 0.52 (median 0.04, table 1). 
 
Characteristics of component trials 
Table 2 shows the characteristics of included trials. In total, 39 of the 167 trials (23%) 
included all randomised patients in the analysis. In 114 trials (69%) there were exclusions, 
and in 14 trials (8%) it was unclear whether exclusions had occurred. Exclusions ranged from 
0.1% to 40% (median 7.2%). Trials with exclusions were less likely to provide information on 
losses to follow-up (P=0.002). Data imputations using the last observation carried forward 
method were reported by 27% of trials with exclusions and 49% of trials without exclusions, 
multiple imputation by 4% and 15%, and for 68% and 15% it was unclear how the trialists 
dealt with missing data in the analysis. Trials with exclusions were published earlier (mean 
1998, SD 6) than trials without exclusions (2001, SD 4; P=0.002) and tended to report 
adequate concealment of allocation and sample size calculations less often. No clear  
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differences were observed for blinding, reporting of primary outcome, type of intervention, 
source of funding, and language of publication. 
Effect of exclusions on estimates of treatment effects 
Figure 2 shows the forest plot of differences in effect sizes between trials with and trials 
without exclusions across the 14 meta-analyses. On average, treatment effects were more 
beneficial in trials with exclusions than in trials without exclusions (difference in effect sizes 
−0.13, 95% confidence interval −0.29 to 0.04, P=0.13), but the variability in bias between 
meta-analyses was considerable (τ2=0.07, P<0.001). Differences in effect sizes ranged from 
−0.82 to 0.35. Tests of interaction between exclusions from the analysis and estimates of 
treatment effects were positive at the conventional level of P=0.05 in five meta-analyses: in 
four meta-analyses estimated effects were more beneficial in trials with exclusions from the 
analysis and in one meta-analysis estimated effects were more beneficial in trials without 
exclusions (fig 2). 
 
Figure 2 Difference in effect sizes between 128 trials with and 39 trials without exclusions of patients 
from analysis. A negative difference in effect sizes indicates that trials with exclusions of patients from 
analysis show more beneficial treatment effects. P values are for interaction between exclusions from 
analysis and effect sizes. Meta-analyses are ordered according to year of publication. NSAIDs=non-
steroidal anti-inflammatory drugs; TENS=transcutaneous electrical nerve stimulation 
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Figure 3 presents results of stratified analyses. Differences between trials with and trials 
without exclusions were evident in meta-analyses with a high degree of between trial 
heterogeneity, but not in meta-analyses with low between trial heterogeneity (P for interaction 
<0.001). Similarly, differences were more pronounced in meta-analyses with large estimated 
treatment benefits in the overall meta-analysis compared with metaanalyses with small 
estimated benefits (P for interaction <0.001) and in meta-analyses of complementary 
interventions compared with conventional medicine (P for interaction <0.001). When 
stratifying for these characteristics, the variability in bias decreased considerably. For 
example, τ2 was 0.03 in meta-analyses of complementary medicine and 0.02 in meta-analyses 
of conventional medicine. When adjusting for concealment of allocation (−0.11, 95% 
confidence interval −0.28 to 0.05, P=0.18) or patient blinding (−0.15, −0.30 to 0.00, 
P=0.047), average differences between trials with and trials without exclusions of patients 
were robust. In both adjusted analyses the variability in bias between meta-analyses was much 
the same as in the primary analysis, with variance estimates τ2 of 0.08 (P<0.001) and 0.06 
(P<0.001), respectively. 
 
Figure 3 Differences in effect sizes between 128 trials with and 39 trials without exclusions of patients from 
analysis stratified according to four characteristics of meta-analyses. See table 1 for a description of meta-
analyses according to these characteristics. A τ2 <0.06 indicates low between trial heterogeneity and a τ2 ≥0.06 
high between trial heterogeneity. An effect size >–0.5 indicates a small benefit of the experimental intervention 
and an effect size ≤–0.5 a large benefit. A negative difference in effect sizes indicates that trials with exclusions 
of patients from analysis show a more beneficial treatment effect. Variability in bias between-meta-analyses is 
expressed as heterogeneity variance τ2 
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Impact of restricting meta-analyses to trials without exclusions 
Figure 4 presents comparisons of overall meta-analyses including all trials with restricted 
meta-analyses including trials without exclusions only. After the restriction the number of 
trials included in a single meta-analysis decreased from a median of 11 to a median of 2 and 
the number of patients from a median of 1731 to a median of 401. Estimates of treatment 
benefits decreased in 10 meta-analyses and increased in four (P=0.10). Between trial 
heterogeneity decreased in 12 meta-analyses and increased in one (P=0.006). For one meta-
analysis only one trial had no exclusions from the analysis, and no between trial heterogeneity 
could be estimated after the restriction.30 Precisions of pooled effect size estimates decreased 
in nine meta-analyses and increased in five (P=0.25). P values became larger in 10 meta-
analyses and smaller in four (P=0.016). After the restriction to trials without exclusions only, 
six meta-analyses lost statistical significance at the conventional level of P=0.05. 
 
Figure 4 Effect sizes, between trial heterogeneity τ2, precision, and P values of overall treatment benefits 
compared between overall meta-analyses including trials with and without exclusions of patients (x axis) and 
restricted meta-analyses including trials without exclusions of patients only (y axis). Dashed line indicates that 
estimates are identical. P values are derived from Wilcoxon rank tests for paired observations. 
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Discussion  
In this meta-epidemiological study of 14 meta-analyses and 167 trials we found that 
excluding randomised patients from the analysis often resulted in biased estimates of 
treatment effects. The average estimate of bias of a difference in effect size of −0.13 may 
seem small (fig 2), however it corresponds to one quarter to one half of a typical treatment 
effect found for interventions in osteoarthritis.15 The impact of exclusions on estimates of 
treatment effects seemed most pronounced in meta-analyses with large treatment benefits, 
metaanalyses on complementary interventions, and metaanalyses with a high degree of 
heterogeneity between trials, but the extent and direction of bias may be unpredictable in a 
specific situation. Tests of interaction between exclusions from the analysis and estimates of 
treatment effects were statistically significant in five meta-analyses; in four of these meta-
analyses, estimated treatment effects were less beneficial in trials without exclusions. 
When restricting meta-analyses to trials without exclusions, P values increased in most cases 
and six meta-analyses lost statistical significance at P=0.05 (fig 4). This increase in P values 
was not only due to a loss of statistical power.31 As a result of the restriction the between trial 
heterogeneity τ2 decreased considerably. Therefore the average loss of statistical precision of 
random effects meta-analyses was smaller than what could be expected after the exclusion of 
over half the trials. Only in five meta-analyses was there a relevant loss of precision after the 
restriction, in six meta-analyses the statistical precision remained much the same, and in three 
meta-analyses the precision increased. 
Strengths and limitations of the study 
In practice, various definitions of the intention to treat principle are used.5 32 In our study we 
did not rely on statements in the trial reports on whether an intention to treat analysis was 
done or not. Rather we required explicit information about the flow of patients through the 
study33 34 or clear statements that all randomised patients were included in the analysis. Some 
might argue that our distinction between trials with and trials without exclusions from the 
analysis was overly stringent. The exclusion of only a small proportion of patients from the 
analysis, for example, may be considered unlikely to have any impact on estimated treatment 
benefits. We would expect that any bias associated with exclusions from the analysis will 
increase with the number of exclusions. Therefore the overall estimate of bias might increase 
with the selection of a less rigorous cut off. Others may argue that our classification was not 
stringent enough and that we should have required an affirmative statement that no crossovers 
had occurred and that all randomised patients were included in the analysis in the group to 
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which they were originally allocated. Only seven of the 167 included trials (4%) explicitly 
provided this information, so we were unable to examine this issue. 
As with other meta-epidemiological studies,69 our study is based on published information 
and depends on the quality of the trial reports. Even though the quality of reporting is 
generally low,35 36 we were able to determine in all but 14 trials whether exclusions from the 
analysis had occurred. Compared with previous meta-epidemiological studies,1 6 8-10 
misclassification of trials due to inadequate reporting11 is therefore less likely to have 
introduced bias in our study. At least two thirds of the trials included in our study had 
incomplete outcome data. Two approaches towards imputation of missing data are generally 
used to replace missing data and allow an intention to treat analysis: the last observation 
carried forward method and multiple imputation. We were unable to examine whether the 
approach used for data imputation influences estimates of treatment effects because of the 
strikingly low quality of reporting.32 34 35 Other types of bias that may affect the results of 
randomised trials include selection bias due to inadequate concealment of allocation, and 
performance and assessor bias due to a lack of blinding of patients and therapists.2 12 In our 
study, the observed association between exclusions of patients from the analysis and estimates 
of treatment effects could be confounded by concealment of allocation: trials with exclusions 
tended to report adequate concealment of allocation less often than trials without exclusions. 
This correlation may have resulted in spurious associations. When accounting for 
concealment of allocation in a sensitivity analysis, however, we found our results to be robust. 
Finally, characteristics of meta-analyses were also correlated. For example, meta-analyses in 
complementary medicine were likely to show large treatment benefits and a high degree of 
heterogeneity between trials. Our understanding of the interplay of these characteristics is 
incomplete. Therefore the results of our stratified analyses (fig 3) should to be interpreted 
with caution. A detailed examination of that problem would require a much larger set of meta-
analyses. 
Context 
As is the case for other types of bias,12 the extent of attrition bias might depend on the type of 
outcome. Ours is the first meta-epidemiological study to investigate pain as a patient reported 
outcome, a measure extensively used in research on osteoarthritis.15 This outcome is more 
prone to bias than objective binary outcomes such as mortality.12 Four studies have examined 
the impact of attrition bias on estimates of treatment benefits in randomised controlled trials 
and meta-analyses on an odds ratio scale.1 6 8-10 The direction and magnitude of attrition bias 
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varied between different studies according to different methods and definitions used, different 
clinical areas addressed, and the potential for misclassification of trials because of inadequate 
reporting.6 8-10 A recent study used individual patient data and found that analyses with 
patients excluded showed more beneficial effects of the experimental treatment than analyses 
according to the intention to treat principle.1 Another study of placebo controlled trials of 
serotonin reuptake inhibitors sponsored by the pharmaceutical industry found that the 
experimental intervention was favoured less in intention to treat analyses than in per protocol 
analyses. Many published reports of these trials ignored the results of intention to treat 
analyses and reported only the more favourable per protocol analyses.37 Several authors 
pointed out that attrition bias can go in either direction and is difficult to predict for a specific 
situation,1 2 which is in accordance with our findings of highly variable effects between meta-
analyses. Previous meta-epidemiological studies, which examined the effect of exclusions 
from the analysis,1 6 8-10 might be reanalysed in the light of our results to examine the 
variability in bias associated with exclusions. 
Implications 
The intention to treat principle aims to compare patients in the groups to which they were 
originally allocated. The most stringent interpretation of intention to treat includes the 
analysis of all patients, regardless of whether they were eligible, received treatment, and 
adhered to the protocol.5 In practice, various interpretations are used, some of which allow for 
exclusions after randomisation. Many trialists exclude randomised patients who did not 
receive at least one dose of the allocated intervention, whereas others exclude patients found 
retrospectively to be ineligible.5 38 Both approaches to excluding patients from the analysis 
may produce unbiased estimates if patients and treating doctors are unaware of the allocated 
intervention and if the decision to exclude patients is based solely on information collected 
before randomisation and unrelated to group assignment and clinical outcome.38 In addition, 
exclusions from the analysis owing to randomly missing outcome data may be less 
problematic than the selective exclusion of patients owing to protocol violations. These 
assumptions are hardly ever verifiable: details on the flow of participants through the various 
stages of a trial and descriptions of procedures used to determine whether patients should be 
excluded from the analysis are often omitted from published reports of randomised trials.5 34 
Therefore it is difficult to determine from published information whether reported exclusions 
from the analyses resulted in bias,2 and strict adherence to the intention to treat principle 
should be advocated.33 39 
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The purpose of an intention to treat analysis is to preserve an unbiased treatment allocation 
and the prognostic balance between treatment groups. In contrast, per protocol analyses 
include only those patients who received treatment as defined in the study protocol and 
provided outcome data. Patients excluded from per protocol analyses are likely to be different 
from those analysed: they may have had an acute exacerbation of the studied condition or 
experienced side effects of the evaluated intervention.3 Trials without exclusions more often 
reported imputations of missing data than those with exclusions. The last observation carried 
forward approach was used most often: missing values were replaced by the last value 
observed. This method is popular for imputation of missing data in musculoskeletal research40 
41 but leads to overly precise estimates and potential bias.42 43 Multiple imputation is more 
difficult to carry out but avoids those problems44: each missing value is replaced by multiple 
simulated values, and the analysis of the resulting multiple versions of the complete dataset 
can account for the uncertainty about missing data. The CONSORT statement urges 
transparent reporting of the flow of participants through the various stages of a trial, including 
a description of withdrawals and losses to follow-up and the reasons for exclusions from the 
analysis.33 39 In our view a detailed description of strategies used to handle missing outcome 
data is also essential. 
Conclusions 
The box summarises our recommendations for practice. Excluding patients from the analysis 
often results in biased estimates of treatment effects in randomised trials. To avoid potential 
attrition bias, trialists should ensure low dropout rates and high compliance rates and 
minimise missing outcome data. Results of intention to treat analyses, which are based on the 
inclusion of all patients in the analysis in the group to which they were originally allocated, 
should always be reported. Sensitivity analyses, which are restricted to patients adhering to 
the protocol, may be described in addition. In systematic reviews and meta-analyses, data 
extraction should be based on results from analyses of all randomised patients, whenever 
possible. The influence of exclusions from analysis on estimated treatment benefits should be 
routinely assessed in stratified analyses. This may be particularly important in complementary 
medicine, in the presence of high heterogeneity between trials, and when pooled effect sizes 
indicate a large benefit of evaluated interventions.
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Recommendations for practice 
• Since excluding patients from the analysis often results in biased estimates of treatment 
effects, trialists should ensure low dropout rates and high compliance rates and minimise 
missing outcome data 
• Trialists should always report results of intention to treat analyses, including all 
randomised patients in the analysis in the group to which they were originally allocated. 
If data imputations are necessary to carry out an intention to treat analysis, multiple 
imputation should be used to replace missing data 
• Those critically appraising trials should generally rely on results from intention to treat 
analyses 
• Authors of systematic reviews should routinely examine the influence of exclusions from 
the analysis on estimated treatment effects. In case of discrepancies between trials with 
and trials without exclusions, trials without exclusions should be given precedence 
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Appendix Table 1 Search strategy 
Medline, Embase, Cinahl were searched via the Ovid platform (www.ovid.com) using the 
search strategy below. The Cochrane Library was searched using the search strategy below 
without the methodological filters for human studies and systematic reviews/meta-analyses. 
The search was last updated November 20, 2007. 
1. osteoarthriti$.ti,ab,sh. 
2. osteoarthro$.ti,ab,sh. 
3. gonarthriti$.ti,ab,sh. 
4. gonarthro$.ti,ab,sh. 
5. coxarthriti$.ti,ab,sh. 
6. coxarthro$.ti,ab,sh. 
7. arthros$.ti,ab. 
8. arthrot$.ti,ab. 
9. ((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or discomfort$)).ti,ab. 
10. ((knee$ or hip$ or joint$) adj3 stiff$).ti,ab. 
11. or/1-10 
12. animal.sh. 
13. human.sh. 
14. 12 and 13 
15. 12 not 14 
16. Cochrane database of systematic reviews.jn. 
17. search.tw. 
18. meta-analysis.pt. 
19. Medline.tw. 
20. systematic review.tw. 
21. or/16-20 
22. 11 not 15 
23. 21 and 22 
24. remove duplicates from 23 
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Abstract 
Objective To evaluate the association of adequate allocation concealment and patient 
blinding with estimates of treatment benefits in osteoarthritis trials. 
Methods We performed a meta-epidemiologic study of 16 meta-analyses with 175 trials that 
compared therapeutic interventions with placebo or non intervention control in patients with 
hip or knee osteoarthritis. We calculated effect sizes from the differences in means of pain 
intensity between groups at the end of follow-up divided by the pooled SD and compared 
effect sizes between trials with and trials without adequate methodology. 
Results Effect sizes tended to be less beneficial in 46 trials with adequate allocation 
concealment compared with 112 trials with inadequate or unclear concealment of allocation 
(difference -0.15; 95% confidence interval [95% CI] -0.31, 0.02). Selection bias associated 
with inadequate or unclear concealment of allocation was most pronounced in meta-analyses 
with large estimated treatment benefits (P < 0.001 for interaction), meta-analyses with high 
between-trial heterogeneity (P = 0.009), and meta-analyses of complementary medicine (P = 
0.019). Effect sizes tended to be less beneficial in 64 trials with adequate blinding of patients 
compared with 58 trials without (difference -0.15; 95% CI -0.39, 0.09), but differences were 
less consistent and disappeared after accounting for allocation concealment. Detection bias 
associated with a lack of adequate patient blinding was most pronounced for non-
pharmacologic interventions (P < 0.001 for interaction). 
Conclusion Results of osteoarthritis trials may be affected by selection and detection bias. 
Adequate concealment of allocation and attempts to blind patients will minimize these biases. 
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Introduction 
Inadequate methodology may flaw the results of randomized osteoarthritis trials.1 Meta-
epidemiologic studies examine the association of specific trial characteristics, such as 
concealment of allocation or patient blinding, with estimated treatment effects in a collection 
of meta-analyses and their component trials.2–5 In meta-analyses of these meta-epidemiologic 
studies, inadequate concealment of allocation and a lack of double blinding were associated 
with exaggerated estimates of treatment benefits.1,6 In a combined analysis of data from 3 
meta-epidemiologic studies of binary outcomes across different medical fields, we recently 
found that overestimations of treatment benefits were more pronounced for subjective 
outcomes as compared with objective outcomes such as overall mortality.4 Subjective 
outcomes, such as patient-reported pain intensity measured on visual analog, numeric rating, 
or Likert scales, are frequently used in osteoarthritis trials, whereas objective binary 
outcomes, such as mortality, are rarely addressed.7–9 
We performed a meta-epidemiologic study in the field of clinical osteoarthritis research to 
determine whether components of methodologic quality are associated with overestimates of 
treatment effects. We previously reported that the exclusion of randomized patients from the 
analysis was associated with likely overestimates of treatment benefits in osteoarthritis trials, 
but the extent and direction of this attrition bias resulting from the biased exclusion of patients 
after entry into the trial remained unpredictable in a specific situation.5 Bias may also occur at 
earlier stages of a trial: selection bias through the biased allocation of patients to comparison 
groups at trial entry if the allocation of patients is not adequately concealed, and detection and 
performance bias if blinding of patients is inadequate, which may result in biased assessment 
of self reported outcomes, differential placebo or nocebo effects across comparison groups, 
and the unequal intake of analgesic cointerventions apart from the treatment under 
evaluation.1 Here we report on the association of estimates of treatment benefits with the 
adequacy of concealment of allocation and patient blinding in clinical osteoarthritis research. 
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Materials and Methods 
Searches and selection of meta-analyses. We searched The Cochrane Library, Medline, 
EMBase, and CINAHL using a combination of keywords and text words related to 
osteoarthritis, which were combined with validated filters for controlled clinical trials and 
meta-analyses. Details of the search strategy are described elsewhere.5 The last update was 
performed on November 20, 2007. 
Meta-analyses of randomized or quasi-randomized trials in patients with osteoarthritis of the 
knee or hip were eligible if they evaluated patient-reported pain in patients allocated to any 
intervention compared with patients allocated to placebo, a sham intervention, or a non-
intervention control group. If one topic was covered by several reports, the most recent report 
was included. Two reviewers independently evaluated the reports for eligibility and 
disagreements were resolved by discussion or by involvement of a third reviewer. Reports of 
all component trials were obtained and no language restrictions were applied. 
Data extraction. Two reviewers independently extracted data from individual trials regarding 
interventions, funding, publication year, design characteristics, study size, and results on a 
standardized form. The primary outcome was pain intensity. If different pain-related 
outcomes were reported, we referred to a previously described hierarchy of outcomes9,10 and 
extracted the outcome that was highest on this list. Global pain took precedence over pain on 
walking and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
pain subscores, for example. If a trial report provided data on global pain scores and 
WOMAC pain subscores, we only recorded data on global pain scores. If more than one time 
point was reported, we extracted the outcome at 3 months after the end of treatment for 
potentially structuremodifying agents, such as chondroitin, and at 12 months after the end of 
treatment for behavior-changing interventions, such as education. For all other interventions, 
we extracted the outcome at the end of treatment. When necessary, means and measures of 
dispersion were approximated from figures. For crossover trials, we extracted data from the 
first period only.11 Disagreements were discussed with a third reviewer and subsequent 
consensus was reached. 
Quality assessment. Concealment of allocation was considered adequate if the investigators 
responsible for patient selection and inclusion were unable to know before allocation which 
treatment was next, e.g., central randomization; the use of sequentially numbered, sealed, and 
opaque assignment envelopes; or coded drug packs. Concealment of allocation of trials, 
which lacked a specific statement, was classified as unclear. Patient blinding was considered 
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adequate if a placebo or sham control intervention was used and experimental and control 
interventions were described as indistinguishable or the use of a double dummy technique 
was reported. Analyses were considered to be performed adequately according to the intent-
to-treat principle if all of the randomized patients were included in the analysis.5 The 
definitions of different types of bias in randomized trials and measures to minimize them are 
provided in Table 1. 
 
Data synthesis. Treatment effects were expressed as effect sizes (ES), dividing the difference 
in mean values at the end of the trial by the pooled SD.10 A negative ES indicates a beneficial 
effect of the experimental intervention. If some required data were unavailable, we used 
approximations as previously described.10 We used standard random-effects meta-analyses to 
combine ES across trials and calculated the DerSimonian and Laird estimate of the variance 
τ2 to determine heterogeneity between trials.12,13 
Within each meta-analysis, we estimated the ES of trials with and without adequate allocation 
concealment separately using a random-effects meta-analysis. For each meta-analysis, we 
derived the difference between pooled estimates from trials with adequate allocation 
concealment and trials without adequate allocation concealment. Then we combined these 
differences using a random-effects meta-analysis fully allowing for heterogeneity between 
meta-analyses,3 and measured the variability in bias estimates between meta-analyses using τ2 
as a measure of heterogeneity.13 Formal tests of interaction between concealment of allocation 
and estimated treatment benefits were performed separately for each meta-analysis based on Z 
scores for the estimated difference in ES between trials with and without adequate 
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concealment of allocation and the corresponding SE. In sensitivity analyses, we additionally 
stratified by patient blinding and intent-to-treat analysis to account for potential confounding 
by these factors. The same procedure was followed for trials with and without adequate 
blinding of patients. A negative difference in ES indicates that trials with adequate allocation 
concealment or adequate patient blinding show a less beneficial treatment effect. Then we 
performed stratified analyses accompanied by interaction tests based on Z scores according to 
the following prespecified characteristics:5 treatment benefit in overall meta-analysis (small 
[ES greater than -0.5] versus large [ES less than or equal to-0.5]), between-trial heterogeneity 
in overall metaanalysis (low [τ2 <0.06] versus high [τ2 ≥0.06]), and type of intervention 
assessed (pharmacologic versus nonpharmacologic interventions; conventional versus 
complementary medicine). The prespecified cutoff of τ2 = 0.06 corresponds to a difference 
between the smallest and largest ES of approximately 1 ES. 
Finally, we compared pooled ES, between-trial heterogeneity, precision defined as 1/SE, and 
P values for pooled ES between random-effects meta-analyses including all trials and 
restricted to meta-analyses including trials with adequate concealment of allocation or 
adequate patient blinding only using Wilcoxon’s rank tests for paired observations. All P 
values were 2-sided. All analyses were performed with Stata statistical software, version 10.1 
(StataCorp, College Station, TX). 
Results 
Selection and characteristics of meta-analyses. We identified 151 reports of meta-analyses 
of osteoarthritis trials. A total of 134 reports were excluded because they either included no 
continuous pain outcome (n = 43), covered duplicate topics (n = 83), or used only active 
control interventions (n = 8).5 One report described 4 meta-analyses and one report described 
2 meta-analyses. Therefore, 21 meta-analyses described in 17 reports were eligible,5 and 16 
meta-analyses of 175 trials and 41,142 patients10,14–24 contributed to the analyses. 
Characteristics of the included meta-analyses are shown in Supplementary Appendix A. The 
median treatment benefit in the 16 included meta-analyses was an ES of -0.43 (range -0.88 to 
-0.07) with a median between-trial heterogeneity variance of 0.04 (range 0.00–0.52). Four 
meta-analyses showed a large treatment effect10,15,21 and 7 showed a high degree of between-
trial heterogeneity.10,15–17,21 Seven meta-analyses addressed pharmacologic 
interventions10,14,15,17,22,24 and 9 addressed nonpharmacologic treatments.16,18 –21,23 Nine were 
related to conventional interventions14,17–20,22–25 and 7 were related to complementary 
medicine.10,15,16,21 
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Concealment of allocation. Fourteen meta-analyses with 158 trials and 40,437 patients 
included both trials with and without adequate concealment of allocation and contributed to 
the analysis. Table 2 shows a comparison of the characteristics of these trials. Forty-six trials 
(29%) reported adequate allocation concealment and 111 trials (70%) were unclear about 
concealment of allocation. One trial (1%) was quasi-randomized using alternation, and 
allocation concealment was considered inadequate. Of trials with adequate concealment, 26  
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(56%) used coded drug packs or devices; 15 (33%) used central randomization; 4 (9%) used 
sequentially numbered, sealed, and opaque assignment envelopes; and 1 (2%) used an onsite 
computer system with allocations kept in a locked unreadable computer file that could be 
accessed only after the characteristics of an enrolled participant were entered into the 
database. Four trials that reported the use of assignment envelopes were not deemed to have 
adequate concealment of allocation because they did not specify that the envelopes were 
sequentially numbered, sealed, and opaque. Trials with adequate allocation concealment were 
more likely to report adequate blinding of patients (P = 0.008) and to perform intent-to-treat 
analyses (P = 0.07), were larger (P = 0.021), and were published more recently (P < 0.001) 
than trials with inadequate or unclear concealment of allocation.  
Figure 1A shows the forest plot of differences in ES between trials with and trials without 
adequate concealment. Trials with adequate allocation concealment tended to show smaller 
treatment benefits than trials with inadequate or unclear concealment, with a difference in ES 
of -0.15 (95% confidence interval [95% CI] -0.31, 0.02; P = 0.08). Differences in ES between 
trials with and trials without adequate concealment ranged from -1.07 to 0.46, and the 
variability in bias estimates between meta-analyses was moderate, with a τ2 estimate of 0.06. 
Tests of interaction between allocation concealment and ES were positive in 3 of 14 meta-
analyses at the conventional level of P = 0.05. The results of stratified analyses are shown in 
Figure 2. Differences in ES between trials with and without adequate concealment were larger 
in meta-analyses with a large treatment benefit as compared with meta-analyses with a small 
benefit (P for interaction < 0.001), meta-analyses with a high degree of between-trial 
heterogeneity (P for interaction = 0.009), and meta-analyses of complementary medicine as 
compared with conventional medicine (P for interaction = 0.019).  
Figure 3A shows the comparisons of overall meta-analyses, including all trials with meta-
analyses restricted to trials with adequate concealment of allocation. Estimates of treatment 
benefits became smaller in 9 and larger in 5 meta-analyses (P = 0.11). Between-trial 
heterogeneity decreased in 12 meta-analyses and increased in 2 (P = 0.003), and P values of 
pooled effects increased in 11 meta-analyses and decreased in 3 (P = 0.026). Statistical 
precision decreased in 9 meta-analyses and increased in 5 (P = 0.36). 
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Figure 1 Forest plots of the differences in effect sizes between A, 46 trials with and 112 trials without adequate 
concealment of allocation, or B, 64 trials with and 58 trials without adequate patient blinding. P values are for 
the interaction between A, adequate concealment, or B, patient blinding and effect sizes. 95% CI = 95% 
confidence interval; NSAIDs = nonsteroidal antiinflammatory drugs; TENS = transcutaneous electrical nerve 
stimulation. 
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Figure 2. The differences in effect sizes (ES) between 46 trials with and 112 trials without adequate allocation 
concealment are shown, stratified according to the following characteristics: treatment benefit in the overall 
meta-analysis, degree of heterogeneity between trials in the overall meta-analysis, pharmacologic intervention 
(yes/no), and complementary medicine (yes/no). An ES greater than -0.5 indicates a small benefit and an ES less 
than or equal to -0.5 indicates a large benefit of the experimental intervention. A τ2<0.06 indicates low between-
trial heterogeneity and a τ2≥0.06 indicates high between-trial heterogeneity. Pharmacologic interventions include 
chondroitin, diacerein, glucosamine, oral and topical nonsteroidal antiinflammatory drugs, opioids, and 
viscosupplementation. Complementary medicine includes acupuncture, chondroitin, glucosamine, pulsed 
electromagnetic fields, and static magnets. A negative difference in ES indicates that trials with adequate 
allocation concealment show a less beneficial treatment effect. Variability in bias is shown as the between–meta-
analysis heterogeneity variance τ2 accompanied by P values for heterogeneity between meta-analyses. 95% CI = 
95% confidence interval. 
Patient blinding. Ten meta-analyses in 122 trials and 27,452 patients included both trials 
with and trials without adequate blinding of patients and contributed to the analysis. The 
characteristics of these trials are shown in Table 3. In 64 trials (52%) patients were adequately 
blinded, in 51 trials (42%) a placebo or sham intervention was used but adequacy of patient 
blinding remained unclear, and in 7 trials (6%) no placebo or sham intervention was used. Of 
all of the trials with adequate patient blinding, 55 (86%) reported indistinguishable 
interventions and 9 (14%) reported the use of double-dummy techniques. Trials with adequate 
patient blinding were more likely to adequately conceal treatment allocation (P = 0.006) and 
to evaluate complementary medical interventions (P = 0.023). 
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Figure 3. Effect sizes, between-trial heterogeneity variance τ2, and P values of overall treatment benefits are 
compared between overall meta-analyses including all trials (x-axis) and restricted meta-analyses including A, 
trials with adequate allocation concealment only, or B, trials with adequate patient blinding only (y-axis). Broken 
lines indicate that the estimates are identical. P values are derived using Wilcoxon’s rank tests for paired 
observations. 
Figure 1B shows the forest plot of differences in ES between trials with and trials without 
adequate blinding. Again, estimated treatment effects in trials with adequate patient blinding 
tended to be smaller compared with treatment effects in trials with inadequate or unclear 
patient blinding, with a difference in ES of -0.15, but the corresponding CI was wide (95% CI 
-0.39, 0.09; P = 0.22). In 2 of 10 meta-analyses, tests of interaction between patient blinding 
and ES were positive. The variability in bias estimates between meta-analyses was high, with 
a τ2 estimate of 0.07, and differences in ES ranged from -1.01 to 0.26 between individual 
meta-analyses. Results of stratified analyses are shown in Figure 4. Differences in ES 
between trials with and without adequate patient blinding were similar in meta-analyses with 
small and large treatment benefits (P for interaction = 0.75) and with high and low between-
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trial heterogeneity (P for interaction = 0.19), but differences were more pronounced in meta-
analyses of nonpharmacologic interventions as compared with metaanalyses of 
pharmacologic interventions (P for interaction < 0.001) and in meta-analyses of 
complementary medicine compared with conventional medicine (P for interaction = 0.07). 
Figure 3B shows the comparisons of overall meta-analyses including all trials with meta-
analyses restricted to trials with adequate patient blinding. Estimates of treatment benefits 
decreased in 6 meta-analyses and increased in 4 (P = 0.28). Heterogeneity between trials 
decreased in 5 meta-analyses and increased in 5 (P = 0.44), and P values increased in 10 
meta-analyses and decreased in none (P = 0.005). Statistical precision decreased in 6 meta-
analyses and increased in 4 (P = 0.11). 
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Figure 4. The differences in effect sizes (ES) between 64 trials with and 58 trials without adequate patient 
blinding are shown, stratified according to the following characteristics: treatment benefit in the overall meta-
analysis, degree of heterogeneity between trials in the overall meta-analysis, pharmacologic intervention 
(yes/no), and complementary medicine (yes/no). An ES greater than -0.5 indicates a small benefit and an ES less 
than or equal to -0.5 indicates a large benefit of the experimental intervention. A τ2<0.06 indicates low between-
trial heterogeneity and a τ2≥0.06 indicates high between-trial heterogeneity. Pharmacologic interventions include 
chondroitin, diacerein, glucosamine, oral and topical nonsteroidal antiinflammatory drugs, and 
viscosupplementation. Complementary medicine includes acupuncture, chondroitin, glucosamine, low-level 
laser therapy, static magnets, and transcutaneous electrical nerve stimulation. A negative difference in ES 
indicates that trials with adequate patient blinding show a less beneficial treatment effect. Variability in bias is 
shown as the between–meta-analysis heterogeneity variance τ2 accompanied by P values for heterogeneity 
between meta-analyses. 95% CI =95% confidence interval. 
Sensitivity analyses. The effects of allocation concealment became more robust after 
accounting for the presence or absence of adequate patient blinding (difference in ES -0.24; 
95% CI -0.41, -0.07), and more precise but attenuated after accounting for intent-to-treat 
analyses (difference in ES -0.08; 95% CI -0.21, 0.04). The variability in bias estimates in 
these analyses was similar after accounting for patient blinding (τ2 = 0.07, P < 0.001), but 
decreased after accounting for intent-to-treat analyses (τ2 = 0.04, P = 0.002). The effects of 
patient blinding entirely disappeared when accounting for allocation concealment (difference 
in ES 0.01; 95% CI -0.18, 0.18) and were attenuated when accounting for intent-to-treat 
analyses (difference in ES -0.06; 95% CI -0.20, 0.09). The variability in bias estimates 
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decreased after accounting for these characteristics: τ2 estimates were 0.03 in both analyses (P 
= 0.08 and 0.05 for heterogeneity, respectively). 
Discussion 
In this meta-epidemiologic study of osteoarthritis trials, we found that trials with inadequate 
or unclear concealment of allocation showed larger estimates of treatment benefits than trials 
with adequate concealment. Evidence of bias was mainly seen in meta-analyses with large 
treatment effects, meta-analyses with high between-trial heterogeneity, and in meta-analyses 
of complementary medicine, with a pattern and magnitude of effects similar to what we found 
previously for bias associated with failure to perform an intent-to-treat analysis.5 The average 
bias associated with a lack of concealment of allocation corresponds to one-fourth to one-half 
of a typical treatment effect found for interventions in osteoarthritis.9 Evidence of bias 
associated with a lack of adequate patient blinding was found less consistently. Patients are 
difficult to blind if allocation is not adequately concealed: if patients and investigators 
enrolling patients are able to decipher the allocation schedule, subsequent blinding will be 
impossible. Unsurprisingly, the effects of blinding entirely disappeared after accounting for 
concealment of allocation in the overall analysis. However, stratified analyses suggested that 
adequate blinding of patients may be important for nonpharmacologic interventions. The 
average bias found for this group of interventions was an ES of -0.67, which is larger than the 
typical treatment effect found for most interventions used for osteoarthritis.9 This effect was 
robust to the adjustment for concealment of allocation in a post hoc analysis (difference in ES 
after accounting for concealment -0.62; 95% CI -1.09, -0.16). 
The assessment of the methodologic quality of a trial is intertwined with the quality of 
reporting: the extent to which a report provides information about the design, conduct, and 
analysis of the trial.1 Unfortunately, reports often omit important methodologic details,26 
including who was actually blinded and whether blinding was successful at the time of 
patient-reported assessments of pain intensity.25,27–29 A widely used approach to this problem 
is to assume that the quality is inadequate unless the information to the contrary is provided. 
This is often justified because faulty reporting generally reflects faulty methods.1,2 A well-
conducted but badly reported trial will, however, be misclassified. Misclassification may have 
been particularly prominent in the assessment of the adequacy of patient blinding in drug 
trials. Some of these trials could have adequately blinded patients using matching placebos 
without describing it. The resulting misclassification would explain the apparent lack of bias 
associated with patient blinding in pharmacologic trials. 
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The current study differs in 3 important aspects from previously published meta-
epidemiologic studies that addressed the impact of allocation concealment and blinding on 
estimated treatment benefits.2,6,30 –34 First, we specifically estimated the extent of bias in trials 
using patient reported pain intensity as a subjective outcome. Subjective outcomes are likely 
to be more prone to bias due to unclear allocation concealment and inadequate blinding than 
objective outcomes such as mortality.4 Second, almost all of the previous meta-epidemiologic 
studies have considered binary outcomes. To our knowledge, only one pilot study including 
35 trials addressed the association between treatment benefits and allocation concealment or 
blinding in continuous outcomes, but was underpowered to obtain conclusive results.35 Third, 
we provide a comprehensive assessment of the extent of unclear concealment of allocation 
and the lack of patient blinding in randomized osteoarthritis trials and the resulting biases. 
Less than one-third of the trials reported adequate concealment of allocation. On average, 
these trials suggested less beneficial treatment effects than the remaining trials. Random 
allocation of patients can be adequately concealed in any trial, irrespective of the types of 
interventions compared. Admittedly, patient blinding is not possible for some interventions, 
such as exercise or self-management. However, even in trials that evaluated interventions that 
were amenable to blinding, only approximately half reported adequate attempts to blind 
patients. 
Selection bias at trial entry might be the underlying mechanism of an overestimation in trials 
with inadequate or unclear allocation concealment, whereas selection bias after entry is the 
likely mechanism resulting in overestimates of treatment benefits in trials that exclude 
randomized patients from the analysis.1,5 Lack of adequate patient blinding might result in 
exaggerated treatment effects due to detection bias in patient-reported outcomes and 
performance bias introduced by the unequal intake of analgesic cointerventions apart from the 
treatment under evaluation.1 Differential placebo or nocebo effects may also be important: 
patients who know that they receive active treatment may perceive less pain than patients in 
the inactive control group. In our study, these possible sources of bias introduced by the 
behavior and perception of patients appeared less important than the selection biases 
discussed above, which are mainly introduced by investigators.1 
Only a combination of adequate allocation concealment and adequate analysis according to 
the intent-to-treat principle will avoid selection biases and render trial results valid and 
credible. Special caution should be taken when interpreting the results of meta-analyses 
indicating large benefits of experimental interventions, a high degree of between-trial 
heterogeneity, or in meta-analyses of complementary medicine. Here, stratified analyses 
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according to the presence or absence of adequate concealment of allocation and intent-to-treat 
analysis should be considered mandatory.5 In case of discrepancies, trials that avoided 
selection biases should be given precedence.  
Trialists should always ensure adequate concealment of allocation and take measures to 
minimize dropout rates and maximize compliance with the trial protocol to allow an analysis 
according to the intent-to-treat principle. Blinding of patients is desirable and should be 
attempted. Authors of reports of osteoarthritis trials should painstakingly follow the 
Consolidated Standards of Reporting Trials statement36,37 to ensure fully transparent reporting 
of methods and results. 
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Abstract  
Objective To examine the presence and extent of small study effects in clinical osteoarthritis 
research. 
Design Meta-epidemiological study.  
Data sources 13 meta-analyses including 153 randomised trials (41,605 patients) that 
compared therapeutic interventions with placebo or non-intervention control in patients with 
osteoarthritis of the hip or knee and used patient reported pain as an outcome. 
Methods We compared estimated treatment benefits between large trials of at least 100 
patients per arm and small trials, explored funnel plots supplemented with lines of predicted 
effects and contours of statistical significance and used three approaches to estimate treatment 
effects: meta-analyses including all trials irrespective of sample size, meta-analyses restricted 
to large trials and treatment effects predicted for large trials.  
Results On average, treatment effects were more beneficial in small than in large trials 
(difference in effect sizes, -0.21, 95%-CI -0.34 to -0.08, P=0.001). Depending on criteria 
used, six to eight funnel plots were suggestive of small study effects. In 6 of 13 meta-
analyses, the overall pooled estimate suggested a clinically relevant, statistically significant 
treatment benefit, whereas analyses restricted to large trials and predicted effects in large 
trials yielded smaller, non-significant estimates.  
Conclusions Small study effects may frequently distort results of meta-analyses. The 
influence of small trials on estimated treatment effects should be routinely assessed.  
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Introduction 
The methodological quality and unbiased dissemination of clinical trials is crucial for the 
validity of systematic reviews and meta-analyses. It has been repetitively suggested that small 
trials tend to report larger treatment benefits than larger trials.1 2 Such small study effects may 
result from a combination of lower methodological quality of small trials, publication and 
other reporting biases,2-8 but could also reflect clinical heterogeneity if small trials were more 
careful in selecting patients and implementing the experimental intervention.9 The funnel plot 
is a scatter plot of treatment effects against standard error as a measure of statistical 
precision.9 10 Imprecision of estimated treatment effects will increase as the sample size of 
component trials increases. Thus, in the absence of small study effects, results from small 
trials with large standard errors will scatter widely at the bottom of a funnel plot while the 
spread narrows with increasing sample size and the plot will resemble a symmetrical inverted 
funnel. Conversely, if small study effects are present, funnel plots will be asymmetrical.9 The 
plot can be enhanced by lines of the predicted treatment effect from meta-regression using the 
standard error as explanatory variable,11 12 and contours that divide the plot into areas of 
statistical significance and non-significance.13 14 A recent study of anti-depressant trials15 
found that these approaches increased the understanding of the interplay of several biases 
associated with small sample size, including publication bias, selective reporting of outcomes 
and inadequate methodology and analysis of trials.14  
Small study effects may be particularly prominent in osteoarthritis research, where several 
recent meta-analyses found pronounced asymmetry of funnel plots.16-18 We previously studied 
the influence of methodological characteristics on estimated effects in a set of clinical 
osteoarthritis trials using patient-reported pain outcomes and found that deficiencies in 
concealment of random allocation, patient blinding and analyses may distort the results in 
these trials.19 20 Different components of inadequate trial methodology often concur. A trial 
with adequate allocation concealment for example, is more likely to report analyses according 
to the intention-to-treat principle.19 20 Meta-epidemiological studies found that smaller trials 
are less likely to use adequate random sequence generation, adequate allocation concealment 
and double blinding,7 8 19 and that different methodological components are associated with 
exaggerated treatment benefits.7 8 19-23 
Here, we explore the presence and extent of small study effects in meta-analyses of 
osteoarthritis trials and determine whether sensitivity analyses based on a restriction of meta-
analyses to large, appropriately powered trials or based on a prediction of treatment effects in 
large trials influences conclusions of meta-analyses.  
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Methods  
Selection of meta-analyses and component trials 
We included meta-analyses of randomised or quasi-randomised, controlled trials in patients 
with osteoarthritis of the knee or hip. Meta-analyses were eligible, if they included a patient-
reported pain-related outcome for any intervention compared to placebo, sham or no control 
intervention. Two reviewers independently evaluated reports of meta-analyses for eligibility. 
Details of the search strategy and selection process are described elsewhere.20 Reports of all 
component trials of included meta-analyses were obtained. No language restrictions were 
applied. 
Data extraction and quality assessment 
Data of individual trials regarding design, interventions, publication year, trial size, sample 
size calculation, exclusions, and results were extracted independently by two reviewers on a 
standardized form as previously described.20 The primary outcome was pain. If different pain-
related outcomes were reported, we extracted one pain-related outcome per study according to 
a pre-specified hierarchy.16 19 24 Concealment of treatment allocation was considered adequate 
if investigators responsible for patient selection were unable to suspect before allocation 
which treatment was next, e.g. central randomisation or sequentially numbered, sealed, 
opaque envelopes. Blinding of patients was considered adequate if experimental and control 
interventions were described as indistinguishable or if a double-dummy technique was used. 
Handling of incomplete outcome data was considered adequate if all randomised patients 
were included in the analysis (intention-to-treat principle). A cut-off of 100 allocated patients 
per treatment arm was used to distinguish between small and large trials. A sample size of 
2x100 patients will yield more than 80% power to detect a small to moderate effect size of -
0.40 at a two-sided α=0.05, which corresponds to a difference of 1 cm on a 10 cm visual 
analogue scale between experimental and control intervention in a two-arm trial. 
Data synthesis 
We expressed treatment effects as effect sizes by dividing the difference in mean values at the 
end of follow-up by the pooled standard deviation. Negative effect sizes indicate a beneficial 
effect of the experimental intervention. If some required data were unavailable, we used 
approximations as previously described.16 Meta-analyses including exclusively small or 
exclusively large trials did not contribute to the analysis. Within each meta-analysis, we 
estimated effect sizes of large (≥100 patients per trial arm) and small trials (<100 patients per 
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trial arm) separately using inverse-variance random-effects meta-analysis, calculated the 
DerSimonian and Laird estimate of the variance τ2 as a measure of between-trial 
heterogeneity,25 26 and derived differences between pooled estimates of large and small trials. 
We then combined these differences across meta-analyses using an inverse-variance random-
effects model, which fully allowed for heterogeneity between meta-analyses.26 27 Negative 
differences in effect sizes indicate that small trials show more beneficial treatment effects than 
large trials. The variability between meta-analyses was expressed as the heterogeneity 
variance τ2. To account for the correlation between sample size and methodological quality, 
we used stratification by these components in analogy to Mantel-Haenszel procedures28 and 
derived differences between small and large trials adjusted for concealment of allocation, 
patient blinding and intention-to-treat analysis. We performed analyses of associations 
between sample size and estimated treatment benefits stratified according to the following 
pre-specified characteristics:20 between trial heterogeneity in the overall meta-analysis (low, 
τ2<0.06, v high, τ2 ≥0.06), treatment benefit in the overall meta-analysis (small, effect sizes 
>−0.5, v large, effect sizes ≤−0.5),24 29 and type of intervention assessed in the meta-analysis 
(drug versus other interventions, conventional versus complementary medicine). These 
stratified analyses were accompanied by interaction tests.  
We drew funnel plots (effect sizes of individual trials plotted against their standard errors) 
that were enhanced by contours that divide the plot into areas of statistical significance and 
non-significance at the traditional level of α=0.05 based on standard Wald tests as previously 
described.13 30 If trials seem to be missing in areas of statistical non-significance, then this 
adds to the notion of the presence of bias.13 14 We added lines of the predicted treatment effect 
to the funnel plots derived from univariable random-effects meta-regression models using the 
standard error as explanatory variable.11 12 Then, we assessed funnel plot asymmetry with 
regression tests, a weighted linear regression of the effect sizes on their standard errors, using 
the inverse of the variance of effect sizes as weights.2 9  
We compared pooled effect sizes from overall random-effects meta-analyses, pooled effect 
sizes from random-effects meta-analyses restricted to large trials only, and predicted effect 
sizes from random-effects meta-regression models using the standard error as explanatory 
variable for trials with a standard error of 0.1.12 14 A standard error of 0.1 is found in a large 
two-arm trial with 200 randomised patients per group, which will have more than 95% power 
to detect an effect size of about -0.40 standard deviation units, which corresponds to the 
median minimal clinically important difference found in recent trials in patients with 
osteoarthritis.31-34 Results were considered concordant if point estimates differed by less than 
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0.10 standard deviation units35 and if the status of statistical significance at a two-sided 
α=0.05 remained unchanged, as indicated by the presence or absence of an overlap of the 
95% confidence interval with the null effect. Finally, we compared pooled effect sizes, 
between-trial heterogeneity, precision defined as the inverse of the standard error, and P 
values for pooled effect sizes between random-effects meta-analyses including all trials and 
meta-analyses including large trials only, using Wilcoxon’s rank tests for paired observations. 
All P values are two-sided. All data analysis was performed in STATA version 10 (Stata 
Corporation, College Station, Texas). 
Results 
The study sample and its origin were described elsewhere.19 20 21 eligible meta-analyses 
described in 17 reports were eligible. Of these, 13 meta-analyses16 36-46 (153 trials with 41,605 
patients) included both, small and large trials and contributed to the analyses. The median 
number of trials included per meta-analysis was 12 (range 3 to 24) and the median number of 
patients 1849 (347 to 13659). The pooled effect sizes ranged from -0.07 to -1.11 and the 
heterogeneity between trials from a τ2 of 0.00 to 0.47. Eight meta-analyses assessed drug 
interventions and 5 meta-analyses non-drug interventions. Four assessed interventions in 
complementary medicine and 9 interventions in conventional medicine.  
Table 1 describes the characteristics of the 153 component trials. 58 (38%) trials included at 
least 100 patients per arm and 95 (62%) trials were smaller. The number of allocated patients 
ranged from 201 to 2957 in large trials, and from 8 to 362 in small trials. Large trials were 
published more recently (P=0.002), were more likely to report adequate concealment of 
allocation (P=0.010) and to report a sample size calculation (P<0.001).  
Figure 1 shows a forest plot of differences in effect sizes between small and large trials across 
the 13 meta-analyses. The average difference in effect sizes between large and small trials 
across the 13 included meta-analyses was -0.21, with more beneficial effects found in small 
trials (95%-CI -0.34 to -0.08, P=0.001). At the level of individual meta-analyses, tests for 
interaction between treatment benefits and trial size were positive in 4 meta-analyses (31%).16 
37 39 45
 The variability across meta-analyses was small to moderate, with a τ2 estimate of 0.03 
(P=0.005). 
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Number of  
allocated patients 
 
 
<100 per arm  
(n=95) 
≥ 100 per arm 
(n=58) P value 
Concealment of allocation 
  0.010 
     Adequate 19 (20%) 22 (38%)  
     Inadequate / unclear 76 (80%) 36 (62%)  
Blinding of patients 
  0.25 
     Adequate 41 (43%) 30 (52%)  
     Inadequate / unclear 54 (57%) 28 (48%)  
Intention-to-treat analysis 
  0.23 
     Yes 16 (17%) 16 (28%)  
     No / unclear 79 (83%) 42 (72%)  
Sample size calculation 
  <0.001 
     Reported 37 (39%) 38 (66%)  
     Not reported 58 (61%) 20 (34%)  
Year of publication 
  0.002 
     1980 – 1999 55 (58%) 14 (24%)  
     2000 – 2007 40 (42%) 44 (76%)  
Drug intervention 
  0.97 
     Yes 70 (74%) 43 (74%)  
     No 25 (26%) 15 (26%)  
Complementary medicine 
  0.09 
     Yes 30 (32%) 11 (19%)  
     No 65 (68%) 47 (81%)  
Table 1 Comparison of characteristics between small and large trials P values are derived from logistic 
regression models adjusted for clustering of trials within meta-analyses. Drug interventions include chondroitin, 
diacerein, glucosamine, NSAIDs, opioids, paracetamol and viscosupplementation. Interventions in 
complementary medicine include acupuncture, balneotherapy, chondroitin, and glucosamine.  
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-2.0 -1.5 -1.0 -0.5 0 0.5 1.0 1.5
Exercise41
Viscosupplementation42
Self-management43
Glucosamine44 
Diacerein45
Balneotherapy51
Acupuncture50
Overall (τ2 = 0.03, p=0.005)
Topical NSAIDs49
Oral NSAIDs49
Aquatic exercise48
Opioids47 
Paracetamol46
-0.12 (-0.28 to  0.05)
-0.35 (-0.63 to -0.06)
0.05 (-0.13 to  0.23)
-0.78 (-1.26 to -0.30) 
-0.15 (-0.37 to  0.07)
-0.85 (-1.84 to  0.15)
-0.63 (-1.10 to -0.17)
-0.21 (-0.34 to -0.08)
-0.10 (-0.32 to  0.13)
-0.19 (-0.49 to  0.12)
-0.10 (-0.63 to  0.43)
-0.12 (-0.29 to  0.05)
0.28 (-0.26 to  0.82)
Small trials show 
less beneficial effects
Small trials show 
more beneficial effects
Difference in effect sizes
(95% CI)Intervention
Chondroitin26 -0.66 (-1.06 to -0.26) 
P value for
interaction
0.15
0.018
0.57
0.001
0.18
0.10
0.007
0.40
0.23
0.71
0.18
0.31
0.001
 
Figure 1 Difference in effect sizes between 95 small trials with less than 100 patients per arm and 58 large trials. 
A negative difference in effect sizes indicates that small trials show more beneficial treatment effects. P values 
are for interaction between sample size and effect sizes. NSAIDs=non-steroidal anti-inflammatory drugs. 
 
Table 2 95% CI: 95% confidence interval; ∆ES: difference in effect size between 95 small and 58 large trials; 
τ2: between meta-analyses heterogeneity variance estimate.  
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Table 2 presents average difference in effect sizes between large and small trials, crude (top) 
and after adjustment for the methodological quality of trials (bottom). Differences in effect 
sizes between small and large trials were robust after adjustment for blinding of patients (-
0.21, 95% CI -0.33 to -0.09, P=0.001), slightly attenuated after adjustment for concealment of 
allocation (-0.16, 95% CI -0.27 to -0.06, P=0.002), but nearly halved after adjustment for 
intention-to-treat analysis (-0.12, 95% CI -0.21 to -0.02, P=0.016). The variability across 
meta-analyses was similar between crude and adjusted analyses.  
Table 3 presents results from analyses stratified according to the magnitude of treatment 
effects, the between-trial heterogeneity found in overall meta-analyses, and according to type 
of experimental intervention. Differences in effect sizes between large and small trials were 
most pronounced in meta-analyses with large treatment benefits, meta-analyses with a high 
degree of between-trial heterogeneity and meta-analyses of complementary interventions (P 
for interaction all <0.001).  
Figure 2 shows funnel plots of all 13 meta-analyses including prediction lines from meta-
regression models with the standard error as an explanatory variable and 5% contour areas to 
display areas of significance and non-significance. For six funnel plots, both, the scatter of 
effect estimates and the prediction line indicated asymmetry (Panels A, D, G, H, L, M).16 37 39 
42 44 45
 For another two funnel plots, mainly the prediction lines suggested asymmetry (Panels 
C and E),40 46 whereas the remaining 5 funnel plots appeared symmetrical and prediction lines 
nearly upright (Panels B, F, I, J, K).36 38 41 43 44  The regression test was statistically significant 
at P≤0.05 in four meta-analyses (Panels D, G, H, M)16 37 39 42 and showed a statistical trend in 
another two (P≤0.10, Panels A, L).44 45 In 5 funnel plots, the contours to distinguish between 
areas of statistical significance and non-significance at P=0.05, suggested missing trials in 
areas of non-significance (Panels A, C, D, H, L).16 42 44-46  
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Table 3 Stratified analyses 
Comparison 
No of  
meta-
analyses 
No 
of 
trials 
Difference in effect 
sizes (95% CI) 
Variability 
(P value) 
P for 
interaction 
Overall 13 153 -0.21 (-0.34 to -0.08) 0.03 (0.005)  
Treatment benefit in overall meta-analysis    <0.001 
 Small 10 115 -0.13 (-0.22 to -0.03) 0.01 (0.17)  
 Large 3 38 -0.72 (-1.02 to -0.43) 0.00 (0.90)  
Heterogeneity between trials in overall meta-analysis   <0.001 
 Low 8 87 -0.08 (-0.16 to -0.00) 0.00 (0.66)  
 High 5 66 -0.55 (-0.73 to -0.36) 0.00 (0.46)  
Pharmacological intervention     0.67 
 Yes 8 113 -0.23 (-0.39 to -0.08) 0.03 (0.021)  
 No 5 40 -0.17 (-0.40 to 0.06) 0.03 (0.041)  
Complementary medicine     <0.001 
 Yes 4 41 -0.70 (-0.95 to -0.45) 0.00 (0.96)  
 No 9 112 -0.10 (-0.18 to -0.03) 0.00 (0.43)  
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Figure 2 Funnel plots of 13 included meta-analyses 
including prediction lines from univariable meta-
regression models with the standard error as 
explanatory variable (red) and 5% contour areas to 
display areas of significance (grey) and non-
significance (white). P-values were derived from 
regression tests for asymmetry. NSAIDs=non-steroidal 
anti-inflammatory drugs. 
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Figure 3 presents a graphical summary of results of individual meta-analyses of all trials 
(black), meta-analyses restricted to large trials (blue) and predicted effect sizes for trials with 
a standard error of 0.1 (red). Results of all three analytical approaches were concordant in 7 
meta-analyses (Figure 3, Panels B, E, F, H, I, J, K).36 38 41-44 In the remaining 6, both 
approaches, the restricted analysis and the predicted effect were discordant to the overall 
analysis (Panels A, C, D, G, L, M).16 37 39 44-46 In 3 of these, statistical significance at the 
conventional level of 0.05 was lost when restricting the analysis to large trials and when 
predicting the effect (Panels D, G, M), in the other 3, significance was lost when predicting 
the effect, but not when restricting the analysis (Panels A, C, L).44-46 The median estimated 
treatment benefit decreased from -0.39 (range -1.11 to -0.06) in meta-analyses of all trials to -
0.23 (range -0.59 to -0.04) in meta-analyses restricted to large trials (P=0.005) and the median 
between-trial heterogeneity decreased from a τ2 of 0.20 (range 0.00 to 0.69) to a τ2 of 0.04 
(range 0.00 to 0.31, P=0.030). P-values of pooled effect sizes increased from a median of 
<0.001 (range <0.001 to 0.13) to 0.007 (range <0.001 to 0.61, P=0.016) in restricted meta-
analyses, whereas precisions of pooled effect sizes were much the same (median 13 [range 2 
to 24] versus 14 [range 7 to 21], P=0.70).  
 
 
Article 3: Small study effects in meta-analyses of osteoarthritis trials 
78 
-1.0 -0.5 0 0.5 1.0
F) Exercise
-1.0 -0.5 0 0.5 1.0
M) Viscosupplementation
-1.0 -0.5 0 0.5 1.0
K) Self-management
-1.0 -0.5 0 0.5 1.0
G) Glucosamine
-1.0 -0.5 0 0.5 1.0
E) Diacerein
-1.0 -0.5 0 0.5 1.0
J) Paracetamol
-1.0 -0.5 0 0.5 1.0
H) Opioids
-1.0 -0.5 0 0.5 1.0
B) Aquatic exercise
-1.0 -0.5 0 0.5 1.0
I) Oral NSAIDs
-1.0 -0.5 0 0.5 1.0
L) Topical NSAIDs
-1.0 -0.5 0 0.5 1.0
A) Acupunture
Overall meta-analyses
Restricted to large trials
Predicted at SE=0.1
-1.0 -0.5 0 0.5 1.0
C) Balneotherapy
-1.0 -0.5 0 0.5 1.0
D) Chondroitin
 
Figure 3. Results of individual random-
effects meta-analyses of all trials (black), 
results of random-effects meta-analyses 
restricted to large trials with at least 100 
patients per arm (blue), and effect sizes for 
trials with a standard error of 0.1 predicted 
from random-effects meta-regression 
models (red). NSAIDs = non-steroidal 
anti-inflammatory drugs, SE = standard 
error 
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Discussion 
In this meta-epidemiological study in 13 meta-analyses of 153 osteoarthritis trials, we found 
larger estimated treatment benefits in small trials of less than 100 patients per trial arm as 
compared with larger trials. The average difference between small and large trials was about 
half the magnitude of a typical treatment effect found for interventions in osteoarthritis.24 
Small study effects were more prominent in 5 of the 13 meta-analyses, however. These 
showed a large extent of statistical heterogeneity, larger pooled estimates of treatment benefit 
than would typically be expected from effective intervention in osteoarthritis, and mainly 
covered complementary medical interventions. Taking into account contours used to 
distinguish between areas of statistical significance and non-significance, and lines of 
treatment effects predicted for different standard errors, we found 8 funnel plots suggestive of 
small study effects. Finally, we used three different approaches to estimate treatment effects 
of the 13 interventions included in this study: pooling all trials irrespective of sample size, 
restricting the analysis to large trials of more than 100 patients per trial arm, and predicting 
treatment effects for large trials using the corresponding standard error as independent 
variable. Estimates from these three approaches were discordant in 6 meta-analyses, with the 
overall pooled estimate suggesting a clinically relevant, statistically significant treatment 
benefit, which was not found in the other two approaches aimed at estimating the effect in 
large trials only. 
Large trials tend to be of higher quality than small trials and the observed association between 
sample size and treatment effect could be confounded by methodological quality.7 8 47 When 
accounting for patient blinding, we found the association between sample size and treatment 
effect completely robust. Accounting for concealment of allocation resulted in a slight 
attenuation, whereas adjusting for the presence or absence of an intention-to-treat analysis 
nearly halved the association between sample size and treatment effect. This suggests that 
problems with exclusions from the analysis after randomisation may contribute to the 
observed small study effects, which is in line with a recent study of anti-depressant trial.15 
This study suggested that, in addition to publication and reporting biases, switching from an 
intention-to-treat to a per protocol analysis contributed to discrepancies between published 
and unpublished results.14 The assessment of components of methodological quality will 
depend strongly on reporting quality48 and may be affected by misclassification, whereas 
sample size or standard error may be extracted more easily. Sample size or statistical 
precision may therefore be the best single proxy for the cumulative effect of the different 
sources of bias in randomised osteoarthritis trials and probably also in other fields: selection, 
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performance, detection and attrition bias,49 selective reporting of outcomes3 4 and publication 
bias.6 50  
The most important limitation of our study is that we cannot exclude alternative explanations 
of small study effects other than bias: smaller trials may have been more careful in 
implementing the intervention or in including patients who are particularly likely to benefit 
from the intervention, which could result in larger treatment effects and true clinical 
heterogeneity.2 9 51 In addition, the selection of component trials was based on the literature 
searches and selection criteria of published meta-analyses. Some of the searches in these 
meta-analyses may have been too superficial and some of the selection criteria too narrow to 
include a large proportion of unpublished trials. However, the meta-analyses included in our 
study are likely to be representative of the field and we believe therefore that our results are 
generalisable. Another limitation is that our analysis is based on published information only 
and depends on the quality of reporting, which is often unsatisfactory.49  
To our knowledge, this is the first meta-epidemiological study to systematically assess small 
study effects in a series of meta-analyses with continuous clinical outcomes. In an analysis of 
trials with binary outcomes, Kjaergard et al7 8 found more beneficial treatment effects in small 
trials with inadequate methodology as compared with large trials. Shang et al, in an analysis 
of homeopathy trials, found smaller trials and those of lower quality to show more beneficial 
treatment effects than larger and higher-quality trials.11 Moreno et al recently assessed the 
performance of contour enhanced funnel plots and a regression based adjustment method to 
detect and adjust for small study effects in placebo-controlled antidepressant trials previously 
submitted to the US Food and Drug Administration (FDA) and matching journal 
publications.14 Applying the regression based adjustment method to the journal data produced 
a similar pooled effect to that observed by a meta-analysis of the complete unbiased FDA 
data. In contrast to our study, they regressed treatment effects against their variance. In funnel 
plots, treatment effects will typically be plotted against their standard error, however, and 
significance tests will be generally based on z or t values, which again are calculated by 
dividing treatment effects by their standard error. Therefore, we deem it preferable to regress 
treatment effects against the standard error rather than the variance. A second discrepancy is 
that Moreno et al predicted effects for infinitely large trials of a variance of zero. By 
definition, such a trial would be overpowered to detect a minimally clinically relevant 
difference between groups and we deem it preferable to predict treatment effects for large 
trials with adequate power to detect small, albeit relevant effects. The chosen standard error of 
0.1 at which treatment effects will be found in a large two-arm trial with a continuous primary 
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outcome including 200 randomised patients per group to yield more than 95% power to detect 
an effect size of -0.40 standard deviation units and still more than 80% power to detect an 
effect size of about -0.30 standard deviation units. Trials considerably larger than that will 
hardly be needed in case of a continuous primary outcome.  
The meta-regression model used to predict effects incorporates residual heterogeneity 
unexplained by regressing treatment effect against standard error. In case of large unexplained 
heterogeneity, it will appropriately indicate uncertainty in the predicted estimate as reflected 
by a wide 95% prediction interval, even though an analysis restricted to large trials may yield 
precise estimates. This was observed in 5 meta-analyses of our study37 39 44-46 and taken as an 
indication of residual uncertainty necessitating additional explorations of sources of 
heterogeneity or additional, appropriately designed large scale trials. For continuous 
outcomes, definitions of large trials and methodologies used for assessing funnel plot 
asymmetry may be generally suitable as reported here. Trials with an average of 100 patients 
per trial arm will yield about 80% power to detect a small to moderate effect size of -0.40 
standard deviation units, which corresponds to the median minimal clinically important 
difference found in recent studies in patients with osteoarthritis.32-34 For binary outcomes, the 
definition of large trials will depend on control group event rates and a definition of what 
constitutes a moderate, but clinically relevant effect. In addition, the regression test for funnel 
plot asymmetry originally reported9 may be associated with an inappropriately high rate of 
false positives if odds ratios or risk ratios are used. Therefore, a modification of the test 
should be considered as reported by Harbord et al.51 Non-parametric tests will result in lower 
power than the regression tests discussed here and may be less appropriate.  
An inspection of funnel plots and stratified analyses according to sample size accompanied by 
appropriate interaction tests should be considered routine procedures in any meta-analysis, 
possibly accompanied by a regression test for funnel plot asymmetry and prediction of effects 
in large trials using meta-regression.47 In the presence of asymmetry of funnel plots, 
systematic reviewers should also report meta-analyses restricted to large trials or effects 
predicted for large trials. Readers and clinicians should be careful in interpreting results of 
small trials of low methodological quality and meta-analyses including mainly such trials.  
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Abstract 
Background Osteoarthritis is the most common form of joint disease and the leading cause of 
pain and physical disability in the elderly. Transcutaneous electrical nerve stimulation 
(TENS), interferential current stimulation and pulsed electrostimulation are used widely to 
control both acute and chronic pain arising from several conditions, but some policy makers 
regard efficacy evidence as insufficient. 
Objectives To compare transcutaneous electrostimulation with sham or no specific 
intervention in terms of effects on pain and withdrawals due to adverse events in patients with 
knee osteoarthritis. 
Search strategy We updated the search in CENTRAL, MEDLINE, EMBASE, CINAHL and 
PEDro up to 5 August 2008, checked conference proceedings and reference lists, and 
contacted authors. 
Selection criteria Randomised or quasi-randomised controlled trials that compared 
transcutaneously applied electrostimulation with a sham intervention or no intervention in 
patients with osteoarthritis of the knee. 
Data collection and analysis We extracted data using standardised forms and contacted 
investigators to obtain missing outcome information. Main outcomes were pain and 
withdrawals or dropouts due to adverse events. We calculated standardised mean differences 
(SMDs) for pain and relative risks for safety outcomes and used inverse-variance random-
effects meta-analysis. The analysis of pain was based on predicted estimates from meta-
regression using the standard error as explanatory variable. 
Main results In this update we identified 14 additional trials resulting in the inclusion of 18 
small trials in 813 patients. Eleven trials used TENS, four interferential current stimulation, 
one both TENS and interferential current stimulation, and two pulsed electrostimulation. The 
methodological quality and the quality of reporting was poor and a high degree of 
heterogeneity among the trials (I2 = 80%) was revealed. The funnel plot for pain was 
asymmetrical (P < 0.001). The predicted SMD of pain intensity in trials as large as the largest 
trial was -0.07 (95% CI -0.46 to 0.32), corresponding to a difference in pain scores between 
electrostimulation and control of 0.2 cm on a 10 cm visual analogue scale. There was little 
evidence that SMDs differed on the type of electrostimulation (P = 0.94). The relative risk of 
being withdrawn or dropping out due to adverse events was 0.97 (95% CI 0.2 to 6.0). 
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Authors’ conclusions In this update, we could not confirm that transcutaneous 
electrostimulation is effective for pain relief. The current systematic review is inconclusive, 
hampered by the inclusion of only small trials of questionable quality. Appropriately designed 
trials of adequate power are warranted. 
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Background 
Osteoarthritis is an age-related condition, occurring more frequently in women than in men. 
Its prevalence, causal associations and outcomes vary markedly according to the joint site 
affected.1 Osteoarthritis is characterised by focal areas of loss of articular cartilage in synovial 
joints, accompanied by subchondral bone changes, osteophyte formation at the joint margins, 
thickening of the joint capsule and mild synovitis.2 The objectives of management of knee 
osteoarthritis are to relieve pain and to maintain or improve function. Different modalities in 
physiotherapy have been suggested to improve the clinical course of knee osteoarthritis, with 
potentially fewer adverse effects than medical treatment,3 4 but some policymakers consider 
the evidence for effectiveness to be insufficient.5 
Transcutaneous electrostimulation, the application of any electrical current through the skin 
with the aim of pain modulation, is a frequently used modality in knee osteoarthritis.6 7 It is 
based on the ’Gate-Control Theory’ of pain perception as described by Melzack and Wall.8 
The theory suggests that the stimulation of large diameter, (A-beta) primary sensory afferent 
cutaneous fibres activates inhibitory interneurons in the spinal cord dorsal horn and, 
thereby,may attenuate the transmission of nociceptive signals from small diameter A-delta 
and C fibres. Other suggested mechanisms include a stimulation of β endorphin production.9-
11
 and even the potential for articular cartilage repair.12 13  
Several types of electrostimulation are available. Conventional transcutaneous electrical nerve 
stimulation (TENS), in its narrow sense, uses moderate to high frequency current of 40 to 150 
Hz and 50 to 100 µsec pulse width, typically at a low intensity, to stimulate sensory fibres. 
Several other types of TENS were subsequently developed, which differ in intensity, pulse 
width or frequency. Acupuncture-like TENS (AL TENS) uses a low frequency current of 0.5 
to 10 Hz and a pulse width of > 150 µsec at a high intensity to stimulate both motor and 
sensory fibres. The stimulation may be painful, and the intensity of the current will depend on 
the patient’s individual pain tolerance. Burst TENS was developed to minimise patients’ 
discomfort, as experienced with AL TENS. It uses short bursts of high frequency current of 
typically 80 to 100 Hz, which are repetitively applied at low intensity and a burst frequency of 
around 5 Hz, to stimulate motor and sensory fibres. The intensity used is slightly higher than 
used with conventional TENS. Brief TENS uses a high frequency current of more than 100 
Hz and 150 to 250 µsec pulse width at the maximal intensity tolerated by the patient to 
stimulate not only motor and sensory, but also nociceptor fibres. Modulation TENS combines 
several of the modalities above, typically using alternations of low and high frequency 
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currents.14 15 Classical interferential current stimulation simultaneously uses two non-
modulated biphasic pulsed currents applied with two sets of electrodes with four electrical 
poles; one current is fixed at approximately 4000 Hz and the other ranging typically from 
4000 to 4100 Hz. The superimposition of the two currents results in a new frequency with a 
range from 1 to 100 Hz.16 Modulated interferential current stimulation uses directed currents 
between two electrical poles and vectorially sums currents in the tissue, with a carrier 
frequency typically set at 4000 Hz, a beat frequency at 80 Hz, and a modulation frequency set 
between 0 to 150 Hz. The effective frequency is defined by the sum of beat and modulation 
frequency and varies between 80 and 230 Hz. The high frequency of the carrier currents in 
inferential current stimulation leads to a considerably lower impedance of skin and 
subcutaneous tissue as compared with conventional TENS and minimises patients’ 
discomfort. Lastly, pulsed electrostimulation applies high frequency current of 100 Hz and a 
pulse width of 640 to 1800 µsec, typically using knee garments with flexible, embedded 
electrodes and a small battery-operated generator, allowing application times of several hours 
rather than 15 to 60 minutes, as is the case for any other of the modalities described above. 
Objectives 
We set out to compare transcutaneous electrostimulation with sham or no specific 
intervention in terms of effects on pain and function and safety outcomes in patients with 
knee osteoarthritis and to explore whether potential variation between trials could be 
explained by characteristics of the electrostimulation, by biases affecting individual trials or 
by publication bias. 
Methods 
Criteria for considering studies for this review 
Types of studies Randomised or quasi-randomised controlled trials with a control group 
receiving a sham intervention or no intervention. 
Types of participants Studies including at least 75% of patients with clinically and/or 
radiologically confirmed osteoarthritis of the knee. 
Types of interventions Any type of transcutaneous electrostimulation with electrodes set to 
stimulate nerves supplying the knee joint area aiming at pain relief. We did not consider 
transcutaneous electrostimulation aiming at muscle strength enhancement, such as 
neuromuscular electrostimulation, and electrostimulation not directly aimed at stimulating 
nerves of the knee joint area, such as transcranial applications or transcutaneous spinal 
electroanalgesia. There were no restrictions related to the type of electrode used. 
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Types of outcome measures 
Main outcomes Main outcomes were pain intensity as the effectiveness outcome17 18 and 
withdrawals or drop-outs because of adverse events as the safety outcome. If data on more 
than one pain scale were provided for a trial, we referred to a previously described hierarchy 
of pain-related outcomes1 19 and extracted data on the pain scale that is highest on this 
hierarchy: 
1. Global pain 
2. Pain on walking 
3. WOMAC osteoarthritis index pain subscore 
4. Composite pain scores other than WOMAC 
5. Pain on activities other than walking 
6. Rest pain or pain during the night 
7. WOMAC global algofunctional score 
8. Lequesne osteoarthritis index global score 
9. Other algofunctional scale 
10. Patient’s global assessment 
11. Physician’s global assessment 
If pain outcomes were reported at several time points, we extracted the estimate at the end of 
the treatment period. 
Secondary outcomes Secondary outcomes were function, the number of patients 
experiencing any adverse event and patients experiencing any serious adverse events. We 
defined serious adverse events as events resulting in hospitalisation, prolongation of 
hospitalisation, persistent or significant disability, congenital abnormality/birth defect of 
offspring, life-threatening events or death. If data on more than one function scale were 
provided for a trial, we extracted data according to the hierarchy presented below. 
1. Global disability score 
2. Walking disability 
3. WOMAC disability subscore 
4. Composite disability scores other than WOMAC 
5. Disability other than walking 
6. WOMAC global scale 
7. Lequesne osteoarthritis index global score 
8. Other algofunctional scale 
9. Patient’s global assessment 
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10. Physician’s global assessment 
If function outcomes were reported at several time points, we extracted the estimate at the end 
of the treatment period. For safety outcomes, we extracted end of trial data. 
Search methods for identification of studies 
Electronic searches We searched the Cochrane Central Register of Controlled Trials 
(CENTRAL) (The Cochrane Library 2008, issue 3), MEDLINE and EMBASE through the 
Ovid platform (www.ovid.com), CINAHL through EBSCOhost, Physiotherapy 
EvidenceDatabase (PEDro, http:/ / www.pedro.fhs.usyd.edu.au/, from 1929 onwards), all 
from implementation to 5 August 2008, using a combination of keywords and text words 
related to electrostimulation combined with keywords and text words related to osteoarthritis 
and a validated filter for controlled clinical trials.20 The search strategy is presented in 
Appendix 1 and Appendix 2. 
Searching other sources We manually searched conference proceedings, used Science 
Citation Index to retrieve reports citing relevant articles, contacted content experts and 
trialists and screened reference lists of all obtained articles, including related reviews. Finally, 
we searched several clinical trial registries ( www.clinicaltrials.gov, 
www.controlledtrials.com, www.actr.org.au, www.umin.ac.jp/ ctr) to identify ongoing trials. 
The last update of the manual search was on 2 February 2009. 
Data collection and analysis 
Selection of studies Two review authors evaluated independently all titles and abstracts for 
eligibility (see Figure 1). We resolved disagreements by discussion. We applied no language 
restrictions. If multiple reports described the same trial, we considered all. 
Data collection Two review authors (AR and EN, RS or LK) extracted trial information 
independently using a standardised, piloted data extraction form accompanied by a codebook. 
We resolved disagreements by consensus or discussion with a third author (SR or PJ).We 
extracted the type of electrostimulation, including the mode of function (types of stimulator 
and electrode), the pulse form (intensity, rate and width), the electrode placement site and the 
frequency and duration of treatment. Other data extracted included the type of control 
intervention used, patient characteristics (gender, average age, duration of symptoms, type of 
joint), characteristics of pain, function and safety outcomes, design, trial size, trial duration 
(defined as time from randomisation until end of follow up), type and source of financial 
support and publication status. When necessary, we approximated means and measures of 
dispersion from figures in the reports. For cross-over trials, we extracted data from the first 
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period only. Whenever possible, we used results from an intention-to-treat analysis. If effect 
sizes could not be calculated, we contacted the authors for additional data. 
Quality assessment Two review authors (AR and EN, RS or LK) independently assessed 
randomisation, blinding, selective outcome reporting and handling of incomplete outcome 
data in the analyses.21 22 We resolved disagreements by consensus or discussion with a third 
author (SR or PJ). We assessed two components of randomisation: generation of allocation 
sequences and concealment of allocation. We considered generation of sequences adequate if 
it resulted in an unpredictable allocation schedule; mechanisms considered adequate included 
random-number tables, computer-generated random numbers, minimisation, coin tossing, 
shuffling of cards and drawing of lots. Trials using an unpredictable allocation sequence were 
considered randomised; trials using potentially predictable allocation mechanisms, such as 
alternation or the allocation of patients according to date of birth, were considered quasi-
randomised. We considered allocation concealment adequate if the investigators responsible 
for patient selection were unable to suspect before allocation which treatment was next; 
methods considered adequate included central randomisation and sequentially numbered, 
sealed, opaque envelopes. We considered blinding of patients adequate if a sham intervention 
was used that was identical in appearance from the control intervention. Transcutaneous 
electrostimulation generally does not allow blinding of therapists, whereas pain as the main 
effectiveness outcome is patient-reported by definition. Therefore, we did not assess blinding 
of therapists and outcome assessors. We considered handling of incomplete outcome data 
adequate if all randomised patients were included in the analysis (intention-to-treat principle). 
Finally, we used GRADE to describe the quality of the overall body of evidence,22 23 defined 
as the extent of confidence in the estimated treatment benefits and harms. 
Data synthesis We summarised continuous outcomes using standardised mean differences 
(SMD), with the differences in mean values at the end of treatment across treatment groups 
divided by the pooled standard deviation. If differences in mean values at the end of the 
treatment were unavailable, we used differences in mean changes. If some of the required data 
were unavailable, we used approximations as previously described.19 A SMD of -0.20 
standard deviation units can be considered a small difference between experimental and 
control group, a SMD of -0.50 a moderate difference, and -0.80 a large difference.1 24 SMDs 
can also be interpreted in terms of the percent of overlap of the experimental group’s scores 
with the scores of the control group. A SMD of -0.20 indicates an overlap in the distributions 
of pain or function scores in about 85% of cases, a SMD of -0.50 in approximately 67% and a 
SMD of -0.80 in about 50% of cases.1 24 On the basis of a median pooled SD of 2.5 cm found 
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in large-scale osteoarthritis trials that assessed pain using a 10 cm visual analogue scale 
(VAS),25 SMDs of -0.20, -0.50 and -0.80 correspond to approximate differences in pain 
scores between experimental and control groups of 0.5, 1.25 and 2.0 cm on a 10 cm VAS. 
SMDs for function were back transformed to a standardised WOMAC disability score26 
ranging from 0 to 10 on the basis of a median pooled SD of 2.1 units observed in large-scale 
osteoarthritis.25 We expressed binary outcomes as relative risks. 
We used standard inverse-variance random-effects meta-analysis27 to combine trials overall 
and stratified according to gross categories of electrostimulation (TENS, interferential current 
stimulation or pulsed electrostimulation).We quantified heterogeneity between trials using the 
I2 statistic,28 which describes the percentage of variation across trials that is attributable to 
heterogeneity rather than to chance and the corresponding χ2 test. I2 values of 25%, 50% and 
75% may be interpreted as low, moderate and high between-trial heterogeneity, although the 
interpretation of I2 depends on the size and number of trials included.29 The association 
between trial size and treatment effects was investigated in funnel plots, plotting effect sizes 
on the vertical axis against their standard errors on the horizontal axis. We assessed 
asymmetry by the asymmetry coefficient: the difference in effect size per unit increase in 
standard error,30 which is mainly a surrogate for sample size, and used uni-variable meta-
regression analysis to predict treatment effects in trials as large as the largest trials included in 
the meta-analysis, using the standard error as the explanatory variable.31 In view of the biased 
nature of the predominantly small trials included in the meta-analysis of pain intensity, we 
considered the predicted estimates of effectiveness more reliable than the pooled estimates. 
For the analysis on the effectiveness outcomes pain and function, we differentiated between 
TENS, interferential current stimulation and pulsed electrostimulation. Then, we performed 
effectiveness analyses stratified by the following trial characteristics: concealment of 
allocation, use of a sham intervention in the control group, blinding of patients, analysis in 
accordance with the intention-to-treat principle, trial size, difference in the use of analgesic 
cointerventions, specific type of electrostimulation, duration of stimulation per session, 
number of sessions per week, duration of electrostimulation per week as an overall measure 
of treatment intensity, and duration of treatment period. A cut-off of 200 patients was used to 
distinguish between small and large trials; a sample size of 100 patients per group will yield 
more than 80% power to detect a small to moderate SMD of -0.40 at a two-sided P of 0.05. 
For the analysis according to specific type of stimulation, we distinguished between high 
frequency TENS, burst TENS, modulation TENS, low frequency TENS, interferential current 
stimulation or pulsed electrostimulation. We classified conventional TENS and brief TENS as 
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high frequency TENS. Cut-offs of 20 and 60minutes were used for the duration of 
electrostimulation per session, corresponding to the typical treatment duration in physical 
therapy, and the optimum stimulation duration suggested by Cheing 2003. A cut-off of four 
weeks was used for the overall duration of the treatment period (time from randomisation to 
last session), in line with the previous version on this review. Cut-offs of three and seven were 
used for the number of sessions per week; one and five hours for the duration of 
electrostimulation per week, corresponding to the distribution of tertiles. We used uni-
variable random-effects meta-regression models to determine whether treatment effects were 
affected by these factors.32 Then, we converted SMDs of pain intensity and function to odds 
ratios33 to derive numbers needed to treat (NNT) to cause one additional treatment response 
on pain or function as compared with control, and numbers needed to harm (NNH) to cause 
one additional adverse outcome. We defined treatment response as a 50% improvement in 
scores,34 which corresponds to an average decrease of 1.2 standard deviation units. Based on 
the median standardised pain intensity at baseline of 2.4 standard deviation units and the 
median standardised decrease in pain scores of 0.72 standard deviation units observed in large 
osteoarthritis trials,25 we calculated that a median of 31% of patients in the control group 
would achieve an improvement of pain scores of 50% or more. This percentage was used as 
the control group response rate to calculate NNTs for treatment response on pain. Based on 
the median standardised WOMAC function score at baseline of 2.7 standard deviation units 
and the median standardised decrease in function scores of 0.58 standard deviation units,25 
26% of patients in the control group would achieve a reduction in function of 50% or more. 
Again, this percentage was used as the control group response rate to calculate NNTs for 
treatment response on function. We used median risks of 150 patients with adverse events per 
1000 patient-years, four patients with serious adverse events per 1000 patient-years and 17 
drop-outs due to adverse events per 1000 patient-years observed in placebo groups in large 
osteoarthritis trials25 to calculate NNHs for safety outcomes. We performed analyses in 
RevMan version 5 (RevMan 2008) and STATA version 10.1 (StataCorp, College 
Station,Texas). All P values are two-sided. 
Results 
Description of studies We identified 1697 references to articles and considered 85 to be 
potentially eligible (Figure 1). Twenty-two reports describing 18 completed trials in 813 
patients and two protocols describing uncompleted trials13 35 met our inclusion criteria. Six 
trials evaluated high frequency TENS,36-43 one high frequency and burst TENS,11 one high 
frequency TENS and interferential current stimulation,44 one low frequency, high frequency 
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and modulation TENS with alternating low and high frequency current,45 one burst TENS,46 
two low frequency TENS,47 48 four interferential current stimulation,49-52 and three evaluated 
pulsed electrostimulation.13 53 54 The protocol of Palmer 2007 did not specify which type of 
TENS would be used.  
 
Figure 1 Flow chart. † interventions: any type of transcutaneous applied electrical stimulation primarily aiming 
at pain relief, with electrode placement involving knee innervation, ‡ described in 17 reports, including a 
protocol of an ongoing trial, *one trial including both interferential current stimulation and TENS versus control, 
** including a protocol of an ongoing trial, *** primary authors of 5 reports on 4 cross-over trials were unable to 
provide data before cross-over 
The description of the uncompleted trials can be found in the ’Characteristics of ongoing 
studies’ table. Of the completed trials, 17 trials used a parallel group and one a 2 x 2 factorial 
design.51 Twelve trials used a sham intervention in the control group, five used no 
intervention37 44 47 51 52 and one trial had both a sham and a no intervention control.38-40 
Standardised cointerventions, provided in both experimental and control groups, were used in 
five trials with no intervention controls37-40 44 47 52 and in two trials with a sham intervention.36 
49
 Cetin 2008 used hot packs and exercise, Adedoyin 2002 dietary advice and exercise, Quirk 
1985,Cheing 2002 and Adedoyin 2005 exercise, Bal 2007 used infra-red therapy and Ng 2003 
an educational pamphlet. In addition, Itoh 2008 assigned 50% of patients to acupuncture 
using a factorial design. 
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Characteristics of the currents varied considerably, even within a specific type of 
electrostimulation. In the three trials evaluating low frequency TENS, pulse width and pulse 
frequency ranged from 200 µsec and 2 Hz to 1000 µsec and 4 Hz, with intensities set to reach 
a comfortable level in one,45 and resulting in muscle contraction in two trials.47 48 In trials of 
high frequency TENS, pulse width and pulse frequency ranged from 80 µsec and 32 Hz43 to 
200 µsec and 100 Hz,41 with the majority of intensities described as strong but comfortable. In 
trials of burst TENS, Fargas-Babjak 1989 used a pulse frequency of 200 Hz, a train length of 
125 µsec and a repetition frequency of 4 Hz with intensity increased up to the patients’ limits 
of tolerability, while Grimmer 1992 used a pulse frequency of 80 Hz, an unclear train length 
and pulse width and a repetition frequency of 3 Hz, with the intensity resulting in a strong, 
tolerable tingling sensation and visible, but comfortable muscle contraction. In the five trials 
of interferential current stimulation, the beat frequency ranged from30 to 130 Hz and 
intensities resulted typically in tingling sensations in four trials,44 49 51 52 and pain in one.50 The 
two trials of pulsed electrostimulation were the only ones to use intensities below the sensory 
threshold.53 54 The trials used the same device, which produces monophasic, spike-shaped 
pulses in a frequency of 100 Hz. The intensity of the current was initially increased until a 
tingling sensation was felt and subsequently reduced until this sensation disappeared. 
The trials differed in type, number and localisation of electrodes used (see ’Characteristics of 
included studies’). The median duration of electrostimulation per session was 25 minutes 
(range 15 minutes to 8.2 hours), with a duration of 15 to 20 minutes in 10 trials,37 41 43 44 47-52 
30 to 40 minutes in six;11 36 41 42 45 46 and 60 minutes or more in 4 trials.38-41 53 54 The median 
number of treatment sessions per week was 3.5 (range 1 to 14), with up to three sessions per 
week in eight trials,11 37 43 44 49-52 four to six in seven,36 38-42 45 47 48 and seven or more in three 
trials.46 53 54 This resulted in a median duration of electrostimulation of 1.5 hours per week 
(range 15 minutes to 57.4 hours). The median length of the treatment period was four weeks 
(range one day to 12 weeks). All but one trial explicitly included patients with knee 
osteoarthritis only, with the diagnosis based on clinical and/or radiographic evidence. Fargas-
Babjak 1989 included patients with either knee or hip osteoarthritis, and failed to report the 
percentage of patients with knee osteoarthritis, but it was considered likely that this 
percentage was above 75%. The majority of patients had a clinical severity requiring simple 
non-surgical treatments.1 In one trial of pulsed electrostimulation, the majority of patients (41 
out of 58) were candidates for total knee arthroplasty, however.53 The description of patient 
characteristics was generally poor. Only four trials36 42 48 53 reported the average disease 
duration, which ranged from two to 8.4 years. 
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Four cross-over trials could not be included because of incomplete reporting, which did not 
allow the distinction between treatment phases.55-57 All but Lewis 1985 were included in the 
previous version of this review.6 Three other trials were excluded because of an active control 
intervention using another type of electrostimulation.58-60 Detailed reasons for exclusion are 
displayed in ’Characteristics of excluded studies’ 
Risk of bias in included studies Figure 2 summarises the methodological characteristics and 
source of funding of included trials. One trial reported both adequate sequence generation and 
adequate concealment of allocation,53 five trials reported only adequate sequence 
generation,42 43 45 47 51 and one trial reported adequate concealment, but provided insufficient 
detail on the generation of allocation sequence.11 Two trials were quasi-randomised, one used 
alternation to allocate patients to experimental and control intervention,49 the other allocated 
patients according to hospital registration number.36 In the remaining nine trials, low quality 
of reporting hampered any judgement regarding sequence generation and concealment of 
allocation. 
Six trials11 42 45 46 53 54 were described as double-blind. Thirteen trials used sham interventions, 
all using identical devices in experimental and control groups.11 36 38-43 45 46 48-50 53 54 In 10 out 
of 13 trials, sham devices had broken leads so that no current could pass, whereas the 
indicator light or digital display of intensity control functioned normally. In the two pulsed 
electrostimulation trials, all patients were instructed to increase the intensity until a tingling 
sensation was felt, after which they were asked to reduce intensity just below the perception 
(sensory) level. Pulsed electrostimulation sham devices were adapted with an automatic shut-
off as soon as the amplitude was reduced.53 54 Only the sham device used in Defrin 2005 was 
not considered to lead to adequate patient blinding, as the sham device was described as shut 
off. Only the two trials of pulsed electrostimulation, however, which used currents below the 
sensory threshold, were deemed to have fully credible blinding of patients.53 54 
Sixteen out of 18 completed trials contributed to the analysis of pain outcomes. Of these, only 
three trials,11 36 49 which had analysed all randomly assigned patients, were considered to have 
an intention-to-treat analysis of pain outcomes at end of treatment. In three trials37 47 50 it was 
unclear whether exclusions of randomised patients from the analysis had occurred, in five 
trials42 45 46 48 53 exclusions were reported, but their percentage remained unclear and in the 
remaining six trials the median reported exclusion rate was 7% in the experimental and 11.5% 
in the control groups (range 0% to 25% in both experimental and control groups). Two out of 
nine trials contributing to the analysis of function outcomes were considered to have an 
intention-to-treat analysis.36 52 In one trial37 it was unclear whether exclusions of randomised  
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Figure 2. Methodological characteristics 
and source of funding of included trials. (+) 
indicates low risk of bias, (?) unclear and (-) 
a high risk of bias on a specific item. 
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patients from the analysis had occurred, in three trials42 48 53 exclusions were reported, but 
their percentage remained unclear and in the remaining three trials the median reported 
exclusion rate was 11.5% in experimental and 12% in control groups (range 0% to 25% in 
experimental, and 11% to 25% in control groups, respectively). 
Only three trials explicitly specified primary outcomes,49 51 54 although one of these specified 
more than two.54 Only one trial reported a sample size calculation.44 None of the trials had a 
sufficient sample size of at least 200 patients overall to achieve sufficient power for detecting 
a small to moderate SMD. Only three trials reported their source of funding: one was 
supported by a nonprofit organisation and a commercial body,46 the other two by a 
commercial body only.53 54 
For the effectiveness outcomes pain and function, the quality of the evidence 23 was classified 
as very low in view of the risk of bias in the included, predominantly small trials of 
questionable quality, the large heterogeneity between trials, the potential for selective 
reporting of function outcomes and the exploratory nature of the model used to predict SMDs 
of pain in trials as large as the largest trials (’Summary of findings for the main comparison’). 
For the safety outcomes, the quality of the evidence23 was classified as moderate to low, again 
because of the predominantly small trials of questionable quality, the small number of trials 
reporting the outcomes and the small number of events resulting in imprecise estimates. 
Effects of interventions 
Knee pain Sixteen trials with 18 comparisons (726 patients) contributed to the meta-analysis 
of pain outcomes (Figure 3). The analysis suggested an overall large SMD of -0.86 (95% CI -
1.23 to -0.49), which corresponds to a difference in pain scores of 2.1 cm on a 10 cm VAS 
between electrostimulation and control, favouring electrostimulation. Within the types of 
electrostimulation, a very large effect was found for interferential current stimulation (SMD -
1.20, 95% CI -1.99 to -0.42), a large effect in TENS (SMD -0.85, 95%CI -1.36 to -0.34) and a 
moderate effect in pulsed electrostimulation (SMD -0.41, 95% CI -0.77 to -0.05). However, 
interaction tests provided little evidence for differences between different types. Pooling all 
types of electrostimulation, an I2 of 80% indicated a high degree of between-trial 
heterogeneity (P for heterogeneity < 0.001), which was not substantially reduced when 
pooling types of electrostimulation separately. Four trials41 42 45 50 showed unrealistically large 
SMDs of twice to three times the magnitude of what would be expected for total joint 
replacement.1 The funnel plot appeared asymmetrical (Figure 4, P for asymmetry < 0.001) 
and the corresponding asymmetry coefficient was -7.6 (95% CI -10.6 to -4.5).  
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Figure 3. Forest plot of 16 trials comparing the effects of any type of transcutaneous electrostimulation and 
control (sham or no intervention) on knee pain. Values on x-axis denote standardised mean differences. The plot 
is stratified according to type of electrostimulation. Law 2004 reported on knee level, we inflated the standard 
error with sqrt(number knees)/sqrt(number patients) to correct for clustering of knees within patients. Adedoyin 
2005 and Cheing 2002 contributed with two comparisons each. In Adedoyin 2005, the standard error was 
inflated and the number of patients in the control group was halved to avoid duplicate counting of patients when 
including 2 both comparisons in the overall meta-analysis. Data relating to the 3, 2, 3 and 4 active intervention 
arms in Cheing 2003, Grimmer 1992, Law 2004 and Defrin 2005, respectively, were pooled. 
 
Figure 4. Funnel plot for effects 
on knee pain. Numbers on x-
axis refer to standardised mean 
differences (SMDs), on y-axis to 
standard errors of SMDs. 
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Variable N of trials 
N of patients  
(experimental) 
N of patients  
(control) Pain intensity 
Heterogen
eity 
P for 
interaction 
 n n n SMD (95% CI) I2 (%)  
All trials 16 440 286 -0.86 (-1.23 to -0.49) 80%  
Allocation concealment 
     0.47 
Adequate 2 79 39 -0.52 (-0.91 to -0.13) 0%  
Inadequate or unclear 14 361 247 -1.03 (-1.49 to -0.57) 84%  
Type of control intervention* 
    0.12 
Sham intervention 12 354 216 -1.13 (-1.59 to -0.67) 82%  
No control intervention 5 86 70 -0.31 (-0.80 to 0.19) 58%  
Blinding of patients 
     0.37 
Adequate 11 309 205 -1.05 (-1.52 to -0.59) 82%  
Inadequate or unclear 6 131 79 -0.63 (-1.31 to 0.05) 81%  
Use of analgesic cointerventions 
    0.36 
Similar between groups 4 124 83 -0.57 (-1.16 to 0.02) 74%  
Not similar or unclear 12 316 23 -1.10 (-1.60 to -0.59) 84%  
Intention-to-treat analysis 
     0.73 
Yes 3 83 63 -0.76 (-1.43 to -0.09) 72%  
No or unclear 13 357 223 -1.00 (-1.48 to -0.53) 84%  
Type of ES** 
     0.94 
High frequency TENS 8 177 139 -0.82 (-1.51 to -0.12) 86%  
Burst TENS 2 39 38 -0.85 (-1.32 to -0.38) 0%  
Modulation TENS 1 13 3 -1.41 (-2.92 to 0.10) N/A  
Low frequency TENS 3 46 40 -0.82 (-1.29 to -0.34) 0%  
Interferential current 
stimulation 4 88 44 -1.20 (-1.99 to -0.42) 71%  
Pulsed ES 2 77 52 -0.41 (-0.77 to -0.05) 0%  
Duration of ES per session† 
    0.69‡ 
≤ 20 minutes 8 166 112 -0.95 (-1.55 to -0.35) 78%  
30 to 40 minutes 6 156 99 -1.45 (-2.28 to -0.62) 85%  
≥ 60 minutes 4 118 91 -0.47 (-0.96 to 0.02) 58%  
Number of sessions per week 
    0.90‡ 
≤ 3 6 163 91 -0.81 (-1.48 to -0.14) 82%  
4 to 6 7 182 125 -1.33 (-2.11 to -0.54) 88%  
≥ 7 3 96 70 -0.51 (-0.83 to -0.19) 0%  
Duration of ES per week*** 
    0.74‡ 
≤1 hour 5 123 71 -0.85 (-1.72 to 0.01) 86%  
>1 to 5 hours 8 180 122 -1.42 (-2.11 to -0.74) 81%  
> 5 hours 5 137 109 -0.53 (-0.96 to -0.11) 55%  
Duration of treatment period 
    0.14 
< 4 weeks 7 190 114 -1.39 (-2.13 to -0.66) 86%  
≥ 4 weeks 9 250 172 -0.64 (-1.06 to -0.22) 75%  
Table 1 Results of stratified analyses of pain outcomes ES: electrostimulation; *In Cheing 2002, two 
independent comparisons contributed in the two different strata. **Adedoyin 2005, Grimmer 1992 and Law 
2004 contributed to two, two and three different strata: high-frequency TENS and interferential current 
stimulation, high-frequency TENS and burst, and high-, low-frequency and modulation TENS, respectively. †= 
Cheing 2003 contributed to all three different strata, with the same 8 control patients displayed in each stratum. 
‡= p-values from test for trend. 
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This coefficient indicates that the benefit of electrostimulation increases by 7.6 standard 
deviation units for each unit increase in the standard error of the SMD, which is mainly a 
surrogate for sample size. The predicted SMD in trials as large as the largest trial (Zizic 1995, 
n = 71, standard error = 0.24) was -0.07 (95%CI -0.46 to 0.32), which corresponds to a 
difference in pain scores of 0.2 cm on a 10 cm VAS between electrostimulation and control. 
Referring to a median pain intensity of 6.1 cm in placebo groups at baseline, this corresponds 
to a difference of 4% improvement (95% CI -13% to +20%) between electrostimulation and 
control (’Summary of findings for the main comparison’). 
Table 1 presents results from stratified analyses. Estimates of SMD varied to some degree 
depending on concealment of allocation, adequacy of patient blinding, use of analgesic 
cointerventions and characteristics of electrostimulation, but 95% CIs of SMDs were wide 
and tests of interaction and tests for trend not statistically significant. There was little 
evidence to suggest that SMDs depended on the type of electrostimulation used (P for 
interaction = 0.94). Contrary to what would be expected in the presence of relevant placebo 
effects, we found some evidence towards larger benefits of electrostimulation in trials with a 
sham intervention as compared with trials without (P for interaction = 0.12). In addition, there 
was some evidence for larger benefits of electrostimulation associated with short durations of 
the overall treatment period of less than four weeks as compared with four weeks or more (P 
for interaction = 0.14). The analysis could not be stratified according to sample size, because 
none of included trials reached the prespecified sample size of 200 patients to be considered 
as adequately sized. 
Withdrawals or drop-outs because of adverse events Eight trials (348 patients) contributed 
to the meta-analysis of patients withdrawn or dropped out because of adverse events (Figure 
5). Of these, four TENS trials and one interferential current stimulation trial reported that no 
withdrawals or drop-outs due to adverse events had occurred, neither in experimental nor in 
control groups, therefore relative risks could not be estimated. In the remaining three trials, 
there was no evidence that transcutaneous electrostimulation is unsafe (relative risk 0.97), but 
95% confidence intervals were wide and ranged from 0.16 to 6.00. Pooling all types of 
electrostimulation, an I2 of 20%indicated a low degree of between-trial heterogeneity (P for 
heterogeneity = 0.29).  
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Figure 5. Forest plot of 8 trials comparing patients withdrawn or dropped out because of adverse events between 
any transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis denote risk ratios. 
Risk ratios could not been estimated in 5 trials, because no dropout occurred in either group. The plot is stratified 
according to type of electrostimulation. Data relating to the 3 and 2 active intervention arms in Cheing 2003 and 
Grimmer 1992, respectively, were pooled. 
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Figure 6. Forest plot of 9 trials comparing the effects of any type of transcutaneous electrostimulation and 
control (sham or no intervention) on function. Values on x-axis denote standardised mean differences. The plot 
is stratified according to type of electrostimulation. In Adedoyin 2005, the standard error was inflated and the 
number of patients in the control group was halved to avoid duplicate counting of patients when including both 
comparisons in the overall meta-analysis. 
 
 
Figure 7. Funnel plot for effects on 
functioning of the knee.Numbers on x-
axis refer to standardised mean 
differences (SMDs), on y-axis to 
standard errors of SMDs. 
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Function Nine trials (407 patients) contributed to the meta-analysis of function. The analysis 
suggested a small SMD of -0.34 (95% CI -0.54 to -0.14, Figure 6), which corresponds to a 
difference in function scores of 0.7 units on a standardised WOMAC disability scale ranging 
from 0 to 10, favouring electrostimulation. Referring to a median function score of 5.6 units 
in placebo groups at baseline, this corresponds to a difference of 20% improvement (95% CI 
+11% to +29%) between electrostimulation and control (’Summary of findings for the main 
comparison’). The estimated difference in the percentage of treatment responders between 
patients allocated to electrostimulation and patients allocated to placebo of 3% translated into 
an NNT to cause one additional treatment response on function of 29 (95% CI 19 to 69) 
(’Summary of findings for the main comparison’).Differences between types of 
electrostimulation were not statistically significant. An I2 of 0% suggested no between-trial 
heterogeneity (P for heterogeneity = 0.57). The funnel plot did not appear asymmetrical ( 
Figure 7, P for asymmetry = 0.52). The corresponding asymmetry coefficient was 1.4 (95% 
CI, -3.5 to 6.3).  
Table 2 presents results from stratified analyses. Estimates of SMD varied to some degree 
depending on type of control intervention, adequacy of patient blinding, characteristics of 
electrostimulation and overall treatment period, but 95%CIs of SMDs were wide and tests for 
interaction and tests for trend not statistically significant. There was little evidence to suggest 
that SMDs depended on the type of electrostimulation used (P for interaction = 0.32). Again, 
the analysis could not be stratified according to sample size, because none of included trials 
reached the pre-specified sample size of 200 patients to be considered as adequately sized. 
Other safety outcomes Three trials (175 patients) contributed to the meta-analysis of patients 
experiencing any adverse event (Figure 8) and four trials (195 patients) to the meta-analysis 
of patients experiencing any serious adverse event (Figure 9). In general, there was no 
evidence to suggest that electrostimulation is unsafe, but 95% CIs were wide and results 
inconclusive. 
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Variable N of trials 
N of patients  
(experimental) 
N of 
patients  
(control) 
Function Heterogeneity P for interaction 
     SMD (95% CI) I2 (%)  
All trials 9 226 181 -0.34 (-0.54 to -0.14) 0%  
Allocation concealment 
     0.88 
adequate 1 39 19 -0.29 (-0.85 to 0.26) N/A  
inadequate or unclear 8 187 162 -0.34 (-0.56 to -0.12) 5%  
Type of control intervention 
     0.14 
sham intervention 5 151 120 -0.46 (-0.70 to -0.21) 0%  
no control intervention 4 75 61 -0.10 (-0.45 to 0.24) 0%  
Blinding of patients 
     0.14 
adequate 5 151 120 -0.46 (-0.70 to -0.21) 0%  
inadequate or unclear 4 75 61 -0.10 (-0.45 to 0.24) 0%  
Use of analgesic cointerventions 
   0.95 
similar between groups 2 69 48 -0.33 (-0.70 to 0.05) 0%  
not similar or unclear 7 157 133 -0.34 (-0.60 to -0.08) 15%  
Intention-to-treat analysis 
     0.76 
Yes 2 40 42 -0.28 (-0.71 to 0.16) 0%  
No or unclear 7 186 139 -0.35 (-0.58 to -0.12) 5%  
Type of ES** 
     0.32 
High frequency TENS 4 84 70 -0.18 (-0.50 to 0.14) 0%  
Burst TENS 0      
Modulation TENS 0      
Low frequency TENS 1 25 25 -0.88 (-1.46 to -0.30) N/A  
Interferential current 
stimulation 3 40 34 -0.27 (-0.75 to 0.20) 0%  
Pulsed ES 2 77 52 -0.36 (-0.72 to -0.00) 0%  
Duration of ES per session 
     0.80‡ 
≤ 20 minutes 5 100 86 -0.29 (-0.69 to 0.11) 44%  
30 to 40 minutes 2 49 43 -0.37 (-0.79 to 0.04) 0%  
≥ 60 minutes 2 77 52 -0.36 (-0.72 to -0.00) 0%  
Number of sessions per week 
    0.32‡ 
≤ 3 4 75 61 -0.10 (-0.45 to 0.24) 0%  
4 to 6 3 74 68 -0.54 (-0.88 to -0.20) 2%  
≥ 7 2 77 52 -0.36 (-0.72 to -0.00) 0%  
Duration of ES per week 
     0.32‡ 
≤ 1 hour 4 75 61 -0.10 (-0.45 to 0.24) 0%  
> 1 to 5 hours 3 74 68 -0.54 (-0.88 to -0.20) 2%  
> 5 hours 2 77 52 -0.36 (-0.72 to -0.00) 0%  
Duration of treatment period 
     0.18 
< 4 weeks 3 74 68 -0.54 (-0.88 to -0.20) 2%  
≥ 4 weeks 6 152 113 -0.23 (-0.47 to 0.02) 0%  
Table 2. Results of stratified analyses of function. ES: electrostimulation; **Adedoyin 2005 contributed to two 
different strata: high-frequency TENS and interferential current stimulation; ‡= p-values from test for trend. 
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Figure 8 Forest plot of 3 trials comparing patients experiencing any adverse event between any transcutaneous 
electrostimulation and control (sham or no intervention). Values on x-axis denote risks ratios. The risk ratio in 
one TENS trial could not be estimated because no adverse event occurred in either group. The plot is stratified 
according to type of electrostimulation. 
 
Figure 9 Forest plot of 4 trials comparing patients experiencing any serious adverse event between any 
transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis denote risk ratios. Risk 
ratios could not been estimated in 3 trials, because no serious adverse event occurred in either group. The plot is 
stratified according to type of electrostimulation. Data relating to the 3 active intervention arms in Cheing 2003 
were pooled. 
 
Article 4: Transcutaneous electrical nerve stimulation for osteoarthritis of the knee 
110 
Discussion 
Summary of main results Our systematic review of trials comparing any type of 
transcutaneous electrostimulation with a sham or non-intervention control revealed a lack of 
adequately sized, methodologically sound and appropriately reported trials and a moderate to 
high degree of heterogeneity between trials, which made the interpretation of results difficult, 
particularly for joint pain as the primary therapeutic target of transcutaneous 
electrostimulation. In an attempt to minimise biases associated with small trials of 
questionable quality, we used meta-regression to predict effects of transcutaneous 
electrostimulation on pain and found the predicted effect sizes for pain negligibly small. The 
rates of withdrawals or drop-outs due to adverse events were comparable in experimental and 
control groups, but 95% CIs were wide and therefore inconclusive. 
Quality of the evidence An inspection of funnel plots and a formal analysis of asymmetry 
indicated asymmetry for knee pain, but not for function, which suggested the presence of 
biases associated with small sample size particularly when estimating the effects of 
electrostimulation on knee pain. Asymmetrical funnel plots should be seen not only as an 
indication of publication bias, but as a generic tool for examination of small study effects: the 
tendency for the smaller studies to show larger treatment effects, possibly due to a 
combination of publication bias, selective reporting of outcomes and methodological 
problems particularly in small trials.61 62 If reporting is inadequate, as was the case in our 
systematic review, then the standard error as a proxy for study size may be a more precise 
measure of trial quality than formal assessments of methodological quality. When modelling 
effects expected in trials as large as the largest trial included in our systematic review, we 
found effects on pain near null -0.07 (95% CI -0.46 to 0.32), which were clearly smaller than 
the pooled SMD actually found for pain in the meta-analysis -0.86 (95% CI -1.23 to -0.49). 
The effect of electrostimulation on function was small, but potentially clinically relevant, and 
the accumulated evidence appeared less affected by biases associated with small sample size. 
The methodological quality and the quality of reporting was poor. Insufficient information 
was noted in several randomised controlled trials about the treatment assignment procedure 
and concealment of allocation. Primary outcomes were specified in only three trials. Although 
several studies reported blinding of patients, complete blinding is difficult to achieve due to 
the sensory differences between treatment and placebo, as well as unintended communication 
between patient and evaluator.63 Only Grimmer 1992 and Bal 2007 mentioned the inclusion 
of patients to be restricted to those without prior TENS experience; another two trials were 
likely to have achieved adequate blinding of patients with currents below the sensory 
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threshold used in the experimental group, which were likely to be indistinguishable from the 
sham intervention also for patients with treatment experience.53 54 The majority of papers did 
not provide adequate information regarding withdrawals, drop-outs and losses to follow up, 
nor indicated whether patients with incomplete clinical data were included in the data 
analysis. Several trials omitted to describe adverse events, which is of concern. 
Potential biases in the review process Our review is based on a broad literature search, and 
it seems unlikely that we missed relevant trials. Trial selection and data extraction, including 
quality assessment, were done independently by two authors to minimise bias and 
transcription errors. Components used for quality assessment are validated and reported to be 
associated with bias.21 64 
As with any systematic review, our study is limited by the quality of included trials. As 
indicated above, trials generally suffered from poor methodological quality, inadequate 
reporting and small sample size. Some trials41 42 50 showed unrealistically large SMDs of 
twice to three times the magnitude of what would be expected for total joint replacement.1 
Including these trials in the meta-analysis is likely to result in an overestimation of the 
benefits of transcutaneous electrostimulation. 
Agreements and disagreements with other studies or reviews Interestingly, there are 
nearly as many systematic reviews and meta-analyses on transcutaneous electrostimulation in 
osteoarthritis as randomised trials. Here, we will focus mainly on the similarities and 
differences between ours and the previous version of this review,6 which included seven 
transcutaneous electrical nerve stimulation (TENS) trials. We updated the search and used 
broader selection criteria, which resulted in 14 additional trials; 11 trials used TENS as the 
experimental treatment, four interferential current stimulation, one both TENS and 
interferential current stimulation, and two pulsed electrostimulation. As in the review of Osiri 
2000, both parallel group and cross-over RCTs were included. For the cross-over studies, we 
only collected data from the first intervention phase in order to eliminate carry-over effects, 
whereas Osiri and colleagues included pooled data over all phases. We excluded three 
previously included cross-over trials, because the investigators were unable to provide data 
from the first phase only. In this update, we performed a more detailed quality assessment of 
component trials, followed by a detailed exploration of sources of variation between trials, 
including concealment of allocation, blinding, intention-to-treat analysis, characteristics of 
analyse continuous data, Osiri and colleagues used weighted mean differences or SMDs of the 
change from baseline scores, whereas we used SMDs of end of treatment scores and based 
our conclusions on treatment effects on pain predicted in uni-variable metaregression models 
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by using the standard error as the explanatory variable. In addition, fixed-effect models were 
used in the previous version unless there was statistically significant heterogeneity between 
trials based on χ2 testing. Model selection based on the mechanistic application of 
heterogeneity tests should be avoided, however. Here, we used random-effects models, which 
will generally be more conservative in terms of the estimated precision, but will be more 
affected by small study effects than a fixed-effect model, which makes an exploration of 
sources of variation, including different types of bias, mandatory. Results from the previous 
and current versions are therefore not directly comparable. Nevertheless, pooled SMDs for 
pain were favourable in our and the previous review,6 with us reporting a pooled SMD of -
0.86 (95% CI -1.23 to -0.49), whereas Osiri 2000 reported a SMD of -0.45 (95% CI -0.70 to -
0.19), with confidence intervals overlapping widely. Although both Osiri and we 
acknowledge the risk of bias in summary estimates, Osiri concluded that transcutaneous 
electrostimulation is “shown to be effective in pain control over placebo”. We disagree with 
these conclusions: when modelling effects expected in trials as large as the largest trial 
included, we found the SMD of pain near null and clinically irrelevant (-0.07, 95% CI -0.46 to 
0.32). Osiri 2000 recorded function separately for the outcomes ’stiffness of the knee’, ’50-
foot walking time’, ’quadriceps muscle strength’ and ’knee flection’ with only one trial 
contributing to each of the categories. We choose a different approach, using a hierarchy 
developed to minimise the impact of selective reporting of outcomes and to allow for a 
synthesis of evidence across different studies using divergent definitions of function. Our 
effect sizes and conclusion concerning function are less favourable compared to those made 
by Osiri 2000. In this version, we also summarised safety data and found no evidence to 
suggest that electrostimulation is unsafe. Finally, unlike Osiri 2000, we also included trials of 
interferential current stimulation and pulsed electrostimulation. One of the two trials of pulsed 
electrostimulation54 is covered in another Cochrane Review by Hulme 2002 on 
electromagnetic fields, even though the device used (BioniCare BIO-1000) does not generate 
electromagnetic fields, but electric currents.65  
Authors’ conclusions 
Implications for practice Despite more than 20 years of clinical research, there is a lack of 
adequate evidence to support the use of any type of transcutaneous electrostimulation in 
patients with knee osteoarthritis. The effects on both knee pain and function are potentially 
clinically relevant and deserve further clinical evaluation. 
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Implications for research The current systematic review is inconclusive, hampered by the 
inclusion of only small trials of questionable quality.62. Adequately sized randomised parallel-
group trials in about 2 x 100 patients with knee osteoarthritis are necessary to determine 
whether a specific type of transcutaneous electrostimulation is indeed associated with a 
clinically relevant benefit on pain. A sample size of 2 x 100 patients will yield more than 80% 
power to detect a small to moderate SMD of -0.40 at a two-sided P of 0.05, which 
corresponds to a difference of 1 cm on a 10 cm visual analogue scale (VAS) between 
experimental and control intervention. The trials should enrol patients without prior 
experience of any type of transcutaneous electrostimulation or evaluate success of blinding at 
the end of trial, use adequate concealment of allocation, experimental and sham interventions 
that are close to indistinguishable and an intention-to-treat analysis. Transcutaneous electrical 
nerve stimulation (TENS) devices are marketed as small, inexpensive, easy-to-use home 
units, but in the majority of trials TENS was administered by a therapist in a practice or 
hospital setting. Future research may focus on the effectiveness of self-administered TENS, 
with accurate recording of the duration of electrostimulation per day to assess compliance and 
enable the exploration of possible dose-effect relationships. 
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Appendix 1 MEDLINE, EMBASE and CINAHL search strategy 
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Appendix 1. MEDLINE, EMBASE and CINAHL search strategy (continued) 
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Appendix 2. CENTRAL and PEDro search strategy 
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Abstract 
Objective To study the inter-observer variation related to extraction of continuous and 
numerical rating scale data from trial reports for use in meta-analyses. 
Design Observer agreement study. 
Data sources A random sample of 10 Cochrane reviews that presented a result as a 
standardised mean difference (SMD), the protocols for the reviews and the trial reports (n=45) 
were retrieved. 
Data extraction Five experienced methodologists and five PhD students independently 
extracted data from the trial reports for calculation of the first SMD result in each review. The 
observers did not have access to the reviews but to the protocols, where the relevant outcome 
was highlighted. The agreement was analysed at both trial and meta-analysis level, pairing the 
observers in all possible ways (45 pairs, yielding 2025 pairs of trials and 450 pairs of meta-
analyses). Agreement was defined as SMDs that differed less than 0.1 in their point estimates 
or confidence intervals. 
Results The agreement was 53% at trial level and 31% at meta-analysis level. Including all 
pairs, the median disagreement was SMD=0.22 (interquartile range 0.07-0.61). The experts 
agreed somewhat more than the PhD students at trial level (61%v 46%), but not at meta-
analysis level. Important reasons for disagreement were differences in selection of time 
points, scales, control groups, and type of calculations; whether to include a trial in the meta-
analysis; and data extraction errors made by the observers. In 14 out of the 100 SMDs 
calculated at the meta-analysis level, individual observers reached different conclusions than 
the originally published review. 
Conclusions Disagreements were common and often larger than the effect of commonly used 
treatments. Meta-analyses using SMDs are prone to observer variation and should be 
interpreted with caution. The reliability of meta-analyses might be improved by having more 
detailed review protocols, more than one observer, and statistical expertise. 
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Introduction 
Systematic reviews of clinical trials, with meta-analyses if possible, are regarded as the most 
reliable resource for decisions about prevention and treatment. They should be based on a 
detailed protocol that aims to reduce bias by pre-specifying methods and selection of studies 
and data.1 However, as meta-analyses are usually based on data that have already been 
processed, interpreted, and summarised by other researchers, data extraction can be 
complicated and can lead to important errors.2  
There is often a multiplicity of data in trial reports that makes it difficult to decide which ones 
to use in a meta-analysis. Furthermore, data are often incompletely reported,2 3 which makes it 
necessary to perform calculations or impute missing data, such as missing standard 
deviations. Different observers may get different results, but previous studies on observer 
variation have not been informative, because of few observers, few trials, or few data.4 5 We 
report here a detailed study of observer variation that explores the sources of disagreement 
when extracting data for calculation of standardised mean differences. 
Methods 
Using a computer generated list of random numbers, we selected a random sample of 10 
recent Cochrane reviews published in the Cochrane Library in issues 3 or 4 in 2006 or in 
issues 1 or 2 in 2007. We also retrieved the reports of the randomised trials that were included 
in the reviews and the protocols for each of the reviews. Only Cochrane reviews were 
eligible, as they are required to have a pre-specified published protocol. 
We included reviews that reported at least one result as a standardised mean difference 
(SMD). The SMD is used when trial authors have used different scales for measuring the 
same underlying outcome—for example, pain can be measured on a visual analogue scale or 
on a 10-point numeric rating scale. In such cases, it is necessary to standardise the 
measurements on a uniform scale before they can be pooled in a meta-analysis. This is 
typically achieved by calculating the SMD for each trial, which is the difference in means 
between the two groups, divided by the pooled standard deviation of the measurements.1 By 
this transformation, the outcome becomes dimensionless and the scales become comparable, 
as the results are expressed in standard deviation units. 
The first SMD result in each review that was not based on a subgroup result was selected as 
our index result. The index result had to be based on two to 10 trials and on published data 
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only (that is, there was no indication that the review authors had received additional outcome 
data from the trial authors). 
Five methodologists with substantial experience in meta-analysis and five PhD students 
independently extracted the necessary data from the trial reports for calculation of the SMDs. 
The observers had access to the review protocols but not to the completed Cochrane reviews 
and the SMD results. An additional researcher (BT) highlighted the relevant outcome in the 
protocols, along with other important issues such as pre-specified time points of interest, 
which intervention was the experimental one, and which was the control. If information was 
missing regarding any of these issues, the observers decided by themselves what to select 
from the trial reports. The observers received the review protocols, trial reports, and a copy of 
the Cochrane Handbook for Systematic Reviews6 as PDF files. 
The data extraction was performed during one week when the 10 observers worked 
independently at the same location in separate rooms. The observers were not allowed to 
discuss the data extraction. If the data were available, the observers extracted means, standard 
deviations, and number of patients for each group; otherwise, they could calculate or impute 
the missing data, such as from an exact P value. The observers also interpreted the sign of the 
SMD results—that is, whether a negative or a positive result indicated superiority of the 
experimental intervention. If the observers were uncertain, the additional researcher retrieved 
the paper that originally described the scale, and the direction of the scale was based on this 
information. All calculations were documented, and the observers provided information about 
any choices they made regarding multiple outcomes, time points, and data sources in the trial 
reports. During the week of data extraction the issue of whether the observers could exclude 
trials emerged, as there were instances where the observers were unable to locate any relevant 
data in the trial reports or felt that the trial did not meet the inclusion criteria in the Cochrane 
protocol. It was decided that observers could exclude trials, and the reasons for exclusion 
were documented. 
Based on the extracted data, the additional researcher calculated trial and meta-analysis SMDs 
for each observer using Comprehensive Meta-Analysis Version 2. To allow comparison with 
the originally published meta-analyses, the same method (random effects or fixed effect 
model) was used as that in the published meta-analysis. In cases where the observers had 
extracted two sets of data from the same trial—for example, because there were two control 
groups—the data were combined so that only a single SMD resulted from each trial.1 
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Agreement between pairs of observers was assessed at both meta-analysis and trial level, 
pairing the 10 observers in all possible ways (45 pairs). This provides an indication of the 
likely agreement that might be expected in practice, since two independent observers are 
recommended when extracting data from papers for a systematic review.1 2 5 6 Agreement was 
defined as SMDs that differed less than 0.1 in their point estimates and in their confidence 
intervals. The cut point of 0.1 was chosen because many commonly used treatments have an 
effect of 0.1 to 0.5 compared with placebo2; furthermore, an error of 0.1 can be important 
when two active treatments have been compared, for there is usually little difference between 
active treatments. Confidence intervals were not calculated, as the data from the pairings were 
not independent. 
To determine the variation in meta-analysis results that could be obtained from the 
multiplicity of different SMD estimates across observers, we conducted a Monte Carlo 
simulation for each meta-analysis. In each iteration of the simulation, we randomly sampled 
one observer for each trial and entered his or her SMD (and standard error) for that trial into a 
meta-analysis. Thus each sampled meta-analysis contained SMD estimates from different 
observers. If the sampled observer excluded the trial from his or her meta-analysis, the 
simulated meta-analysis also excluded that trial. We examined the distribution of meta-
analytic SMD estimates across 10 000 simulations. 
Results 
The flowchart for inclusion of meta-analyses is shown in figure 1. Out of 32 potentially 
eligible meta-analyses, the final sample consisted of 10.7-16 The 10 meta-analyses comprised 
45 trials, which yielded 450 pairs of observers at the meta-analysis level and 2025 pairs at the 
trial level. 
 
 
 
 
 
 
 
Figure 1 Flowchart for selection of 
meta-analyses 
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The level of information in the review protocols is given in table 1. None of the review 
protocols contained information on which scales should be preferred. Three protocols gave 
information about which time point to select and four mentioned whether change from 
baseline or values after treatment should be preferred. Nine described which type of control 
group to select, but none reported any hierarchy among similar control groups or any 
intentions to combine such groups. 
 
Table 1 Level of information provided in the 10 meta-analysis protocols used in this study for data extraction 
The outcomes analysed in the 10 meta-analyses were diverse: in six, the outcome was a 
clinician reported score (three symptom scores, one general functioning score, one hepatic 
density score, and one neonatal score); in one, it was objective (range of movement in ankle 
joints); and in three, it was self reported (pain, tinnitus, and patient knowledge). 
Agreement at trial level  
In table 2 the different levels of agreement are shown. Across trials, the agreement was 53% 
for the 2025 pairs (61% for the 450 pairs of methodologists, 46% for the 450 pairs of PhD 
students, and 52% for the 1125 mixed pairs). The agreement rates for the individual trials 
ranged from 4% to 100%. Agreement between all observers was found for four of the 45 
trials. 
 
Table 2 Levels of overall agreement between observer pairs in the calculated standardised  
mean differences (SMDs)* from 10 meta-analyses (which comprised a total of 45 trials) 
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Table 3 presents the reasons for disagreement, which fell into three broad categories: different 
choices, exclusion of a trial, and data extraction errors. The different choices mainly 
concerned cases with multiple groups to choose from when selecting the experimental or the 
control groups (15 trials), which time point to select (nine trials), which scale to use (six 
trials), and different ways of calculating or imputing missing numbers (six trials). The most 
common reasons for deciding to exclude a trial was that the trial did not meet the inclusion 
criteria described in the protocol for the review (14 trials) and that the reporting was so 
unclear that data extraction was not possible (14 trials). Data extraction errors were less 
common but involved misinterpretation of the direction of the effect in four trials. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Reasons for disagreement among the 41 
trials on which the observer pairs disagreed in the 
calculated standardised mean differences 
The importance of which standard deviation to use was underpinned in a trial that did not 
report standard deviations.17 The only reported data on variability were F test values and P 
values from a repeated measure, analysis of variance, performed on changes from baseline. 
The five PhD students excluded the trial because of the missing data, whereas the five 
experienced methodologists imputed five different standard deviations. One used a standard 
deviation from the report originally describing the scale, another used the average standard 
deviation reported in the other trials in the meta-analysis, and the other three observers 
calculated standard deviations based on the reported data, using three different methods. In 
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addition, one observer selected a different time point from the others. The different standard 
deviations resulted in different trial SMDs ranging from −1.82 to 0.34 in their point estimates. 
Agreement at meta-analysis level 
Across the meta-analyses, the agreement was 31% for the 450 pairs (33% for the 100 pairs of 
methodologists, 27% for the 100 pairs of PhD students, and 31% for the 250 mixed pairs) 
(table 2). The agreement rates for the individual meta-analyses ranged from 11% to 80% 
(table 4). Agreement between all observers was not found for any of the 10 meta-analyses. 
 
Table 4 Levels of agreement at the meta-analysis level between observer pairs in the calculated 
standardised mean differences (SMDs) from 10 meta-analyses* 
 
Figure 2 Sizes of the disagreements between observer pairs in the calculated standardised 
mean differences (SMDs) from 10 meta-analyses. Comparisons are at the meta-analysis  
level. (*All the underlying trials were excluded) 
The distribution of the disagreements is shown in figure 2. Ten per cent agreed completely, 
21% had a disagreement below our cut point of 0.1, 38% had a disagreement between 0.1 and 
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0.49, and 28% disagreed by at least 0.50 (including 10% that had disagreements of ≥1). The 
last 18 pairs (4%) were not quantifiable since one observer excluded all the trials from two 
meta-analyses. The median disagreement was SMD=0.22 for the 432 quantifiable pairs with 
an interquartile range from 0.07 to 0.61. There were no differences between the 
methodologists and the PhD students (table 2). 
Figure 3 shows the SMDs calculated by each of the 10 observers for the 10 meta-analyses, 
and the results from the originally published meta-analyses. Out of the total of 100 calculated 
SMDs, seven values corresponding to significant results in the originally published meta-
analyses were now non-significant, three values corresponding to non-significant results were 
now significant, and four values, which were related to the same published meta-analysis, 
showed a significantly beneficial effect for the control group whereas the original publication 
reported a significantly beneficial effect for the experimental group.11 The SMDs for this 
meta-analysis had particularly large disagreements, partly because only two trials were 
included, leaving less possibility for the pooled result to average out. The reasons for the large 
disagreements were diverse and included selection of different time points, control groups, 
intervention groups, measurement scales, and whether to exclude one of the trials. 
 
Figure 3 Forest plots of standardised mean differences (SMDs) and 95% confidence intervals calculated from 
data from each of the 10 observers for the 10 meta-analyses 
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The results of the Monte Carlo investigation are presented in figure 4. For four of the 10 
meta-analyses7 11 13 14 there was considerable variation in the potential SMDs, allowing for 
differences in SMDs of up to 3. In two of these, around half of the distribution extended 
beyond even the confidence interval for the published result of the meta-analysis.711 The 
other meta-analyses had three and two trials respectively, and the distributions reflect the 
wide scatter of SMDs from these trials. 
 
Figure 4 Histograms of standardised mean differences (SMD) estimated in the Monte Carlo simulations for  
each of 10 meta-analyses 
Discussion 
We found that disagreements between observers were common and often large. Ten per cent 
of the disagreements at the meta-analysis level amounted to an SMD of at least 1, which is far 
greater than the effect of most of the treatments we use compared with no treatment. As an 
example, the effect of inhaled corticosteroids on asthma symptoms, which is generally 
regarded as substantial, is 0.49.18 Important reasons for disagreement were differences in 
selection of time points, scales, control groups, and type of calculations, whether to include a 
trial in the meta-analysis, and finally data extraction errors made by the observers. 
The disagreement depended on the reporting of data in the trial reports and on how much 
room was left for decision in the review protocols. One of the reviews exemplified the 
variation arising from a high degree of multiplicity in the trial reports combined with a review 
protocol leaving much room for choice.11 In the review protocol, the time point was described 
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as “long term (more than 26 weeks),” but in the two trials included in the meta-analysis there 
were several options. For one trial,19 there were two: end of treatment (which lasted 9 months) 
or three month follow up. For the other,20-22 there were three: 6, 12, and 18 month follow-up 
(treatment lasted 3 weeks). The observers used all the different time points, and all had a 
plausible reason for their choice: in concordance with the time point used in the other trial, the 
maximum period of observation, and the least drop out of patients. 
Strengths and weaknesses 
The primary strength of our study is that we took a broad approach and showed that there are 
other important sources of variation in meta-analysis results than simple errors. Furthermore, 
we included a considerable number of experienced as well as inexperienced observers and a 
large number of trials to elucidate the sources of variation and their magnitude. Finally, the 
study setup ensured independent observations according to the blueprint laid out in the review 
protocols and likely mirrored the independent data extraction that ideally should happen in 
practice. 
The experimental setting also had limitations. Single data extraction produces more errors 
than double data extraction.5 In real life, some of the errors we made would therefore 
probably have been detected before the data were used for meta-analyses, as it is 
recommended for Cochrane reviews that there should be at least two independent observers 
and that any disagreement should be resolved by discussion and, if necessary, arbitration by a 
third person.1 We did not perform a consensus step, as the purpose of our study was to 
explore how much variation would occur when data extraction was performed by different 
observers. However, given the amount of multiplicity in the trial reports and the uncertainties 
in the protocols, it is likely that even pairs of observers would disagree considerably with 
other pairs. 
Other limitations were that the observers were under time pressure, although only one person 
needed more time, as he fell ill during the assigned week. The observers were presented with 
protocols they had not developed themselves, based on research questions they had not asked, 
and in disease areas where they were mostly not experts. Another limitation is that, even 
though one of the exclusion criteria was that the authors of the Cochrane review had not 
obtained unpublished data from the trial authors, it became apparent during data extraction 
that some of the trial reports did not contain the data needed for the calculation of an SMD. It 
would therefore have been helpful to contact trial authors. 
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Other similar research 
The SMD is intended to give clinicians and policymakers the most reliable summary of the 
available trial evidence when the outcomes have been measured on different continuous or 
numeric rating scales. Surprisingly, the method has not previously been examined in any 
detail for its own reliability. Previous research has been sparse and has focused on errors in 
data extraction.2 4 5 In one study, the authors found errors in 20 of 34 Cochrane reviews, but, 
as they gave no numerical data, it is not possible to judge how often these were important.4 In 
a previous study of 27 meta-analyses, of which 16 were Cochrane reviews,2 we could not 
replicate the SMD result for at least one of the two trials we selected for checking from each 
meta-analysis within our cut point of 0.1 in 10 of the meta-analyses. When we tried to 
replicate these 10 meta-analyses, including all the trials, we found that seven of them were 
erroneous; one was subsequently retracted, and in two a significant difference disappeared or 
appeared.2 The present study adds to the previous research by also highlighting the 
importance of different choices when selecting outcomes for meta-analysis. The results of our 
study apply more broadly than to meta-analyses using the SMD, as many of the reasons for 
disagreement were not related to the SMD method but would be important also when 
analysing data using the weighted mean difference method, which is the method of choice 
when the outcome data have been measured on the same scale. 
Conclusions 
Disagreements were common and often larger than the effect of commonly used treatments. 
Meta-analyses using SMDs are prone to observer variation and should be interpreted with 
caution. The reliability of meta-analyses might be improved by having more detailed review 
protocols, more than one observer, and statistical expertise. Review protocols should be more 
detailed and made permanently available, also after the review is published, to allow other 
researchers to check that the review was done according to the protocol. In February 2008, the 
Cochrane Collaboration updated its guidelines and recommended that researchers in their 
protocols list possible ways of measuring the outcomes—such as using different scales or 
time points—and specify which ones to use. Our study provides strong support for such 
precautions. Reports of meta-analyses should also follow published guidelines1 23 to allow for 
sufficient critical appraisal. Finally the reporting of trials needs to be improved, according to 
the recommendations in the CONSORT statement,24 reducing the need for calculations and 
imputation of missing data. 
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Abstract 
Context: Authors performing meta-analyses of clinical trials often face a multiplicity of data 
in the trial reports. There may be several possible follow-up times, and the same outcome can 
be measured on different, but similar scales. The challenge of data multiplicity has not yet 
been examined in relation to meta-analyses. 
Objectives: To examine the scope for multiplicity in a sample of meta-analyses using the 
standardised mean difference (SMD) as an effect measure, and to examine the impact of the 
multiplicity on the results. 
Data source and study selection: We selected all Cochrane reviews published in The 
Cochrane Library in the issues 3, 2006 to 2, 2007 that presented a result as an SMD. We 
retrieved the trial reports that corresponded to the first SMD result in each review and 
retrieved the review protocols. These index SMDs were used to identify a specific outcome 
for each meta-analysis from its protocol. 
Data extraction: Based on the protocols and the index outcome, two observers independently 
extracted the data necessary to calculate SMDs from the trial reports for any outcome 
measures or time points compatible with the protocol. Any information on which control 
groups to select was also used. Based on the extracted data, all possible SMDs were 
calculated in Monte Carlo simulations. 
Results: Nineteen meta-analyses (83 trials) were included. The review protocols in many 
instances lacked information about which data to choose. Twenty-four (29%) trials reported 
data on multiple intervention groups, 30 (36%) provided data on multiple time points and 28 
(34%) trials reported the index outcome measured on multiple scales. In 18 out of 19 meta-
analyses, we found multiplicity of data in trial reports in at least one trial. Pooled SMD results 
were affected in 17 of 19 (89%) meta-analyses. In 18 meta-analyses including trials with 
multiple data, the median variability across meta-analyses was a median difference between 
two randomly selected SMDs within the same meta-analysis of 0.11 standard deviation units 
(range 0.03 to 0.41). 
Conclusions: Multiplicity can impact importantly on meta-analyses. To reduce the risk of 
bias in reviews, protocols should pre-specify which results are preferred in relation to time 
points, intervention groups and scales. 
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Introduction 
Meta-analyses of randomized controlled trials are pivotal for making evidence-based 
decisions. Multiple eligible data in reports of included trials is a challenge to systematic 
reviewers, but has not yet received much attention. There is often multiplicity of data in trial 
reports regarding multiple outcomes, multiple time points, multiple treatment groups, and 
subgroup analyses.1 The choice of the outcome of interest is generally based on clinical 
judgement. However, a fundamentally similar outcome can be measured on several different 
scales and standardization to a common metric is required before the outcome can be 
combined in the meta-analysis. This is typically achieved by calculating the standardized 
mean difference (SMD) for each trial, which is the difference in means between the two 
groups, divided by the pooled standard deviation of the measurements.2 By this 
transformation, the outcome becomes dimensionless and the scales become comparable, as 
the results are expressed in standard deviation units. For example, a meta-analysis addressing 
the pain as an outcome might include some trials that measured pain on a visual analogue 
scale and some trials that measured pain on a 20-point numeric rating scale.  This possibility 
of combining outcomes measured on different scales potentially adds a layer of multiplicity, 
as the outcome of interest may be measured on more than one scale not only across trials but 
also within the same trial. Multiplicity of data in trial reports might lead to data driven 
decisions about what data are included in the meta-analysis and hence is a potential threat to 
the validity of meta-analysis results. 
In this study, we empirically assessed the effect of multiple time points, multiple scales and 
multiple treatment groups on SMD results in a randomly selected sample of Cochrane 
reviews.  
Methods  
Material: We selected all new Cochrane reviews, published in The Cochrane Library during 
one year (Issues 3, 2006 to 2, 2007) that presented a result as an SMD. We retrieved the 
reports of all randomised trials that contributed to the first SMD result in each review, and 
retrieved the latest protocols for all reviews (downloaded in June 2007). Reviews were 
eligible if they reported at least one result as a standardized mean difference (SMD), if the 
SMD result were based on two to ten randomized controlled trials and if the outcome was 
included in the review protocol. Reviews were excluded if only subgroup results were 
presented. The first pooled SMD result in each review that was not based on a subgroup result 
was selected as our index SMD result. The index SMD result had to be based on published 
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data only, i.e. there was no indication in the review that the review authors had received 
additional outcome data from the trial authors. These index SMD results identified a single 
outcome for each meta-analysis. Following the published protocol, two observers (BT, EN) 
independently extracted all possible and reasonable data from the trial reports that could be 
used to calculate the desired SMD for this outcome. If some required data were unavailable, 
we used approximations as previously described.3 Interim analyses were not included. 
Disagreements were resolved by discussion. We did not contact trial authors for unpublished 
data. 
Data synthesis: For each meta-analysis, we assessed the extent of observed multiplicity by 
calculating absolute numbers and percentages of trials that reported more than one 
experimental or control group, more than one time point, and more than one measurement 
scale that were specified for the outcome of the index SMD result.  
We conducted Monte Carlo simulations for each meta-analysis:  To estimate the impact of 
overall multiplicity, in each trial we randomly sampled one SMD and its corresponding 
standard error from all possible SMDs generated by all multiple reported data to calculate 
pooled SMDs using fixed- or random-effects models, as originally done in the published 
reviews. In each meta-analysis we examined the distribution of pooled SMDs across 10,000 
simulations using histograms. To estimate the impact of a single source of multiplicity (time 
points, intervention groups, measurement scales), we allowed only one source of multiplicity 
to vary at a time when randomly sampling SMDs for each trial. The other sources of 
multiplicity were standardized at pre-specified standard values (time point: post treatment, 
scale: first scale mentioned in text, groups: pooled groups). For example in the analysis 
regarding multiplicity originating from scales, the analysis is based on post treatment values 
and pooled groups (if there were several possible groups). The values of the different scales 
for this time point and these groups were then randomly sampled for the calculations of the 
pooled SMD results. The variability of SMD results due to multiplicity across possible 
variants of a meta-analysis was expressed as the empirical standard deviation of the 
distributions of pooled SMDs results obtained from the Monte Carlo simulations. Meta-
analyses only including trials without multiple data did not contribute to these analyses.  
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Results 
Figure 1 shows the flowchart for the selection of meta-analyses. Of 32 potentially eligible 
systematic reviews, we excluded 8 because no pooled SMD index result could be selected, 2 
because all SMD results were based on unpublished data, 1 because only subgroup results 
were reported, 1 because no protocol was available and 1 because the SMD result was not 
described in the protocol. The 19 eligible meta-analyses included 83 trials that contributed to 
the study. 4-22 Table 1 shows characteristics of included systematic reviews. 8 systematic 
reviews addressed an intervention for a psychiatric condition, 2 an intervention for a 
musculoskeletal condition, 2 an intervention for a neurological condition, 1 an intervention 
for a gynaecologic, hepatologic and respiratory condition, respectively, and 4 interventions 
for other conditions. Psychological interventions were studied in 10 meta-analyses, 
pharmacological interventions in 4, physical interventions in 3, pharmacological 
interventions, and other interventions in 2 meta-analyses (exercise and humidified air). The 
outcomes analyzed in the 19 meta-analyses were diverse: in 3 meta-analyses the index 
outcome was pain, in 13 the index outcome was a symptom severity scale and for 3 meta-
analyses, other index outcomes were selected. 
 
Potentially eligible reviews (n=32) 
 
 
 
Excluded (n=12) 
                                No SMD result based exclusively on randomized trials (n=6)    
                                No pooled SMD result (n=2) 
                                Only SMD results based on unpublished data (n=2) 
                                Only subgroup result (n=1) 
                                No available review protocol (n=1) 
       Outcome not available in protocol (n=1) 
      
 
Eligible reviews (n=19)  
 
 
          One meta-analysis selected from each review (n=19) 
 
Figure 1 Flowchart for selection of meta-analyses. 
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Table 1 Characteristics of included systematic reviews 
Author Outcome Disease Intervention Group 
Yousefi-
Nooraie 
Low-back-related 
disability Low-back pain Low level laser therapy Cochrane Back Group 
Ahmad Pain Hysterosalpingography (tubal patency) Analgesic Cochrane Menstrual Disorders and Subfertility Group 
Gava Symptom level Obsessive compulsive disorder Psychological treatment Cochrane Depression, Anxiety and Neurosis Group 
Woodford Range of movement Stroke EMG biofeedback Cochrane Stroke Group 
Martinez 
Subjective tinnitus 
loudness Tinitus Cognitive behavioural therapy Cochrane Ear, Nose and Throat Disorders Group 
Orlando Radiological response Non-alcoholic fatty liver disease Bile acids Cochrane Hepato-Biliary Group 
Furukawa Global judgement Panic disorders 
Combined treatment Psychotherapy and 
antidepressant Cochrane Depression, Anxiety and Neurosis Group 
Hunot Worry/fear symptoms Generalised anxiety disorder Psychological therapies Cochrane Depression, Anxiety and Neurosis Group 
Buckley 
General functioning 
score Schizophrenia Supportive therapy Cochrane Schizophrenia Group 
Ipser 
Symptom severity 
scales Treatment-resistant anxiety disorders Pharmacotherapeutic augmentation Cochrane Depression, Anxiety and Neurosis Group 
O’Kearney Depression Obsessive compulsive disorder Behavioural/cognitive-behavioural therapy Cochrane Depression, Anxiety and Neurosis Group 
Mistaen 
Patient knowledge 
regarding disease or 
symptom management Postdischarge problem Telephone follow-up Cochrane Consumers and Communication Group 
Abbass Anxiety/depression Common mental disorders Psychotherapy Cochrane Depression, Anxiety and Neurosis Group 
Afolabi 
Neonatal neurological 
and adaptive score Caesarean section Epidural Cochrane Pregnancy and Childbirth Group 
Uman Pain 
Needle-related procedural pain and 
distress  Psychological interventions Cochrane Pain, Palliative and Supportive Care Group 
Larun Anxiety Anxiety Exercise Cochrane Depression, Anxiety and Neurosis Group 
Trinh Pain Neck disorder Acupuncture Cochrane Back Group 
Moore 
Symptom severity or 
symptom score Croup Humidified air Cochrane Acute Respiratory Infections Group 
Mytton School responses Agression/violence Violence prevention program Cochrane Injuries Group 
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Information in the review protocols: The level of information in the review protocols is 
given in Table 2. None of the review protocols contained information on which scales should 
be preferred. Eight protocols gave information about which time point to select. One gave 
enough information regarding time point to fully avoid multiplicity, as the outcome was post 
treatment. A typical statement leaving much room for data-driven decisions regarding the 
selection of a time point was: “All outcomes were reported for the short term (up to 12 
weeks), medium term (13 to 26 weeks), and long term (more than 26 weeks)”.7 Another 
example was a review regarding humidified air for treating croup, 15 which stated, “The 
outcomes will be separately recorded for the week following treatment.” The selected 
outcome was croup symptom score and the three included trials had time points from 20 min 
to 12 hours to choose between. In such a case the protocol does not help. Eighteen protocols 
described which type of control group to select but none reported any hierarchy among 
similar control groups or any intentions to combine such groups.  
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Table 2 Content of review protocols 
Observed multiplicity in trial reports: Table 3 presents the extent of multiplicity observed 
in the 19 reviews including 83 trials. Across all reviews 55 (66%) trials had multiple data 
from one or more of the three sources. Twenty-four (29%) trials reported data on more than 
one intervention or more than one control group, 30 (36%) trials provided data on more than 
one eligible time point and 28 (34%) trials reported the index outcome using more than one 
eligible measurement scale. In 11 of 19 (58%) meta-analyses, we found at least one trial that 
provided data on more than one intervention or more than one control group. 13 (68%) meta-
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analyses included at least one trial that reported more than one eligible time point and 11 
(58%) meta-analyses at least one trial that reported the index outcome using more than one 
eligible measurement scale. We found one meta-analysis, where all 3 included trials did only 
report data of one intervention and control group, one eligible time point and one 
measurement scale for the index outcome.18  
  No trials with multiplicity regarding: 
 
No trials 
included 
Any 
source 
Intervention 
groups 
Time 
points 
Measurement 
scales 
Yousefi-Nooraie et al. 3 2 (67%) 0 (0%) 1 (33%) 1 (33%) 
Ahmad et al. 5 3 (60%) 1 (20%) 2 (40%) 1 (20%) 
Gava et al. 7 6 (86%) 4 (57%) 3 (43%) 5 (71%) 
Woodford & Price 5 4 (80%) 2 (40%) 2 (40%) 3 (60%) 
Martinez Devesa et al. 4 4 (100%) 3 (75%) 3 (75%) 1 (25%) 
Orlando et al. 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Furukawa et al. 7 6 (86%) 6 (86%) 2 (29%) 4 (57%) 
Hunot et al. 9 5 (56%) 2 (22%) 0 (0%) 5 (56%) 
Buckley & Pettit  2 2 (100%) 0 (0%) 2 (100%) 0 (0%) 
Ipser et al. 7 6 (86%) 0 (0%) 5 (71%) 3 (43%) 
O'Kearney et al. 2 1 (50%) 1 (50%) 0 (0%) 0 (0%) 
Mistaen & Poot 3 1 (33%) 1 (33%) 0 (0%) 0 (0%) 
Abbass et al. 2 2 (100%) 0 (0%) 1 (50%) 2 (100%) 
Afolabi et al. 2 1 (50%) 0 (0%) 1 (50%) 0 (0%) 
Uman et al. 9 2 (22%) 2 (22%) 0 (0%) 0 (0%) 
Larun et al. 5§ 4 (80%) 1 (20%) 3 (60%) 2 (40%) 
Trinh et al. 3 3 (100%) 0 (0%) 3 (100%) 1 (33%) 
Moore & Little 3 2 (67%) 0 (0%) 2 (67%) 0 (0%) 
Mytton et al. 2 1 (50%) 1 (50%) 0 (0%) 0 (0%) 
All included reviews 83 55 (66%) 24 (29%) 30 (36%) 28 (34%) 
Table 3 Observed multiplicity in the meta-analyses. §One trial from Larun et al. were excluded because lack of 
data in trial reports. 
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Effects of multiplicity on results of meta-analyses: Figure 2 presents distributions of 
possible pooled SMDs in each meta-analysis, when randomly selecting one possible SMD 
result per trial. The dots below the distributions indicate how many trials were included in the 
meta-analyses, open dots are trials without multiplicity, and filled dots are trials with 
multiplicity. We found that pooled SMD results were affected by any type of multiplicity of 
data in the included trials in 17 of 19 (89%) meta-analyses, in 1 meta-analysis we did not find 
multiple data in the trial reports18 and in 1 meta-analysis the observed multiplicity had no 
effect on the pooled SMD results.7 In all 11 (58%) meta-analyses including at least one trial 
with more than one experimental or control group, we found variability in the pooled SMD 
results due to this type of multiplicity. In 12 (63%) meta-analyses there was variability in the 
pooled SMD results due to multiplicity of data regarding time points (Figure 2, 3rd column). 
In one meta-analysis with two trials that reported more than one eligible time point, we did 
not find multiple possible pooled SMDs due to these different time points.7 In 9 (47%) meta-
analyses we found variability in pooled SMD results from trial data of multiple measurement 
scales used for the index outcome. In two meta-analyses, one trial in each meta-analysis 
reported data on more than one measurement scale for the index outcome, but this multiplicity 
did not affect the pooled SMD results.6, 22 
Table 4 presents the variability of pooled SMD results according to different sources of 
multiplicity. We found that in 18 meta-analyses including trials with multiple data reported 
for any of the three sources evaluated. The median standard deviation was 0.11 (range 0.03 to 
0.41), which corresponds to a median difference between two randomly selected SMDs 
within the same meta-analysis. The median difference across the 11 meta-analyses that 
included trials with multiple data regarding intervention groups was 0.05 standard deviation 
units (range 0.01 to 0.23) between two randomly selected SMDs calculated from different 
eligible intervention groups. The median standard deviation across 13 meta-analyses that 
included trials with data on multiple eligible time points was 0.06 (range 0.02 t 0.41) and 
across 11 meta-analyses including trials that provided data of multiple measurement scale for 
the index outcome was 0.09 (range 0.01 to 0.15). 
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Figure 2 Monte Carlo distributions of possible pooled SMDs in each meta-analysis. The dots below the 
distributions indicate how many trials were included in the meta-analyses, open dots are trials without 
multiplicity, and filled dots are trials with multiplicity.
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Source of multiplicity Number of meta-analyses  
with multiple data 
Variability in SMD results  
across meta-analyses  
(standard deviation [range]) 
Any source 18 of 19 (95%) 0.11 (0.03 to 0.41) 
Intervention groups 11 of 19 (58%) 0.05 (0.01 to 0.23) 
Time points 13 of 19 (68%) 0.06 (0.02 to 0.41) 
Measurement scales 11 of 19 (58%) 0.09 (0.01 to 0.15) 
Table 4 Variability in meta-analyses results 
Comment 
In 17 out of 19 meta-analyses included in our study, we found multiplicity of data in trial 
reports in at least one trial, which frequently resulted in substantial variabilities of pooled 
SMD results. The magnitude of impact of multiple data in trial reports regarding intervention 
groups, time points or measurement scales on meta-analyses results varied considerably 
across meta-analyses ranging from essentially no impact to an impact of multiple data 
corresponding to a small to moderate treatment benefit (a standard deviation of 0.2 across 
possible meta-analysis results). In our study we were able to estimate the impact of individual 
sources of multiple data in trial reports on the meta-analyses results, enabling us to judge 
whether the three different sources individually impacted on the pooled SMD results. 
We randomly selected Cochrane reviews in our study and therefore, included a broad 
selection of interventions and outcomes that were expressed as SMDs. The variability of 
pooled SMD results due to multiple trial data did not seem to be particular for certain types of 
interventions or outcomes, although it varied substantially across meta-analyses. To estimate 
the impact of multiplicity on meta-analyses results, we randomly selected one SMD per trial 
from a pool of eligible SMDs that were calculated from multiple data in trial reports with 
equal probability. This process explores the magnitude of what is possible due to multiple 
reported data. However, there might be implicit rules regarding data-extraction within 
specialties. For example reviewers might find that one scale is more commonly used, e.g. 
Hamilton, than another and therefore select this scale if possible. This unwritten hierarchy of 
scales naturally reduces the perceived multiplicity, but should be made explicit to enhance 
transparency.  
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We relied on published information in the trial reports. Our results are transparent as we 
limited ourselves to published results. However, selective reporting of outcomes in trials 23-26 
might have distorted our results: Positive, statistically significant results are more likely to be 
published than non-significant results.27 In the presence of publication bias we might have 
underestimated the overall multiplicity. Our study is only able to provide an estimate of 
multiplicity among published results. Effective multiplicity might be even higher as published 
and unpublished results are likely to be different from each other. Our study was only possible 
because Cochrane Reviews are required to publish their protocols. We believe that for most 
meta-analyses published outside the Cochrane Library, no protocol is available28 and the 
choice of multiple data possibly extracted is even larger than we observed in our study. 
We examined three frequent sources of multiplicity of data in trial reports: time points, 
intervention groups and measurement scales. However, there are other types of multiple data 
in trial reports. For example, results might be reported from different types of analyses: 
intention-to-treat analyses might be reported alongside with per-protocol analyses. We were 
unable to explore this issue, because only few included trials provided results from more than 
one analysis. For each meta-analysis we specified an index outcome and could therefore not 
examine the impact of the selection of different outcomes for the reliability of meta-analyses 
results.  
Our study provides an estimation of the extent and impact of multiplicity of data in trial 
reports on the results of meta-analyses. To our knowledge, our study is the first to show 
empirically that reliability of meta-analyses results might be compromised due to multiple 
data on time points, measurement scales and intervention groups provided in trial reports. We 
have previously reported results from an observer agreement study performed on a sample of 
the meta-analyses included in this study.2 We found that disagreements among observers were 
common and often large, the main reasons for disagreement being: different choices (groups, 
time points, scales and calculations) whether to include certain trials and data extraction 
errors.2 A recent paper by Bender et al. describes the problem of multiple comparisons in 
systematic reviews.1 The authors identified common reasons for multiplicity in reviews, but 
did not estimate the impact on the meta-analytic results.1 
Multiplicity due to selection of time points and groups is not unique to SMD; future research 
could therefore be done into whether multiplicity also is an issue for effect measures like the 
mean difference, for which the outcomes have to be measured on the same scale, or binary 
outcomes. 
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The extent of multiplicity of data found in trial reports reflects the information provided in the 
review protocols: A badly specified outcome in the review protocol will have led to a larger 
extent of observed multiplicity for this outcome than a precisely specified outcome in the 
review protocol, if an equal amount of data is found in the reports of included trials. Some 
might argue that data extraction for a meta-analysis is dependent on what is reported in trials 
and cannot be entirely specified in advance without knowledge of the included trials. 
However, systematic reviewers are usually not completely unaware of the potentially included 
trials at the protocol writing stage. In addition, we argue that to minimise data-driven 
selection of time points, measurement scales or intervention groups included in the meta-
analyses, researchers should specify these decisions at protocol stage. If amendments to the 
protocol are indicated, these should be transparently reported.29, 30 Whether more detailed 
protocols increase the reliability of meta-analyses results remains to be shown.  
Implications: This study demonstrates that multiplicity is a real problem, two solutions come 
to mind: one might be to report and analyse everything another to make the protocols for 
systematic reviews more detailed. The first solution presents two large challenges, first how 
to interpret the results? If for example one scale in a trial shows a positive effect of an 
intervention and another scale in the same trial shows a negative effect. The other challenge is 
that this approach would involve multiple testing of the same outcome, as there would be 
multiple comparisons involving the same outcome. A possible way of dealing with observed 
multiplicity could be a multivariate meta-analysis, accounting for correlations among 
outcomes, time points and comparisons. The second solution regarding more detailed 
protocols would imply that reviewers specified which time points, scales and groups to 
consider and presented a hierarchy for scales and groups. It is however difficult to foresee 
everything in a protocol; this makes the obligation of the reporting to be clear of the 
systematic so much greater. The reporting needs to allow the reader to follow the process 
leading to the results; this also includes descriptions of choices made during the data 
extraction process. It is not possible to report everything, so what really matters and what 
issues are less important? Our study shows that time points, scales and groups have an impact 
on the results and therefore are important to report.  
As for randomised trials, systematic reviews should have a detailed protocol. Only Cochrane 
reviews are required to have a published protocol. A descriptive study performed by Moher et 
al showed that only around ten percent of non-Cochrane reviews stated working from a 
protocol. 30 As pointed out in the PRISMA statement, protocol amendments should not 
necessarily be considered inappropriate but should definitely be acknowledged as such and 
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published. 29, 30 Our study suggests that protocol amendments are likely to produce differences 
in results und thus, protocol amendments should be discouraged unless clearly justified.  
Conclusions: Variability in meta-analyses results is substantial due to multiplicity in trial 
reports paired with protocols lacking details defining what time points, scales and treatment 
groups ought to be included. Reviews are study designs in their own right and reviewers 
should anticipate multiplicity of data in trial reports and take this into account when writing 
protocols. To enhance reliability of meta-analyses results, we suggest that protocols should 
clearly define time points to be extracted, give a hierarchy of scales and clearly define eligible 
treatment and control groups and give strategies for handling multiple groups. Clinical 
judgment will be important to define at protocol stage, which time points and scales to be 
included. Ideally, the choice of time points and scales should be evidence based, but empirical 
evidence for the most interesting time points and a hierarchy of scales according to good 
validity and responsiveness are rarely available.  
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Abstract 
Objective To examine how different methodological approaches such as funnel plots, 
stratified analyses accompanied by interaction tests and heterogeneity-adjusted trial sequential 
analysis contribute to our understanding of bias and inconclusive results in meta-analyses. 
Methods We re-analysed the trials of intravenous magnesium in acute myocardial infarction 
using funnel plots accompanied by tests for asymmetry, analyses stratified for allocation 
concealment and sample size, and heterogeneity-adjusted trial sequential analysis. 
Results Visual inspection of funnel plots and regression lines suggested asymmetry at all 
stages of the meta-analysis, but tests for funnel plot asymmetry became statistically 
significant only after the inclusion of LIMIT-2, the only adequately sized trial at that time. 
Differences in pooled effects between trials with and without allocation concealment and 
between large and small trials were apparent, but interaction tests for allocation concealment 
were positive only in fixed-effect meta-analyses. In heterogeneity-adjusted trial sequential 
analysis, the z-curve didn’t cross the boundary before ISIS-4, a large scale trial in 58’050 
patients, became available and the necessary information size of nearly 25 000 patients was 
reached, suggesting that the results of both, random- and fixed-effect meta-analyses were 
inconclusive. 
Conclusions Funnel plots with statistical tests of asymmetry, stratified analyses accompanied 
by tests of interaction and heterogeneity-adjusted trial sequential analyses will all contribute 
to our understanding of which meta-analyses can be considered conclusive. 
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In 1991, a meta-analysis of 7 small-scale trials of intravenous magnesium in a total of 1266 
patients with suspected acute myocardial infarction indicated a more than 50% reduction in 
the risk of death associated with magnesium (relative risk 0.48, 95% CI 0.26 to 0.88).1 Yusuf 
et al updated this meta-analysis in 19932 to include LIMIT-2,3 at the time the only adequately 
sized trial, with a power of 80% to detect a moderate to large relative reduction in the risk of 
death of 33% associated with magnesium. Based on a total of 8 trials in 3617 patients with a 
pooled relative risk of 0.59 (95% CI 0.38 to 0.91), the authors concluded that “intravenous 
magnesium is a safe, effective, widely practicable, and inexpensive intervention that has the 
potential of making an important impact on the management of patients with myocardial 
infarction”.2 In 1995, ISIS-4 became available,4 a large scale trial in 58,050 patients, which 
had nearly 95% power to detect a small, but potentially clinically relevant reduction in the 
relative risk of death of 10% associated with magnesium. ISIS-4 clearly refuted the earlier 
meta-analyses and showed a trend towards more deaths in the patients allocated to 
magnesium, with the lower limit of the 95% confidence interval excluding any relevant 
benefit of the intervention (relative risk 1.05, 95% CI 0.99 to 1.12).  
The case of magnesium in acute myocardial infarction cast serious doubts on the 
trustworthiness of meta-analyses. Which meta-analyses were conclusive and which were 
likely to be refuted by subsequent large-scale trials? Intrigued by the magnesium example, 
Egger and Davey Smith5 suggested in 1995 that funnel plots could have been used as a 
diagnostic tool, in which estimates of treatment effect obtained in trials included in the 
magnesium meta-analyses1 2 are plotted against a measure of sample size or statistical 
precision, to detect bias associated with small trials. In the absence of bias, the plot will 
typically resemble a symmetrical inverted funnel with the results of smaller trials more widely 
scattered than those of larger, more precise trials. Publication bias,6 and poor design, 
execution and analysis of small trials7 may result in skewed funnel plots. Visual inspection of 
the funnel plot of magnesium trials and a formal statistical test of its asymmetry indicated that 
the funnel plot was clearly asymmetrical before ISIS-4 became available.1 2  
In 1997, Pogue and Yusuf8 9 took a different approach and suggested that multiple looks in 
meta-analyses of randomised trials may be interpreted similarly to interim looks in a single 
trial. The problem of interim looks in a single trial was originally addressed by Armitage10 
and Pocock11 by group sequential analysis. Lan and DeMets12 extended the suggested concept 
with an alpha-spending function to allow flexible unplanned monitoring in a trial. They 
introduced the cumulative z-curve modelled as a Brownian motion and an alpha-spending 
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function according to O’Brien and Flemming13 for the construction of monitoring boundaries. 
If a treatment effect larger than expected occurs, a trial should be terminated early when the 
cumulative z-curve for this treatment effect crossed the constructed sequential monitoring 
boundary. In early stages of a trial when data are sparse only very extreme results 
corresponding to extreme z-values are accepted to indicate premature termination of a trial. 
The monitoring boundaries become less stringent as more data accumulate and the planned 
sample size of the trial is approached. The same principle could be applied to meta-analyses 
to determine when a meta-analysis is conclusive. Only extreme results leading to z-values that 
cross highly stringent boundaries should be accepted if little information was accrued in a 
meta-analysis of few, small scale trials. Boundaries should become less stringent as more 
information accumulates.8 9 In a cumulative meta-analysis of ten magnesium trials, Pogue and 
Yusuf found that the cumulative z-curve of the meta-analysis did not cross the specified 
monitoring boundary for overall mortality and suggested that the meta-analysis was not 
conclusive.8 However, Egger et al identified 15 trials of magnesium in myocardial infarction 
published before ISIS-4.4 When based on all 15 trials, rather than the ten trials selected by 
Pogue and Yusuf, the meta-analysis crossed the monitoring boundary and became conclusive, 
although the results were still contradicted by ISIS-4.14 The approach failed to become widely 
adopted.  
Recently, Wetterslev et al coined the term “trial sequential analysis” for an extension of 
Pogue and Yusuf’s approach, which reflects an increase in uncertainty if heterogeneity 
between trials is present in a meta-analysis.15 In this issue, two articles by the same group use 
trial sequential analysis to determine whether results of published meta-analyses in 
neonatology16 and across different fields17 are conclusive. Using trial sequential analyses, 
which account for the observed heterogeneity between trials, they find a substantial 
proportion of published meta-analyses potentially inconclusive. In both articles,16 17 the 
authors point out that trial sequential analysis does not deal with systematic errors resulting 
from the inclusion of flawed trials18 and outcome reporting19 or publication biases20 and that 
these sources of systematic errors should be appropriately examined using funnel plots21 and 
analyses stratified according to methodological characteristics of trials accompanied by 
appropriate tests for interaction between trial characteristic and effect estimates.22  
Here, we re-analyse the trials of intravenous magnesium in acute myocardial infarction to 
determine how the different diagnostic measures – funnel plots, stratified analyses according 
to methodological characteristics of trials and heterogeneity-adjusted trial sequential analysis 
– contribute to our understanding of bias and inconclusive results at four stages of the meta-  
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Figure 1 Funnel plots. Funnel plots are presented (A) for 
trials published until 1991, before LIMIT-2 became 
available; (B) until 1995, before ISIS-4 became available; 
(C) until 1995, including ISIS-4; and (D) up to 2004. 
Dotted lines indicate predicted treatment effects 
(regression line) from univariable meta-regression by using 
standard error as explanatory variable; dashed lines 
represent 95% CI. Regression lines are truncated at 
standard errors typically found in adequately sized trials 
with sufficient power to detect a moderate to large relative 
risk reduction of 30–40% (stages A and B) and at the 
standard error found in the largest trial included in the 
meta-analysis (stages C and D). P-values are derived from 
Egger’s test for funnel plot asymmetry. 
analysis: (A) trials available until 1991, before LIMIT-2,3 (B) trials until 1995, before ISIS-44 
became available, (C) all trials until 1995, including ISIS-44 and (D) all trials available to 
date.14,23 Figure 1 presents funnel plots of effect sizes on the horizontal axis against their 
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standard errors on the vertical axis, displaying asymmetry as regression lines with 95% 
confidence bands derived from predicting the treatment effect from univariable meta-
regression analysis with the standard error as the explanatory variable.21 Visual inspection of 
funnel plot and regression line suggest asymmetry at all four stages A to D of the meta-
analysis, but Egger’s test for funnel plot asymmetry23 becomes positive only at stage B, after 
the inclusion of LIMIT-2,3 the only adequately sized trial at that time. In subsequent stages, 
the shape of the funnel plot remains essentially unchanged and Egger’s test for asymmetry 
positive, suggesting bias.  
 
Table 1 Stratified analyses 
Results from stratified analysis according to allocation concealment and sample size are presented using fixed- 
and random-effects models including trials published until 1991 and before LIMIT-2; until 1995 and before 
ISIS-4, until 1995 including ISIS-4 and up to 2004. P-values for interaction between treatment effect and trial 
characteristics were derived using meta-regression for random-effects models and z-tests for fixed-effect models. 
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Table 1 presents the results from corresponding stratified analyses according to concealment 
of allocation and sample size. At stage A, stratified analyses using a fixed-effect and a 
random-effects models indicate no relevant differences between trials with adequate 
concealment and the remaining trials, whereas no adequately sized trials with sample sizes of 
≥ 2200 patients were available. At stage B, after LIMIT-23 became available, differences 
become apparent between trials with and without concealment of allocation and between large 
and small trials, but pooled effects are statistically significant in all stratified analyses and 
interaction tests are positive only in fixed-effect meta-analyses. With the inclusion of ISIS-4,4  
the between trial heterogeneity becomes prominent. Therefore, random-effects models 
attribute considerably more weight to smaller studies than fixed-effect models and results 
from fixed-effect and random-effects meta-analyses including all trials are discordant: there is 
still a clinically relevant mortality reduction according to the random-effects, but a clear-cut 
null-result according to the fixed-effect meta-analysis. Even in the presence of high between-
trial heterogeneity, random and fixed-effect models show concordant results if stratified 
according to trial size: no effect in adequately sized trials and an unrealistically large 
beneficial effect on overall mortality in small trials. Positive tests of interaction in both, 
random and fixed-effect analyses indicate that these differences between adequately sized and 
small trials are unlikely to have occurred by chance alone.  
Figure 2 presents results from trial sequential analysis using fixed-effect meta-analysis (top) 
and random-effects meta-analysis (bottom). The dashed horizontal line represents the 
monitoring boundaries to be reached by the z-value of a meta-analysis to indicate that results 
are conclusive before the number of 24,899 patients is reached, which is necessary to detect a 
relative risk reduction of 15% with 80% power at a two-sided α of 0.01. The boundary 
becomes less stringent with more patients accruing and will converge to a z-value of 2.58 
corresponding to the α-level of 0.01 indicating conclusive results when sufficient numbers of 
patients have been accumulated. Neither in random-effects, nor in fixed-effect meta-analyses, 
the z-curve crosses the boundary before ISIS-4 becomes available and the necessary 
information size of nearly 25,000 patients is reached, suggesting that the results of both, 
random and fixed-effect meta-analyses were inconclusive. After inclusion of ISIS-4,4  
however, results are conflicting: evidence of a null effect according to the fixed-effect model, 
but evidence of a benefit of magnesium according to the random-effects model, which 
vanishes only after the analysis is restricted to trials with adequate sample size (data available 
on request).  
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Figure 2 Heterogeneity-adjusted trial sequential analysis 
Trial sequential analysis of trials of intravenous magnesium using fixed-effect (top) and 
random-effects meta-analysis (bottom). The dashed vertical line indicates that the 
number of patients necessary to detect a relative risk reduction of 15% with 80% power 
at α=0.01 is 24 899 if a baseline risk of 10% and a heterogeneity between trials of 
I2=30% are assumed. The dashed horizontal line represents the monitoring boundaries to 
be reached by the z-value of a meta-analysis to indicate that results are conclusive 
before the necessary number of 24 899 patients is reached. The boundary becomes less 
stringent when more trials and patients are included and will converge to a z-value of 
2.58, corresponding to the α-level of 0.01, to indicate conclusive results when sufficient 
numbers of patients are accumulated. 
It is the overall pattern found in funnel plots, stratified analyses, and heterogeneity-adjusted 
trial sequential analysis, which provides a clear-cut insight into the trustworthiness of the 
different stages of the meta-analysis of magnesium in acute myocardial infarction.1 2 14 23 At 
stage A, formal tests of funnel plot asymmetry and interaction tests accompanying stratified 
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analyses were still negative due to a lack of power, and some would have concluded that the 
evidence accumulated was unbiased and trustworthy. Heterogeneity-adjusted trial sequential 
analysis unequivocally indicates, however, that the evidence was inconclusive at this stage. At 
stage B, trial sequential analysis suggests that the accumulated evidence is still unconvincing 
when LIMIT-23 was included. In addition, the test for funnel plot asymmetry becomes 
positive. At stages C and D, after the inclusion of ISIS-4,4 heterogeneity-adjusted trial 
sequential analyses of random-effects and fixed effects meta-analyses are discordant. Here, 
the appropriately powered tests of funnel plot asymmetry and tests of interaction between 
sample size and treatment effect indicate that the inclusion of trials of inadequate size leads to 
a severe distortion of results.  
Egger and Davey Smith concluded in 1995 that “results of meta-analyses that are exclusively 
based on small trials should be distrusted - even if the combined effect is statistically highly 
significant. Several medium-sized trials of high quality seem necessary to render results 
trustworthy.”5 These conclusions still hold in 2009. If appropriately used and interpreted, 
funnel plots with formal statistical tests of asymmetry, stratified analyses accompanied by 
tests of interaction and heterogeneity-adjusted trial sequential analyses will all contribute to 
our understanding about when to consider a meta-analysis conclusive. 
Acknowledgments: We are grateful to Kristian Thorlund, Jørn Wetterslev and Christian 
Gluud for help with trial sequential analysis of the magnesium trials and for stimulating 
discussions. 
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Discussion and outlook 
This thesis suggests that flaws in the conduct and design of randomised clinical trials and 
meta-analyses frequently result in biased estimates of treatment benefits. Methodological trial 
characteristics, including allocation concealment and exclusions of randomised patients from 
the analysis were associated with estimated treatment benefits and may have biased results of 
individual trials and meta-analyses. In addition, small study effects made the interpretation of 
results from several included meta-analyses difficult. The impact of these characteristics on 
estimated treatment benefits in a specific situation was unpredictable, however. I also 
assessed the impact of methodological quality and sample size on the between-trial 
heterogeneity by restricting meta-analyses to trials with high methodological quality or to 
large trials. The variability between trials was substantially reduced when meta-analyses were 
restricted. In two additional studies, inter-observer variation in data extraction and 
multiplicity of outcome data presented in trial reports frequently hampered the validity of 
results in the studied meta-analyses. Monte Carlo simulations showed that disagreements 
between different observers when extracting data from trial reports and multiplicity of data in 
trial reports resulted in a substantial variability in pooled estimates of treatment benefit.  
To my knowledge, this thesis provides the first systematic examination of bias and variation 
in randomised trials and meta-analyses of patient-reported outcomes measured on a 
continuous or rating scale, and of the impact of multiple choices in data extraction on the 
validity of results from meta-analyses. Most previous meta-epidemiological studies have 
concentrated on the associations of methodological trial characteristics such as allocation 
concealment, double-blinding and dropouts or exclusions with estimated treatment benefits 
measured on an odds ratio scale.1-7 Meta-epidemiological approaches were used in this thesis, 
which allowed assessing the variability in effects between meta-analyses.8 9  
The thesis is based on information extracted from published trial reports and depends on the 
quality of reporting, which is generally low.10 The assessment of methodological 
characteristics such as allocation concealment will depend more on the quality of reporting 
than sample size of a trial.11 12 Trial misclassification, if it is non-differential, will result in an 
underestimation of the true associations between methodological characteristics and treatment 
benefits. However, low quality of reporting and low quality of trial conduct are often 
intertwined: faulty reporting may represent faulty methods.6 13 Therefore, misclassification 
might not be a frequent problem. Because this thesis is based on published trial results, the 
results will also be affected by selective reporting of outcomes and analyses. Selective 
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reporting of different analyses, e.g. reporting of changes rather than absolute values, or 
preferential reporting of more favourable per-protocol analyses rather than more conservative 
intention-to-treat analyses, might have affected the results in this study. I was unable to 
disentangle bias resulting from selective reporting and methodological quality. The variability 
of meta-analyses results due to different observers and multiple outcome data presented in 
trial reports might have been underestimated. The actual multiplicity might be even be more 
pronounced if both, published and unpublished outcome data had been available.  
Meta-epidemiological studies are observational by nature and the associations between 
estimates of treatment benefits and methodological components might be confounded by 
several factors. In this-epidemiological study of 190 trials, confounding by disease and type 
of intervention was minimised by a restriction to meta-analyses of osteoarthritis trials and by 
stratification according to type of intervention.8 Flaws in methodological conduct are likely to 
cluster in trials and therefore, confounding by different methodological components was 
controlled by stratification and reported as sensitivity analyses. Differences between trials 
with and trials without adequate methodology (concealment of allocation, patient blinding and 
intention-to-treat analysis) diminished or disappeared entirely after accounting for sample size 
of the trials. Conversely, the association between sample size and treatment effects were 
completely robust, when accounting for methodological components. Sample size of a trial 
might therefore be the best single proxy for the cumulative impact of methodological 
deficiencies, selective reporting and publication bias. Alternatively, smaller studies may be 
more careful in implementing the intervention or may include patients who are particularly 
likely to benefit from the intervention, both aspects resulting in larger treatment effects and 
true clinical heterogeneity.14-16  
The results presented in this thesis have several implications for researchers performing 
randomised trials and meta-analyses. To avoid potential bias, trialists should always ensure 
adequate concealment of allocation and take measures to minimise dropout rates, maximise 
compliance and minimise missing outcome data. Blinding of patients is desirable and should 
be attempted. Results from intention to treat analyses should always be described in reports of 
randomised trials. The CONSORT statement urges transparent reporting of concealment of 
allocation, measures taken to blind study participants, the flow of participants through the 
various stages of a trial including withdrawals and losses to follow-up and the reasons for 
exclusions from the analysis.17 18 Authors of reports of randomised trials should follow the 
CONSORT statement17 18 to ensure fully transparent reporting of methods and results. 
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In systematic reviews and meta-analyses, a detailed protocol might improve the reliability of 
results. Data extraction should be done by more than one observer, and should be based on 
results from analyses including all randomised patients, whenever possible. Results of meta-
analyses based on methodologically questionable trials should be distrusted. Even a meta-
analysis that includes a large number of patients reaching the required information size to get 
adequate power19 should be interpreted with caution, if mainly trials at high risk of bias 
contributed to the analysis, which may have distorted results.20 The influence of allocation 
concealment, patient blinding, exclusions form the analysis, and sample size should be 
routinely assessed in stratified analyses.  
The Cochrane Collaboration now advocates reporting the risk of bias for each included 
randomised trial in a Cochrane review by assessing individual methodological components 
such as sequence generation, allocation concealment, blinding, incomplete outcome data and 
selective reporting bias, which should help readers to judge the extent of bias in the reported 
meta-analysis.21 Recently, Bayesian hierarchical models have been discussed to adjust 
treatment effects in a meta-analysis for bias.22 These models use empirical prior information 
about the extent and direction of bias in randomised trials and meta-analyses. Meta-
epidemiological studies might provide information that can be used to calculate bias-adjusted 
treatment effects in meta-analyses.22 Further studies that disentangle the interplay between 
different dimensions of methodological quality will provide better understanding of the 
underlying mechanisms.  
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